BIARYL PHOSPHODIESTERASE INHIBITORS

FIELD OF THE INVENTION The present invention relates to novel compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

BACKGROUND OF THE INVENTION

Phosphodiesterases are enzymes that catalyse the hydrolysis of cyclic AMP and/or cyclic GMP in cells to 5-AMP and 5-GMP, respectively, and as such they are critical to cellular regulation of cAMP or cGMP levels. Of the 11 phosphodiesterases identified so far, phosphodiesterase (PDE) 4, PDE7 and PDE8 are selective for cAMP. PDE4 is the most important modulator of cAMP expressed in immune and inflammatory cells such as neutrophils, macrophages and T-lymphocytes (Z. Huang and J. A. Mancini, Current Med. Chem. 13, 2006, pp. 3253-3262). As cAMP is a key second messenger in the modulation of inflammatory responses, PDE4 has been found to regulate inflammatory responses of inflammatory cells by modulating proinflammatory cytokines such as TNFa, IL-2, IFN-y, GM-CSF and LTB4. Inhibition of PDE4 has therefore become an attractive target for the therapy of inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease such as Crohn's disease etc. (M.D. Houslay et al., Drug Discovery Today 10 (22), 2005, pp. 1503-1519). As atopic dermatitis (AD) patients have increased PDE-activity, PDE4- inhibition would also appear to be a viable treatment of AD (Journal of Investigative Dermatology ( 1986), 87(3), 372-6).

The PDE4 gene family consists at least of four genes, A, B, C and D, which have a high degree of homology (V. Boswell Smith and D. Spina, Curr. Opinion Investig. Drugs 6(11), 2006, pp. 1136-1141). The four PDE4 isoforms are differentially expressed in different tissues and cell types. Thus, PDE4B is predominantly expressed in monocytes and neutrophils, but not in cortex and epithelial cells, while PDE4D is expressed in lung, cortex, cerebellum and T-cells (C. Kroegel and M. Foerster, Exp. Opinion Investig. Drugs 16(1), 2007, pp. 109-124). It has been speculated that inhibition of PDE4D in the brain is associated with the adverse effects found when administering PDE4 inhibitors clinically, primarily nausea and emesis, whereas inhibition of PDE4B is associated with anti-inflammatory effects (B. Lipworth, Lancet 365, 2005, pp. 167-175). However, the PDE inhibitors developed so far are not believed to be specific for any of the four PDE4 isoforms.

Numerous PDE4 inhibitors have been studied for their therapeutic effect on inflammatory diseases, primarily asthma and COPD.

The first of these, theophylline, is a weak, non-selective phosphodiesterase inhibitor used in the treatment of respiratory diseases such as asthma and COPD. Treatment with theophylline may, however, give rise to both mild and severe adverse effects, e.g.

arrhythmia and convulsions, restricting the clinical utility of theophylline (Kroegel and Foerster, supra). As phosphodiesterase has remained an attractive target for antiinflammatory therapy, several other, more selective PDE4 inhibitors have been developed and investigated in a clinical setting. The clinical development of many of the first-generation PDE4 inhibitors such as rolipram was discontinued due to dose-limiting side effects, primarily nausea and emesis. Second-generation PDE4 inhibitors with apparently less pronounced adverse effects are currently in clinical trials (Houslay, supra).

WO9410118 discloses tri-substituted phenyl derivatives which may be di-alkoxy substituted, for use as PDE4 inhibitors.

W09412461 discloses 4-substituted catechol diether compounds as selective PDE4 inhibitors. WO 9522520 discloses substituted biphenyl derivatives which may be di-alkoxy substituted, for use as PDE4 inhibitors.

W09527692 discloses substituted biphenyl TNF inhibitors or PDE4 inhibitors.

US2001/0056117, US2002/0128290 and WO2000014085 disclose tri-alkoxy substituted biaryl PDE4 inhibitors, wherein two of the alkoxy substituents are connected to form a ring, thus rigidifying the molecule.

SUMMARY OF THE INVENTION The inventors have surprisingly found that novel compounds of the present invention which are tri-alkoxy substituted biaryl PDE4 inhibitors, but in which the alkoxy substituents are not connected in a ring system exhibit PDE4 inhibitory activity. Thus, the compounds may be useful as therapeutic agents for inflammatory allergic diseases such as bronchial asthma, COPD, allergic rhinitis, and nephritis; autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, and systemic lupus erythematosus; diseases of the central nervous system such as depression, amnesia, and dementia; organopathy associated with ischemic reflux caused by cardiac failure, shock, and cerebrovascular diseases, and the like; insulin-resistant diabetes; wounds; AIDS, and the like.

Compounds of the present invention may also be beneficial in preventing, treating or ameliorating a variety of diseases, such as dermal diseases or conditions, such as proliferative and inflammatory skin disorders and in particular psoriasis, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis, and eczema. Accordingly, the present invention relates to a compound according to formula I

wherein Rl is alkyl, deuterioalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylcarbonyl, each of which is optionally substituted with one ore more substituents selected from halogen, cyano, alkyl, alkoxy, hydroxy, oxo; R2 represents alkyl, deuterioalkyl, alkenyl, alkynyl, cycloalkyi, heterocycloalkyi, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, alkoxycarbonylalkyl, alkylcarbonyl, arylcarbonyl, or alkoxyalkyi, each of which is optionally substituted by one or more, same or different substituents selected from R4;

R3 represents alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl, cycloalkyi, heterocycloalkyi, cycloalkylalkyl, heterocycloalkylalkyl, alkylcycloalkylalkyl, alkylheterocycloalkylalkyl, alkylalkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyl, arylcarbonyl, alkoxyalkyi, heterocycloalkylcarbonyl, cycloalkylcarbonyl, heteroarylcarbonyl, alkoxyalkylcarbonyl, cycloalkoxycarbonylalkyl or cycloalkoxyalkyl, each of which is optionally substituted by one or more, same or different substituents selected from R4;

R4 represents oxo, halogen, cyano, hydroxy or nitro; or

R4 represents alkylaryl, alkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyi, cycloalkyi, heterocycloalkenyl, heterocycloalkyi, hydroxyalkyi, alkoxyalkyi, aryl or heteroaryl, each of which is optionally substituted by one or more, same or different substituents selected from R7;

or R4 represents, -NRaRb, -ORa, -SRa, -S0 ₂ Ra, -S(0)Ra, - S0 ₂ NRaRb, -NRa S0 ₂ Rb, - OC(0)NRaRb, -NRaC(0)ORb, -NRaC(0)NRbRc, -NRaC(0)Rb, -C(0)IMRaRb, -C(0)Ra, - OC(0)Ra, -OC(0)ORa, -C(0)ORa, -P(0)RaRb, P(0)(ORa)ORb, -OP(0)RaRb, - OP(0)(ORa)ORb or NraS(0) ₂ NRbRc;

R7 represents halogen, hydroxy, or oxo; or

R7 represents alkyl, cycloalkyi, heterocycloalkyi, aryl or heteroaryl each of which is optionally substituted by one or more, same or different substituents selected from R8; or R7 represents -ORd, -SRd, - S0 ₂ Rd, - S0 ₂ NRdRe, -NRd S0 ₂ Re, -NRdC(0)Re, - C(0)NRdRe, OC(0)Re, -C(0)Ord, OC(0)Re or NRdC(0)ORe; R8 represents alkyl, oxo, hydroxy, halogen, alkoxy or haloalkyi;

Ra, Rb, Rc independently represents hydrogen; or

Ra, Rb and Rc independently represents alkylaryl, alkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyi, cycloalkyi, heterocycloalkenyl, heterocycloalkyi, hydroxyalkyi, alkoxyalkyi, aryl or heteroaryl, each of which is optionally substituted by one or more, same or different substituents selected from R7; Rd and Re independently represents hydrogen; or

Rd and Re independently represents alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl, haloalkyl, heterocycloalkenyl, heterocycloalkyl, aryl, heteroaryl or hydroxyalkyl, each of which is optionally substituted by one or more, same or different substituents selected from R8;

Position 1 of ring A is connected to either Z _: or Z ₂ ;

X and Y are CRfRg, NRh, O or S, wherein Rf and Rg independently represent H, halogen, cyano, hydroxy, alkyl, alkoxy, haloalkyl, haloalkoxy; and Rh represents hydrogen, alkyl or haloalkyl ; with the proviso that at least one of X and Y represents CRfRg ;

Zi, Z ₂ Z ₃ and Z ₄ independently are CRi or N, wherein Ri represents a bond, hydrogen, alkyl, halogen, alkoxy, cyano, haloalkyl, haloalkoxy, or hydroxy; with the proviso that when position 1 of ring A is connected to Z _x then Zi is CRi ; and when position 1 of ring A is connected to Z ₂ then Z ₂ is CRi ; and pharmaceutically acceptable and physiologically cleavable esters, pharmaceutically acceptable salts, hydrates, N-oxides or solvates thereof; with the proviso that when R1 = R2=R3= CH ₃ , X = Y = -CH ₂ -, position 1 of ring A is connected to Z ₂ , then at least one of Zi, Z ₃ , and Z ₄ is different from CH ; and with the proviso that when R1 = R2= R3= CH ₃ , X = Y = -CH ₂ -, position 1 of ring A is connected to Zi, Z4 is CRi, then Ri is different from methoxy; and with the proviso that when R1 = R2 = CH ₃ , R3 = benzyl, position 1 of ring A is connected to Z ₂ , Zi is N, Z ₃ = Z ₄ = CRi, Ri = CH ₃ , X = O, Y = CRfRg, Rf = H, then Rg is different from CH ₃ .

In another aspect, the present invention relates to a compound according to formula I for use in therapy.

In another aspect, the present invention relates to a compound according to formula I for use in the prophylaxis, treatment or amelioration of dermal diseases or conditions or acute or chronic cutaneous wound disorders. It is expected that some compounds of formula I may be particularly suitable for topical cutaneous treatment as they may be susceptible to ester hydrolysis in serum to an inactive form after skin permeation following cutaneous application and therefore less likely to result in undesired systemic side effects such as nausea. In another aspect, the invention relates to a pharmaceutical composition comprising a compound of general formula I as defined herein and pharmaceutically acceptable and physiologically cleavable esters, pharmaceutically acceptable salts, hydrates, N-oxides or solvates thereof together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s), optionally together with one or more other therapeutically active compound(s).

In yet another aspect, the invention relates to a use of a compound according to formula I as defined herein, and pharmaceutically acceptable and physiologically cleavable esters, pharmaceutically acceptable salts, hydrates, N-oxides or solvates thereof in the manufacture of a medicament for the prophylaxis, treatment or amelioration of dermal diseases or conditions, or acute or chronic cutaneous wound disorders.

In yet another aspect, the invention relates to a method of preventing, treating or ameliorating dermal diseases or conditions, or acute or chronic cutaneous wound disorders, the method comprising administering to a person suffering from at least one of said diseases an effective amount of one or more compounds of formula I as defined herein and pharmaceutically acceptable and physiologically cleavable esters,

pharmaceutically acceptable salts, hydrates, N-oxides or solvates thereof;

optionally together with a pharmaceutically acceptable carrier or one or more excipients, optionally in combination with other therapeutically active compounds.

In yet another aspect, the present invention relates to a method for the preparation or manufacture of a compound of general formula I comprising a method as anywhere described herein, such as method A, B, C, or D, or such as any one of the general methods or procedures described in the examples or preparations herein, and optionally further processing of a compound obtained, to give a compound of general formula I as anywhere defined herein.

DETAILED DESCRPTION OF THE INVENTION

The term "hydrocarbon radical" is intended to indicate a radical containing only hydrogen and carbon atoms, it may contain one or more double and/or triple carbon-carbon bonds, and it may comprise cyclic moieties in combination with branched or linear moieties. Said hydrocarbon comprises 1-20 carbon atoms, and preferably comprises 1- 12, e.g. 1-6, e.g. 1-4, e.g. 1-3, e.g. 1-2 carbon atoms. The term includes alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl and aryl, as indicated below. The term "aryl" is intended to indicate a radical of aromatic carbocyclic rings comprising 6-20 carbon atoms, such as 6-14 carbon atoms, preferably 6-10 carbon atoms, in particular 5- or 6-membered rings, including fused carbocyclic rings with at least one aromatic ring, such as phenyl, naphthyl, indenyl and indanyl. The term "heteroaryl" is intended to indicate radicals of heterocyclic aromatic rings comprising 1-6 heteroatoms (selected from O, S and N) and 1-20 carbon atoms, such as 1-5 heteroatoms and 1-10 carbon atoms, such as 1-5 heteroatoms and 1-6 carbon atoms, such as 1-5 heteroatoms and 1-3 carbon atoms, in particular 5- or 6-membered rings with 1-4 heteroatoms selected from 0, S and N, including fused bicyclic rings with 1-4 heteroatoms, and wherein at least one ring is aromatic, e.g. pyridyl, quinolyl, isoquinolyl, indolyl, thiadiazolyl, oxodiazolyl, tetrazolyl, furanyl, pyridyl, thiazolyl, benzooxazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thienyl, pyrazinyl, isothiazolyl, benzimidazolyl, and benzofuranyl. In the present context, the term "alkyl" is intended to indicate a radical obtained when one hydrogen atom is removed from a hydrocarbon. Said alkyl comprises 1-20, preferably 1-12, such as 1-6, such as 1-4 or such as 1-3 carbon atoms. The term includes the subclasses normal alkyl (n-alkyl), secondary and tertiary alkyl, such as methyl, ethyl, n-propyl, isopropyl, /7-butyl, isobutyl, sec. -butyl, tert. -butyl, pentyl, isopentyl, hexyl and isohexyl.

The term "cycloalkyl" is intended to indicate a saturated cycloalkane radical comprising 3-20 carbon atoms, preferably 3-10 carbon atoms, in particular 3-8 carbon atoms, such as 3-6 carbon atoms, including fused bicyclic rings, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

The term "heterocycloalkyl" is intended to indicate a cycloalkane radical as described above, wherein one or more carbon atoms are replaced by heteroatoms, comprising 1- 20 carbon atoms, e.g. 2-5 or 2-4 carbon atoms, further comprising 1-6 heteroatoms, preferably 1, 2, or 3 heteroatoms, selected from 0, N, or S, e.g. piperidinyl, pyrrolidinyl, morpholinyl, oxetanyl, [l,3]dioxolanyl and [l,3]dioxolyl, or including fused bicyclic rings with 1-4 heteroatoms, wherein at least one ring comprises a heteroatom, and wherein the other ring may for example be a carbocyclic ring, e.g. isoindolyl.

The term "alkenyl" is intended to indicate a mono-, di-, tri-, tetra- or pentaunsaturated hydrocarbon radical comprising 2-10 carbon atoms, in particular 2-6 carbon atoms, such as 2-4 carbon atoms, e.g. ethenyl, propenyl (allyl), methylbutenyl, butenyl, pentenyl or hexenyl.

The term "cycloalkenyl" is intended to indicate mono-, di- tri- or tetraunsaturated non- aromatic cyclic hydrocarbon radicals, comprising 3-20 carbon atoms, including fused bicyclic rings, typically comprising 3-10 carbon atoms, such as 3, 4, or 6 carbon atoms, e.g. cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cylcoheptenyl.

The term "heterocycloalkenyl" is intended to indicate a cycloalkene radical as described above, wherein one or more carbon atoms are replaced by heteroatoms, comprising 1- 20 carbon atoms, e.g. 2-4 carbon atoms, further comprising 1-6 heteroatoms, preferably 1, 2, or 3 heteroatoms, selected from O, N, or S, including fused bicyclic rings with 1-4 heteroatoms, wherein at least one ring comprises a heteroatom and wherein the other ring may for example be a carbocyclic ring, e.g. dihydrofuranyl, or 2,5-dihydro-lH- pyrrolyl.

The term "alkynyl" is intended to indicate an hydrocarbon radical comprising 1-5 triple C-C bonds and 2-20 carbon atoms, typically comprising 2-10 carbon atoms, in particular 2-6 carbon atoms, such as 2-4 carbon atoms, e.g. ethynyl, propynyl, butynyl, pentynyl or hexynyl.

The term "halogen" is intended to indicate a substituent from the 7 ^th main group of the periodic table, such as fluoro, chloro and bromo. The term "haloalkyl" is intended to indicate an alkyl group as defined above substituted with one or more halogen atoms as defined above, e.g. fluoro or chloro, such as difluoromethyl, or trifluoromethyl.

The term "alkoxy" is intended to indicate a radical of the formula -OR', wherein R' is alkyl as indicated above, e.g. methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, etc. The term "hydroxyalkyl" is intended to indicate an alkyl group as defined above substituted with one or more hydroxy, e.g. hydroxymethyl, hydroxyethyl,

hydroxypropyl. The term "deuterioalkyl" is intended to indicate an alkyl group as defined above substituted with one or more deuterium, e.g deuteriomethyl, dideuteriomethyl, trideuteriomethyl, 2-deuterioethyl, 2,2-dideuterioethyl, 2,2,2-trideuterioethyl or

1, 1,2,2,2-pentadeuterioethyl. The term "amino" is intended to indicate a radical of the formula -NR" ₂ , wherein each R" independently represents hydrogen, or a hydrocarbon radical as indicated above, e.g. - NH ₂ , dimethylamino, -NHMe, -NHEt, tert. -butylamino.

The term "alkoxycarbonyl" is intended to indicate a radical of the formula -C(0)-0-R', wherein R' is alkyl as indicated above, e.g. methoxycarbonyl, ethoxycarbonyl, n- propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl etc.

The term "alkoxycarbonylalkyl" is intended to indicate a radical of the formula -R-C(O)- O-R', wherein R and R' are alkyl groups as indicated above, e.g.

methoxycarbonylmethyl, ethoxycarbonylmethyl, n-propoxycarbonylethyl,

isopropoxycarbonylethyl, tert-butoxycarbonylmethyl etc.

The term "cycloalkoxycarbonylalkyl" is intended to indicate a radical of the formula -R- C(0)-0-R', wherein R is an alkyl group as indicated above and R' is a cycloalkyl group as indicated above.

The term "alkylcarbonyl" is intended to indicate a radical of the formula -C(0)-R', wherein R' is alkyl as indicated above, e.g. acetyl.

The term "alkylcarbonyloxy" is intended to indicate a radical of the formula -0-C(0)-R', wherein R' is alkyl as indicated above.

The term "alkoxycarbonyloxy" is intended to indicate a radical of the formula -O-C(O)- O-R', wherein R' is alkyl as indicated above. The term "heterocycloalkylcarbonyl" is intended to indicate a radical of the formula - C(0)-R', wherein R' is heterocycloalkyl as indicated above. The term "cycloalkylcarbonyl" is intended to indicate a radical of the formula -C(0)-R', wherein R' is cycloalkyl as indicated above.

The term "heteroarylcarbonyl" is intended to indicate a radical of the formula -C(0)-R', wherein R' is heteroaryl as indicated above.

The term "alkoxyalkylcarbonyl" is intended to indicate a radical of the formula -C(0)-R'- O-R, wherein R' and R are alkyl as indicated above. The term "cycloalkoxyalkylcarbonyl" is intended to indicate a radical of the formula - C(0)-R'-0-R, wherein R' is alkyl and R is cycloalkyl as indicated above.

The term "cycloalkylcarbonyl" is intended to indicate a radical of the formula -C(0)-R, werein R is cycloalkyl as indicated above.

The term "heterocycloalkylcarbonyl" is intended to indicate a radical of the formula - C(0)-R", wherein R" is heterocycloalkyl as indicated above.

The term "cycloalkoxyalkyl" is intended to indicate a radical of the formula -R'-O-R, wherein R' is alkyl and R is cycloalkyl as indicated above.

The term "heterocyclic ring" is intended to include the definitions heteroaryl,

heterocycloalkyl and heterocylcoalkenyl as defined above, including annelated ring systems with each other or with cyclic hydrocarbons, e.g. 2,5-dihydrobenzo(b)dioxocine, 2,3,5,8-tetrahydro-[l,4]dioxocine, 5,8-dihydro-[l,4]dioxocine, 2,3-dihydro-lH-isoindole.

The term "alkylaryl" is intended to indicate an aryl radical as defined above, which is substituted with an alkyl radical as defined above, e.g. tolyl (=toloyl), ethylbenzene, etc. The term "arylalkyl" is intended to indicate an alkyl radical as defined above, which is substituted with an aryl radical as defined above, e.g. benzyl, phenylethyl,

naphthylmethyl, etc.

The term "alkoxyalkyi" is intended to indicate an alkyl radical as defined above, which is substituted with an alkoxy radical as defined above, i.e. -R'-O-R', wherein each R' is alkyl, same or different, as indicated above, e.g . methoxymethyl, ethoxymethyl. The term "aryloxy" is intended to indicate -O-R'", wherein R'" is aryl as indicated above, e.g. phenoxy.

The term "arylcarbonyl" is intended to indicate -C(0)-R"", wherein R"" is an aryl radical as defined above, e.g. benzoyl, naphthylcarbonyl.

When two or more of the above defined terms are used in combination, such as arylalkyl, heteroarylalkyi, cycloalkylalkyi and the like, it is to be understood that the first mentioned radical is a substituent on the latter mentioned radical, where the point of attachment to another part of the molecule, is on the latter radical.

Thus, the term "cycloalkylalkyi" is intended to indicate a radical of the formula -R'- c cloalkyl, wherein R' is alkyl as defined above such as;

The term "alkylcycloalkylalkyl" is intended to indicate a radical of the formula -R'- cycloalkyl-R, wherein R and R' are alkyl as defined above.

The term "alkylheterocycloalkylalkyi" is intended to indicate a radical of the formula -R'- heterocycloalkyl-R, wherein R and R' are alkyl as defined above.

The term "arylalkyl" is intended to indicate a radical of the formula -R'-Ar, wherein R' is alk l as defined above and Ar is aryl as defined above such as;

The term "pharmaceutically acceptable salt" is intended to indicate salts prepared by reacting a compound of formula I with a suitable inorganic or organic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric, phosphoric, formic, acetic, 2,2- dichloroaetic, adipic, ascorbic, L-aspartic, L-glutamic, galactaric, lactic, maleic, L-malic, phthalic, citric, propionic, benzoic, glutaric, gluconic, D-glucuronic, methanesulfonic, salicylic, succinic, malonic, tartaric, benzenesulfonic, ethane-l,2-disulfonic, 2-hydroxy ethanesulfonic acid, toluenesulfonic, sulfamic or fumaric acid. Pharmaceutically acceptable salts of compounds of formula I may also be prepared by reaction with a suitable base such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, silver hydroxide, ammonia or the like, or suitable non-toxic amines, such as lower alkylamines, for example triethylamine, hydroxy-lower alkylamines, for example 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine, cycloalkylamines, for example dicyclohexylamine, or benzylamines, for example Ν,Ν'-dibenzylethylene- diamine, and dibenzylamine, or L-arginine or L-lysine. Salts obtained by reaction with a suitable base include, but are not limited to sodium salts, choline salts, 2- (dimethylamino)-ethanol salts, 4-(2-hydroxyethyl)-morpholin salts, L-lysine salts, N-(2- hydroxyethyl)-pyrrolidine salts, ethanolamine salts, potassium salts,

tetrabutylammonium salts, benzyltrimethylammonium salts, cetyltrimethylammonium salts, tetramethylammonium salts, tetrapropylammonium salts,

tris(hydroxymethyl)aminomethane salts, N-methyl-D-glucamine salts, silver salts, benzethonium salts, and triethanolamine salts. The term "solvate" is intended to indicate a species formed by interaction between a compound, e.g. a compound of formula I, and a solvent, e.g . alcohol, glycerol or water, wherein said species are in a solid form. When water is the solvent, said species is referred to as a hydrate. Compounds of the invention which comprise free hydroxyl groups or free carboxylic acid groups may also exist in the form of pharmaceutically acceptable, physiologically cleavable esters, and as such are included within the scope of the present invention. Such pharmaceutically acceptable esters are preferably prodrug ester derivatives, such being convertible by solvolysis or cleavage under physiologically conditions to the corresponding compounds of the invention which comprise free hydroxyl groups or free carboxylic acid groups respectively, e.g. in-vivo hydrolysable.

Embodiments of the present invention

In an embodiment, the compound of the invention is of general formula I

wherein Rl is alkyl, alkenyl, alkynyl, cycloalkyi, heterocycloalkyi, alkylcarbonyl, each of which is optionally substituted with one ore more substituents selected from halogen, cyano, alkyl, alkoxy, hydroxy, oxo;

R2 represents alkyl, alkenyl, alkynyl, cycloalkyi, heterocycloalkyi, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, alkoxycarbonylalkyl, alkylcarbonyl, arylcarbonyl, or alkoxyalkyi, each of which is optionally substituted by one or more, same or different substituents selected from R4;

R3 represents alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl, cycloalkyi, heterocycloalkyi, cycloalkylalkyl, heterocycloalkylalkyl, alkylcycloalkylalkyl, alkylheterocycloalkylalkyl, alkylalkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyl, arylcarbonyl, or alkoxyalkyi, each of which is optionally substituted by one or more, same or different substituents selected from R4;

R4 represents oxo, halogen, cyano, hydroxy or nitro; or

R4 represents alkylaryl, alkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, cycloalkyi, heterocycloalkenyl, heterocycloalkyi, hydroxyalkyi, alkoxyalkyi, aryl or heteroaryl, each of which is optionally substituted by one or more, same or different substituents selected from R7;

or R4 represents, -NRaRb, -ORa, -SRa, -S0 ₂ Ra, -S(0)Ra, - S0 ₂ NRaRb, -NRa S0 ₂ Rb, - OC(0)NRaRb, -NRaC(0)ORb, -NRaC(0)NRbRc, -NRaC(0)Rb, -C(0)NRaRb, -C(0)Ra, OC(0)Ra, OC(0)ORa, or C(0)ORa;

R7 represents halogen, hydroxy, or oxo; or R7 represents alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl each of which is optionally substituted by one or more, same or different substituents selected from R8; or R7 represents -ORd, - S0 ₂ Rd, - S0 ₂ NRdRe, -NRd S0 ₂ Re, -NRdC(0)Re, -C(0)NRdRe, OC(0)Re, or -C(0)ORd;

R8 represents alkyl, oxo, hydroxy, halogen, alkoxy or haloalkyi; Ra, Rb, Rc independently represents hydrogen; or

Ra, Rb and Rc independently represents alkylaryl, alkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyi, cycloalkyl, heterocycloalkenyl, heterocycloalkyl, hydroxyalkyi, alkoxyalkyi, aryl or heteroaryl, each of which is optionally substituted by one or more, same or different substituents selected from R7;

Rd and Re independently represents hydrogen; or

Rd and Re independently represents alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl, haloalkyi, heterocycloalkenyl, heterocycloalkyl, aryl, heteroaryl or hydroxyalkyi, each of which is optionally substituted by one or more, same or different substituents selected from R8; Position 1 of ring A is connected to either Zi or Z ₂ ;

X and Y are CRfRg, NRh, O or S, wherein Rf and Rg independently represent H, halogen, cyano, hydroxy, alkyl, alkoxy, haloalkyi, haloalkoxy; and Rh represents hydrogen, alkyl or haloalkyi; with the proviso that at least one of X and Y represents CRfRg;

Zi, Z ₂ Z ₃ and Z ₄ independently are CRi or N, wherein Ri represents a bond, hydrogen, alkyl, halogen, alkoxy, cyano, haloalkyi, haloalkoxy, or hydroxy; with the proviso that when position 1 of ring A is connected to Z _x then Zi is CRi; and when position 1 of ring A is connected to Z ₂ then Z ₂ is CRi; and pharmaceutically acceptable and physiologically cleavable esters, pharmaceutically acceptable salts, hydrates, N-oxides or solvates thereof; with the proviso that when R1=R2=R3= CH ₃ , X = Y = -CH ₂ -, position 1 of ring A is connected to Z ₂ , then at least one of Z _x , Z ₃ , and Z ₄ is different from CH; and with the proviso that when R1 = R2 = R3= CH ₃ , X = Y = -CH ₂ -, position 1 of ring A is connected to Z Z4 is CRi, then Ri is different from methoxy; and with the proviso that when R1 = R2 = CH ₃ , R3 = benzyl, position 1 of ring A is connected to Z ₂ ,∑ _! is N, Z ₃ = Z ₄ = CRi, Ri = CH ₃ , X = 0, Y = CRfRg, Rf = H, then Rg is different from CH ₃ .

In an embodiment the compound according to the invention is of the general formula la

In an embodiment the compound according to the invention is of the general formula lb

In an embodiment of the compound according to the invention Rl is alkyl, deuterioalkyl, cycloalkyl, or alkylcarbonyl, each of which is optionally substituted with one ore more substituents selected from halogen, alkoxy, or oxo; R2 represents alkyl, deuterioalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkylheterocycloalkylalkyi or arylalkyl, each of which is optionally substituted by one or more, same or different substituents selected from R4;

R3 represents alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkylcycloalkylalkyl, alkylheterocycloalkylalkyi, alkoxyalkylcarbonyl,

alkylheterocycloalkylalkyi, cycloalkoxycarbonylalkyi, alkylcarbonyl, cycloalkylcarbonyl or alkoxycarbonylalkyl, each of which is optionally substituted by one or more, same or different substituents selected from R4; R4 represents oxo, halogen, cyano, or hydroxy; or

R4 represents alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each of which is optionally substituted by one or more, same or different substituents selected from R7; or R4 represents, -NRaRb, -ORa, -S0 ₂ Ra, -S(0)Ra, - S0 ₂ NRaRb, -NRaS0 ₂ Rb, - OC(0)NRaRb, -NRaC(0)ORb, -NRaC(0)Rb, -C(0)NRaRb, - OC(0)Ra, or C(0)ORa;

R7 represents cyano, halogen or hydroxy; or

R7 represents alkyl or heterocycloalkyl, each of which is optionally substituted by one or more, same or different substituents selected from R8;

or R7 represents -ORd, -SRd, - S0 ₂ Rd, - S0 ₂ NRdRe, -NRdS0 ₂ Re, -NRdC(0)Re, - C(0)NRdRe, OC(0)Re, or -C(0)ORd;

R8 represents alkyl, hydroxy, or halogen;

Ra, Rb, Rc independently represents hydrogen ; or

Ra, Rb and Rc independently represents alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each of which is optionally substituted by one or more, same or different substituents selected from R7;

Rd and Re independently represents hydrogen; or

Rd and Re independently represents alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted by one or more, same or different substituents selected from R8; Position 1 of ring A is connected to either Z _x or Z ₂ ;

X and Y are CRfRg, NRh, O or S, wherein Rf and Rg independently represent H, halogen, cyano, alkyi, or alkoxy; and Rh represents hydrogen or alkyi; with the proviso that at least one of X and Y represents CRfRg;

Z Z ₂ , Z ₃ and Z ₄ independently are CRi or N, wherein Ri represents a bond, hydrogen, alkyi, halogen, or alkoxy; with the proviso that when position 1 of ring A is connected to Zi then Z _: is CRi; and when position 1 of ring A is connected to Z ₂ then Z ₂ is CRi.

In an embodiment of the compound according to the invention Rl is methyl, ethyl or difluoromethyl.

In an embodiment of the compound according to the invention R2 is methyl, ethyl, cyclopropylmethyl, isobutyl or difluoromethyl. In an embodiment of the compound according to the invention R3 is alkyi, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkylcycloalkylalkyl, alkylheterocycloalkylalkyl, alkoxyalkylcarbonyl, cycloalkoxycarbonylalkyl, alkylcarbonyl, cycloalkylcarbonyl or alkoxycarbonylalkyl each of which is optionally substituted by one or more, same or different substituents selected from R4.

In an embodiment of the compound according to the invention R3 is isobutyl, neopentyl, benzyl, 1-methyl-cyclopropylmethyl, 3-methyl-oxetan-3-ylmethyl, 3,3-dimethylbutyl, isopentyl, cyclobutylmethyl, or 1-methyl-cyclobutylmethyl each of which is optionally substituted by one or more, same or different substituents selected from R4.

In an embodiment of the compound according to the invention R4 is selected from the group consisting of hydroxy, -NRaRb, -ORa, - S0 ₂ Ra, -OC(0)NRaRb, -C(0)NRaRb, - OC(0)Ra, S0 ₂ IMRaRb, -NRaS0 ₂ Rb, -NRaC(0)ORb, -NRaC(0)Rb, or C(0)ORa. In an embodiment of the compound according to the invention Ra, Rb and Rc

independently represent hydrogen or alkyi, wherein said alkyi is optionally substituted by one or more substituents selected from halogen, hydroxy and alkoxy. In an embodiment of the compound according to the invention Ra, Rb and Rc independently represent hydrogen or (C1-C5) alkyl wherein said alkyl is optionally substituted by (C1-C5) alkoxy.

In an embodiment of the compound according to the invention X is CRfRg, NRh, or 0.

In an embodiment of the compound according to the invention Y is CRfRg. In an embodiment of the compound according to the invention Rf, Rg and Rh independently represent hydrogen or alkyl .

In an embodiment of the compound according to the invention Rf, Rg and Rh independently represent hydrogen or (Ci-C ₂ ) alkyl .

In an embodiment of the compound according to the invention Z _lr Z ₂ Z ₃ and Z ₄ independently are CRi .

In an embodiment of the compound according to the invention Ri represents a bond, hydrogen, or alkoxy.

In an embodiment of the compound according to the invention Ri represents a bond, hydrogen or methoxy. In an embodiment according to the invention the compound of formula I is selected from :

4-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-indan-l-one (Compound 101) 4-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 102)

4- [2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-indan -l-one (Compound 103) 4- [2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy-phenyl ]-indan-l-one (Compound 104) 4-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-indan-l-one (Compound 105)4- [2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-benzamide (Compound 106)

4-[2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-pheny l]-indan-l-one

(Compound 107)

4-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-N-me thyl-benzamide

(Compound 108) 4-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]-N,N-dimethyl-benzamide (Compound 109)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-N,N- dimethyl-benzamide (Compound 110)

3- [2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-N,N-dimet hyl- benzenesulfonamide (Compound 111)

4- [2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-benzenesu lfonamide

(Compound 112)

4-[2-(3-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]- indan-l-one (Compound 113) 3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-benzami de (Compound 114)

4-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]- 3H-isobenzofuran-l-one (Compound 115) 4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-4-yl)-ph enoxymethyl]- benzamide (Compound 116)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-4-yl) -phenoxymethyl]-N-methyl- benzamide (Compound 117)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-4-yl) -phenoxymethyl]-N,N- dimethyl-benzamide (Compound 118) 4- [2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy-phenyl ]-3H-isobenzofuran- 1-one (Compound 119) 5-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-indan-l-one (Compound 120)

5- [2-(2,2-Dimethyl-propoxy)-3,4-dimethoxy-phenyl]-indan-l-one (Compound 121)

5-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-indan- 1-one (Compound 122)

5-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-indan- 1-one (Compound 123) 4-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]-benzami de (Compound 124)

5-[2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-pheny l]-indan- 1-one

(Compound 125) 4-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]-N-methy l-benzamide

(Compound 126)

4- [2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]-N,N-dimet hyl-benzamide (Compound 127)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]-N,N- dimethyl-benzamide (Compound 128)

5- [2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy-phenyl ]-indan- 1-one (Compound 129)

5-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-ind an- 1-one (Compound 130)

5-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-3H-isobenzof uran- 1-one (Compound 131)

5-[2-(2,2-Dimethyl-propoxy)-3,4-dimethoxy-phenyl]-3H-isob enzofuran-l-one

(Compound 132)

5-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-3H-isobenzofura n-l-one (Compound 133)

5-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy-phen yl]-3H-isobenzofuran- 1-one (Compound 134) 5-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-3H-isobenzo furan-l-one (Compound 135)

4- [2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-phen oxymethyl]- benzamide (Compound 136)

5- [2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-phenyl]-3H -isobenzofuran-l-one (Compound 137) 4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-ph enoxymethyl]-N-methyl- benzamide (Compound 138)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-ph enoxymethyl]-N,N- dimethyl-benzamide (Compound 139)

3- [2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-phen oxymethyl]-N,N- dimethyl-benzamide (Compound 140)

4- [2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-phen oxymethyl]- benzenesulfonamide (Compound 141) 5-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-3H- isobenzofuran-l-one (Compound 142)

5- [2-(3-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-3H-is obenzofuran-l-one (Compound 143)

3-[2 _/ 3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-p henoxymethyl]- benzenesulfonamide (Compound 144)

3-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl) -phenoxymethyl]-N,N- dimethyl-benzenesulfonamide (Compound 145)

3-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl) -phenoxymethyl]- benzamide (Compound 146) 5-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-2,3-dihydro-iso indol-l-one (Compound 147) 5-[2-(2,2-Dimethyl-propoxy)-3,4-dimethoxy-phenyl]-2,3-dihydr o-isoindol-l-one (Compound 148)

5-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-2,3-dihydro- isoindol-l-one (Compound 149)

5-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]- 2,3-dihydro-isoindol-l-one (Compound 150) 5-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy-phen yl]-2,3-dihydro- isoindol-l-one (Compound 151)

5-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-2,3-dihydro -isoindol-l-one

(Compound 152)

4- [2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)-phenox ymethyl]-benzamide (Compound 153)

5- [2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-phenyl]-2, 3-dihydro-isoindol-l- one (Compound 154) 4-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)-phen oxymethyl]-N-methyl- benzamide (Compound 155)

4- [2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)-phenox ymethyl]-N,N- dimethyl-benzamide (Compound 156)

3-[2 _/ 3-Dimethoxy-6-( l-oxo-2,3-dihydro-lH-isoindol-5-yl)-phenoxymethyl]-N,N- dimethyl-benzamide (Compound 157)

3-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)-phen oxymethyl]- benzenesulfonamide (Compound 158)

3-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)-p henoxymethyl]-benzamide (Compound 159)

5- [2-(3-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-2,3-d ihydro-i

soindol-l-one (Compound 160) 4-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)-phen oxymethyl]- benzenesulfonamide (Compound 161)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimeth yl-propionic acid methyl ester (Compound 162)

4-[3,4-Dimethoxy-2-(3-methyl-oxetan-3-ylmethoxy)-phenyl]-ind an-l-one (Compound 163) 4-[3,4-Dimethoxy-2-(3-methyl-oxetan-3-ylmethoxy)-phenyl]-3H- isobenzofuran-l-one (Compound 164)

3- [2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl-pr opionic acid methyl ester (Compound 165)

4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 166)

4- (2-Isobutoxy-3,4-dimethoxy-phenyl)-6,7-dimethoxy-indan-l-one (Compound 167)

4- (2-Isobutoxy-3,4-dimethoxy-phenyl)-7-methoxy-indan-l-one (Compound 168)

5- (2-Isobutoxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 169)

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-3H-isobenzofuran-l-o ne (Compound 170) 5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2,3-dimethyl-2,3-dihydr o-isoindol-l-one (Compound 171)

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2-methyl-2,3-dihydro -isoindol-l-one (Compound 172) 4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2,3-dihydro-isoindol-l- one (Compound 173) 5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2,3-dihydro-isoindol-l- one (Compound 174)

4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-3H-isobenzofuran-l-o ne (Compound 175) 6-(2-Isobutoxy-3,4-dimethoxy-phenyl)-benzofuran-3-one (Compound 176) 4-[2-( l-Hydroxymethyl-cyclopropylmethoxy)-3,4-dimethoxy-phenyl]-in dan-l-one (Compound 177)

4-[3,4-Dimethoxy-2-(l-methoxymethyl-cyclopropylmethoxy)-p henyl]-indan-l-one (Compound 178)

Ethyl-carbamic acid l-[2,3-dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]- cyclopropylmethyl ester (Compound 179) Isopropyl-carbamic acid l-[2,3-dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]- cyclopropylmethyl ester (Compound 180)

Benzyl-carbamic acid l-[2,3-dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- cyclopropylmethyl ester (Compound 181)

4-[2-(l-Aminomethyl-cyclopropylmethoxy)-3,4-dimethoxy-phe nyl]-indan-l-one (Compound 182)

N-{l-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-c yclopropylmethyl}- isobutyramide (Compound 183)

N-{l-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-c yclopropylmethyl}- butyramide (Compound 184) N-{ l-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-cyclopr opylmethyl}- acetamide (Compound 185)

{l-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-cyclop ropylmethyl}-carbamic acid ethyl ester (Compound 186) { l-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-cyclopr opylmethyl}-carbamic acid isopropyl ester (Compound 187)

{l-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-cyclop ropylmethyl}-carbamic acid 2-methoxy-ethyl ester (Compound 188) Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxetan- 3- ylmethyl ester (Compound 189) 4-[3,4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy)-phen yl]-indan-l-one (Compound 190)

4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy-phe nyl]-indan-l-one (Compound 191)

N-{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxet an-3-ylmethyl}- acetamide (Compound 192)

N-{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-o xetan-3-ylmethyl}- isobutyramide (Compound 193)

N-{3-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]-oxetan-3-ylmethyl}- butyramide (Compound 194)

N-{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-o xetan-3-ylmethyl}-2- methoxy-acetamide (Compound 195)

{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxe tan-3-ylmethyl}-carbamic acid ethyl ester (Compound 196) {3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxetan -3-ylmethyl>-carbamic acid isopropyl ester (Compound 197)

{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxe tan-3-ylmethyl}-carbamic acid 2-methoxy-ethyl ester (Compound 198)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimeth yl-propionic

acid (Compound 199)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2,N-trim ethyl-propion

amide (Compound 200)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-N-ethyl-2, 2-dimethyl-propionamide (Compound 201)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2,N,N-tetra methyl-propionamide (Compound 202)

N-Cyclopropyl-3-[2,3-dimethoxy-6-(l-oxo-indan-4-yl)-pheno xy]-2,2-dimethyl- propionamide (Compound 203) 4- [2-(2,2-Dimethyl-3-morpholin-4-yl-3-oxo-propoxy)-3,4-dimetho xy-phenyl]-indan-l- one (Compound 204)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimeth yl-propionic

acid (Compound 205)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2,N-trimeth yl-propion

amide (Compound 206)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2,N,N-te tramethyl-propionamide (Compound 207)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-N-isopropy l-2,2-dimethyl- propionamide (Compound 208)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- N-propyl-propionamide (Compound 209)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofura

n-5-yl)-phenoxy]-2,2-dimethyl-propyl ester (Compound 210) Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2

-dimethyl-propyl ester (Compound 211)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-

5- yl)-phenoxy]-2,2-dimethyl-propyl ester (Compound 212)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofura

n-5-yl)-phenoxymethyl]-oxetan-3-ylmethyl ester (Compound 213)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol- 5-yl)-phenoxymethyl]-oxetan-3-ylmethyl ester (Compound 214)

5-[3,4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy)-phen yl]-3H- isobenzofuran-l-one (Compound 215)

5-[3,4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy)-p henyl]-2,3-dihydro- isoindol-l-one (Compound 216) 4- [3,4-Dimethoxy-2-(3-methoxy-2,2-dimethyl-propoxy)-phenyl]-in dan-l-one

(Compound 217)

5- [3,4-Dimethoxy-2-(3-methoxy-2,2-dimethyl-propoxy)-phenyl]-3H -isobenzofuran-l- one (Compound 218)

5-[3,4-Dimethoxy-2-(3-methoxy-2,2-dimethyl-propoxy)-pheny l]-2,3-dihydro-isoindol-l- one (Compound 219)

3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5-yl)phen oxy)-2,2- dimethylpropanoic acid (Compound 220)

3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5-yl)p henoxy)-/V,2,2- trimethylpropanamide (Compound 221) 3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5-yl)phen oxy)-/V,/V,2,2- tetramethylpropanamide (Compound 222)

3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5-yl)p henoxy)-N-isopropyl-2,2- dimethylpropanamide (Compound 223)

3- (2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5-yl)phenox y)-2,2-dimethyl-N- propylpropanamide (Compound 224)

4- (4-Difluoromethoxy-2-ethoxy-3-methoxy-phenyl)-indan-l-one (Compound 225) 4-(4-Difluoromethoxy-3-methoxy-2-propoxy-phenyl)-indan-l-one (Compound 226)

4-(4-Difluoromethoxy-2-isobutoxy-3-methoxy-phenyl)-indan- l-one (Compound 227)

4-[4-Difluoromethoxy-2-(3-hydroxy-2,2-dimethyl-propoxy)-3 -methoxy-phenyl]-indan-l- one (Compound 228)

4-[4-Difluoromethoxy-3-methoxy-2-(3-methoxy-2,2-dimethyl- propoxy)-phenyl]-indan- 1-one (Compound 229)

4-[4-Difluoromethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethox y)-3-methoxy-phenyl]- indan-l-one (Compound 230

4-[4-Difluoromethoxy-3-methoxy-2-(3-methoxymethyl-oxetan-3-y lmethoxy)-phenyl]- indan-l-one (Compound 231) 4-[3-Difluoromethoxy-2-methoxy-6-(l-oxo-indan-4-yl)-phenoxym ethyl]- benzenesulfonamide (Compound 232) 4-[4-Difluoromethoxy-2-(4-methanesulfonyl-benzyloxy)-3-metho xy-phenyl]-indan-l- one (Compound 233)

4- ((3-(difluoromethoxy)-2-methoxy-6-(l-oxo-2,3-dihydro-lH-inde n-4- y!)phenoxy)methyl)benzamide (Compound 234)

5- (4-Difluoromethoxy-2-ethoxy-3-methoxy-phenyl)-3H-isobenzofur an-l-one (Compound 235)

5-(4-Difluoromethoxy-3-methoxy-2-propoxy-phenyl)-3H-isobe nzofuran-l-one

(Compound 236)

5-(4-Difluoromethoxy-2-isobutoxy-3-methoxy-phenyl)-3H-iso benzofuran-l-one

(Compound 237) 5-[4-Difluoromethoxy-2-(3-hydroxy-2,2-dimethyl-propoxy)-3-me thoxy-phenyl]-3H- isobenzofuran-l-one (Compound 238)

5-[4-Difluoromethoxy-3-methoxy-2-(3-methoxy-2,2-dimethyl- propoxy)-phenyl]-3H- isobenzofuran-l-one (Compound 239)

5-[4-Difluoromethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethox y)-3-methoxy-phenyl]- 3H~isobenzofuran-l-one (Compound 240)

4- [3-Difluoromethoxy-2-hydroxy-6-(l-oxo-l,3-dihydro-isobenzofu ran-5-yl)- phenoxymethyl]-benzenesulfonamide (Compound 241)

5- [4-Difluoromethoxy-3-hydroxy-2-(4-methanesulfonyl-benzyloxy) -phenyl]-3H- isobenzofuran-l-one (Compound 242)

5-(4-(difluoromethoxy)-3-methoxy-2-((3-(methoxymethyl)oxe tan-3- yl)methoxy)phenyi)isobenzofuran-l(3H)-one (Compound 243)

5-(4-(Difluoromethoxy)-2-ethoxy-3-methoxyphenyl)isoindoli n-l-one (Compound 244) 5-(4-(Difluoromethoxy)-3-methoxy-2-propoxyphenyl)isoindolin- l-one (Compound 245) 5-(4-(Difluoromethoxy)-2-isobutoxy-3-methoxyphenyl)isoindoli n-l-one (Compound 246)

5-[4-Difluoromethoxy-3-methoxy-2-(3-hydroxy-2,2-dimethyl- propoxy)-phenyl]-2,3- dihydro-isoindol-l-one (Compound 247)

5-[4-Difluoromethoxy-3-methoxy-2-(3-methyl-oxetan-3-ylmet hoxy)-phenyl]-2,3- dihydro-isoindol-l-one (Compound 248)

5-[4-Difluoromethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethox y)-3-methoxy-phenyl]- 2,3-dihydro-isoindol-l-one (Compound 249) 5-[4-Difluoromethoxy-3-methoxy-2-(3-methoxymethyl-oxetan-3-y lmethoxy)-phenyl]- 2,3-dihydro-isoindol-l-one (Compound 250)

4- [3-Difluoromethoxy-2-methoxy-6-(l-oxo-2,3-dihydro-lH-isoindo l-5-yl)- phenoxymethyl]-benzenesulfonamide (Compound 251)

5- [4-Difluoromet oxy-2-(4-methanesulfonyl-benzyloxy)-3-methoxy-p enyl]-2,3- dihydro-isoindol-l-one (Compound 252)

4-((3-(difluoromethoxy)-2-methoxy-6-(l-oxoisoindolin-5-yl )phenoxy)methyl)benzamide (Compound 253)

2-[3-Difluoromethoxy-2-methoxy-6-(l-oxo-2,3-dihydro-lH-is oindol-5-yl)-phenoxy]-N- propyl-acetamide (Compound 254)

4-(2,4-Diethoxy-3-methoxyphenyl)-2,3-dihydro-lH-inden-l-one

4-(4-Ethoxy-3-methoxy-2-propoxyphenyl)-2,3-dihydro-lH-ind en-l-one (Compound 256)

4-(4-Ethoxy-2-isobutoxy-3-methoxyphenyl)-2,3-dihydro-lH-i nden-l-one (Compound 257) 4-(4-Ethoxy-2-(3-hydroxy-2,2-dimethylpropoxy)-3-methoxypheny l)-2,3-dihydro-lH- inden-l-one (Compound 258)

4-(4-Ethoxy-3-methoxy-2-((3-methyloxetan-3-yl)methoxy)phe nyl)-2,3-dihydro-lH- inden-l-one (Compound 259)

4- (4-Ethoxy-2-((3-(hydroxymethyl)oxetan-3-yl)methoxy)-3-methox yphenyl)-2,3- dihydro-lH-inden-l-one (Compound 260) 4-(4-Ethoxy-3-methoxy-2-(4-(methylsulfonyl)benzyloxy)p enyl)-2,3-dihydro-lH-inden- 1-one (Compound 261)

5- (2,4-Diethoxy-3-methoxyphenyl)isobenzofuran-l(3H)-one (Compound 262) 5-(4-Ethoxy-2-isobutoxy-3-methoxyphenyl)isobenzofuran-l(3H)- one (Compound 264)

5-(4-Ethoxy-2-(3-hydroxy-2,2-dimethylpropoxy)-3-methoxyph enyl)isobenzofuran- l(3H)-one (Compound 265) 5-(4-Ethoxy-3-methoxy-2-((3-methyloxetan-3-yl)methoxy)phenyl )isobenzofuran-l(3H)- one (Compound 266)

5-[4-Ethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethoxy)-3-meth oxy-phenyl]-3H- isobenzofuran-l-one (Compound 267)

5-(4-Ethoxy-3-methoxy-2-(4-(methylsulfonyl)benzyloxy)phen yi)isobenzofuran-l(3H)- one (Compound 268)

4-(3-Ethoxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l-o ne (Compound 269)

4-(2,4-Dimethoxy-3-propoxyphenyl)-2,3-dihydro-lH-inden-l- one (Compound 270)

4-(3-Isobutoxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden- l-one (Compound 271) 4-[3-(3-Hydroxy-2,2-dimethyl-propoxy)-2,4-dimethoxy-phenyl]- indan-l-one

(Compound 272) 4-(2,4-Dimethoxy-3-((3-methyloxetan-3-yl)methoxy)phenyl)-2,3 -dihydro-lH-inden-l- one (Compound 273)

4-(3-((3-(Hydroxymethyl)oxetan-3-yl)methoxy)-2,4-dimethox yphenyl)-2,3-dihydro-lH- inden-l-one (Compound 274)

4-[2,4-Dimethoxy-3-(3-methoxymethyl-oxetan-3-ylmethoxy)-p henyl]-indan-l-one (Compound 275) 4-[2,6-Dimethoxy-3-(l-oxo-indan-4-yl)-phenoxymethyl]-benzene sulfonamide

(Compound 276)

4- (2,4-Dimethoxy-3-(4-(methylsulfonyl)benzyloxy)phenyl)-2,3-di hydro-lH-inden-l-one (Compound 277)

5- (3-Ethoxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (Compound 278) 5-(2,4-Dimethoxy-3-propoxy-phenyl)-3H-isobenzofuran-l-one (Compound 279) 5-(3-Isobutoxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (Compound 280)

5-[2,4-Dimethoxy-3-(3-methyl-oxetan-3-ylmethoxy)-phenyl]- 3H-isobenzofuran-l-one (Compound 281) 5-(3-((3-(hydroxymethyl)oxetan-3-yl)methoxy)-2,4-dimethoxyph enyl)isobenzofuran- l(3H)-one (Compound 282)

5-[2,4-Dimethoxy-3-(3-methoxymethyl-oxetan-3-ylmethoxy)-p henyl]-3H- isobenzofuran-l-one (Compound 283)

4- [2,6-Dimethoxy-3-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-phen oxymethyl]- benzenesulfonamide (Compound 284)

5- (2,4-dimethoxy-3-(4-(methylsulfonyl)benzyloxy)phenyl)isobenz ofuran-l(3H)-one (Compound 285) 4-[2,6-Dimethoxy-3-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-ph enoxymethyl]- benzamide (Compound 286)

4-(3-Difluoromethoxy-2-ethoxy-4-methoxy-phenyl)-indan-l-o ne (Compound 287)

4-(3-Difluoromethoxy-4-methoxy-2-propoxy-phenyl)-indan-l- one (Compound 288)

4-(3-Difluoromethoxy-2-isobutoxy-4-methoxy-phenyi)-indan- l-one (Compound 289) 4-[3-Difluoromethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethoxy)- 4-methoxy-phenyl]- indan-l-one (Compound 290)

4-[3-Difluoromethoxy-4-methoxy-2-(3-methoxymethy!-oxetan- 3-ylmethoxy)-phenyl]- indan-l-one (Compound 291)

4-[2-Difluoromethoxy-3-methoxy-6-(l-oxo-indan-4-yl)-pheno xymethyl]- benzenesulfonamide (Compound 292)

4- [3-Difluoromethoxy-2-(4-methanesulfonyl-benzyloxy)-4-methoxy -phenyl]-indan-l- one (Compound 293)

5- (3-Difluoromethoxy-2-ethoxy-4-methoxy-phenyl)-3H-isobenzofur an- l-one (Compound 294) 5-(3-Difluoromethoxy-4-methoxy-2-propoxy-phenyl)-3H-isobenzo furan-l-one

(Compound 295)

5-(3-Difluoromethoxy-2-isobutoxy-4-methoxy-phenyl)-3H-iso benzofuran-l-one

(Compound 296)

5-[3-Difluoromethoxy-4-methoxy-2-(3-methyl-oxetan-3-ylmet hoxy)-phenyl]-3H- isobenzofuran-l-one (Compound 297)

5-[3-Difluoromethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethox y)-4-methoxy-phenyl]- 3H-isobenzofuran-l-one (Compound 298) 5-[3-Difluoromethoxy-4-methoxy-2-(3-methoxymethyl-oxetan-3-y lmethoxy)-phenyl]- 3H-isobenzofuran-l-one (Compound 299)

4- ((2-(difluoromethoxy)-3-methoxy-6-(l-oxo-l _; 3-dihydroisobenzofuran-5- yl)phenoxy)methyl)benzenesulfonamide (Compound 400)

5- (3-(difluoromethoxy)-4-methoxy-2-(4-

(methylsulfonyl)benzyloxy)phenyl)isobenzofuran-l(3H)-one (Compound 401) 4-((2-(difluoromethoxy)-3-methoxy-6-(l-oxo-l,3-dihydroisoben zofuran-5- yl)phenoxy)methyl)benzamide (Compound 402)

4-(3-Cyclopropylmethoxy-2-ethoxy-4-methoxy-phenyl)-indan- l-one (Compound 403) 4-(3-Cyclopropylmethoxy-4-methoxy-2-propoxy-phenyl)-indan-l- one (Compound 404)

4-(3-Cyclopropylmethoxy-2-isobutoxy-4-methoxy-phenyl)-ind an-l-one (Compound 405)

4-[3-Cyclopropylmethoxy-4-methoxy-2-(3-methyl-oxetan-3-yl methoxy)-phenyl]-indan- 1-one (Compound 406)

4-[3-Cyclopropylmethoxy-2-(3-hydroxymethyl-oxetan-3-ylmet hoxy)-4-methoxy- phenyl]-indan-l-one (Compound 407) 4-[3-Cyclopropylmethoxy-4-methoxy-2-(3-methoxymethyl-oxetan- 3-ylmethoxy)- phenyl]-indan-l-one (Compound 408)

4- [3-Cyclopropylmethoxy-2-(4-methanesulfonyl-benzyloxy)-4-meth oxy-phenyl]-indan-

1- one (Compound 409)

2- [2-Cyclopropylmethoxy-3-methoxy-6-(l-oxo-indan-4-yl)-phenoxy ]-N-propyl- acetamide (Compound 410)

5- (3-Cyclopropylmethoxy-2-ethoxy-4-methoxy-phenyl)-3H-isobenzo furan-l-one

(Compound 411) 5-(3-Cyclopropylmethoxy-4-methoxy-2-propoxy-phenyl)-3H-isobe nzofuran-l-one (Compound 412)

5-(3-Cyclopropylmethoxy-2-isobutoxy-4-methoxy-phenyl)-3H- isobenzofuran-l-one (Compound 413)

5-[3-Cyclopropylmethoxy-4-methoxy-2-(3-methyl-oxetan-3-yl methoxy)-phenyl]-3H- isobenzofuran-l-one (Compound 414) 5-[3-Cyclopropylmethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethox y)-4-methoxy- phenyl]-3H-isobenzofuran-l-one (Compound 415)

5-[3-Cyclopropylmethoxy-4-methoxy-2-(3-methoxymethyl-oxet an-3-ylmethoxy)- phenyl]-3H-isobenzofuran-l-one (Compound 416)

5-[3-Cyclopropylmethoxy-2-(4-methanesulfonyl-benzyloxy)-4 -methoxy-phenyl]-3H- isobenzofuran-l-one (Compound 417)

2-(2-(Cyclopropylmethoxy)-3-methoxy-6-(l-oxo-l,3-dihydroi sobenzofuran-5- yl)phenoxy)-N-propylacetamide (Compound 418)

5-(3-(cyclopropylmethoxy)-2,4-dimethoxyphenyl)-2,3-dihydr o-lH-inden-l-one (Compound 419) 5-(3-(cyclopropylmethoxy)-2,4-dimethoxyphenyl)isobenzofuran- l(3H)-one (Compound 420)

Methyl 3-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4-yl)phenoxy]-2,2 -dimethyl- propanoate (Compound 421)

Methyl 3-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2 -dimethyl- propanoate, (Compound 422)

[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenyl] propanoate

[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenyl] cyclopropanecarboxylate ,3-dimethoxy-6- l-oxoindan-4-y phenyl 2-methylpropanoate

,3-dimethoxy-6- l-oxoindan-4-y phenyl butanoate

,3-dimethoxy-6- l-oxoindan-4-y phenyl cyclobutanecarboxylate,3-dimethoxy-6- l-oxoindan-4-y phenyl 2-methylbutanoate

,3-dimethoxy-6- l-oxoindan-4-y phenyl 3-methylbutanoate

,3-dimethoxy-6- l-oxoindan-4-y phenyl pentanoate

,3-dimethoxy-6- l-oxoindan-4-y phenyl cyclopentanecarboxylate,3-dimethoxy-6- l-oxoindan-4-y phenyl hexanoate

,3-dimethoxy-6- l-oxoindan-4-y phenyl 2-ethylbutanoate

,3-dimethoxy-6- l-oxoindan-4-y phenyl 3,3-dimethylbutanoate,3-dimethoxy-6- l-oxoindan-4-y phenyl 3-methylsulfanylpropanoate,3-dimethoxy-6- l-oxoindan-4-y phenyl 3,3,3-trifluoropropanoate,3-dimethoxy-6- l-oxoindan-4-y phenyl cyclohexanecarboxylate,3-dimethoxy-6- l-oxoindan-4-y phenyl 2-cyclopentylacetate,3-dimethoxy-6- l-oxoindan-4-y phenyl 2-(2-methoxyethoxy)acetate,3-dimethoxy-6- l-oxoindan-4-y phenyl 3-cyclopentylpropanoate,3-dimethoxy-6- l-oxoindan-5-y phenyl acetate

,3-dimethoxy-6- l-oxoindan-5-y phenyl cyclopropanecarboxylate,3-dimethoxy-6- l-oxoindan-5-y phenyl butanoate 2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 2-methylpropanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl cyclobutanecarboxylate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl pentanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 3-methylbutanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 2-methylbutanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl cyclopentanecarboxylate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 2-ethylbutanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl hexanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 3,3-dimethylbutanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 3-methylsulfanylpropanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 3,3,3-trifluoropropanoate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl cyclohexa neca rboxylate

2 _/ 3-dimethoxy-6- l-oxoindan-5-y )phenyl 2-cyclopentylacetate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 2-(2-methoxyethoxy)acetate

2,3-dimethoxy-6- l-oxoindan-5-y )phenyl 3-cyclopentylpropanoate

2,3-dimethoxy-6- l-oxo-3H-isobenzofuran-4-yl)phenyl] propanoate

2,3-dimethoxy-6- l-oxo-3H-isobenzofuran-4-yl)phenyl]

cyclopropanecarboxylate

2,3-dimethoxy-6- l-oxo-3H-isobenzofuran-4-yl)phenyl] butanoate [2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl 2- methylpropanoate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl cyclobutanecarboxylate [2,3-dimethoxy-6' l-oxo-3H-isobenzofuran-4-yl)phenyl ^' pentanoate

[2,3-dimethoxy-6- l-oxo-3H-isobenzofuran-4-yl)phenyl 3- methylbutanoate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl cyclopentanecarboxylate [2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl 3,3-dimethylbutanoate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl hexanoate

[2,3-dimethoxy-6' l-oxo-3H-isobenzofuran-4-yl)phenyl 2- ethylbutanoate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl 3- methylsulfanylpropanoate [2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl cyclohexanecarboxylate [2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl 2-cyclopentylacetate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl 2- (2-methoxyethoxy)acetate [2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-4-yl)phenyl 3- cyclopentylpropanoate [2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-5-yl)phenyl acetate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-5-yl)phenyl cyclopropanecarboxylate [2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-5-yl)phenyl butanoate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-5-yl)phenyl 2-methylpropanoate

[2,3-dimethoxy-6 l-oxo-3H-isobenzofuran-5-yl)phenyl cyclobutanecarboxylate ,3-dimethoxy-6- l-oxo-3H-isobenzofuran-5-yl)phenyl] 3-methylbutanoate

,3-dimethoxy-6- l-oxo-3H-isobenzofuran-5-yl)phenyl] pentanoate

,3-dimethoxy-6- -3H-isobenzofuran-5-yl)phenyl] 2-methylbutanoate

,3-dimethoxy-6- -3H-isobenzofuran-5-yl)phenyl] 3,3-dimethylbutanoate,3-dimethoxy-6- l-oxo-3H-isobenzofuran-5-yl)phenyl] 2-ethylbutanoate

,3-dimethoxy-6- l-oxo-3H-isobenzofuran-5-yl)phenyl] 3-methylsulfanylpropanoate,3-dimethoxy-6- l-oxo-3H-isobenzofuran-5-yl)phenyl] 2-(2-methoxyethoxy)acetate,3-dimethoxy-6- l-oxo-3H-isobenzofuran-5-yl)phenyl] 3-cyclopentylpropanoate,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] 2-methylpropanoate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] cyclobutanecarboxylate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] pentanoate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] 3-methylbutanoate

,3-dimethoxy-6- l-oxoisoindolin-5-y nyl] 2-methylbutanoate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] cyclopentanecarboxylate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] hexanoate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] 3,3-dimethylbutanoate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] 2-ethylbutanoate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] cyclohexanecarboxylate

,3-dimethoxy-6- l-oxoisoindolin-5-y )phenyl] 3-cyclopentylpropanoate methyl (2R)-3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2-methyl-p ropanoate methyl (2S)-3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2-methyl-p ropanoate methyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclopro panecarboxylate ethyl (2S)-3-[2,3-dimethoxy-6-(l-oxoindan-4-y!)phenoxy]-2-methyl-p ropanoate ethyl (2R)-3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2-methyl-p ropanoate ethyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclopro panecarboxylate methyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclobut anecarboxylate ethyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-pr opanoate propyl (2R)-3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2-methyl- propanoate propyl (2S)-3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2-methyl-p ropanoate isopropyl (2S)-3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2-methyl-p ropanoate isopropyl (2R)-3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2-methyl-p ropanoate propyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclopro panecarboxylate ethyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclobut anecarboxylate isopropyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate propyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-pr opanoate isopropyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate cyclobutyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate isobutyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate propyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclobut anecarboxylate butyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclopro panecarboxylate cyclobutyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-pr opanoate isopropyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate butyl 3-[2,3-dimethoxy-6-( l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-propanoate isobutyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-pr opanoate

3-fluoropropyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate cyclobutyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]met yl]cyclobutanecarboxylate cyclopentyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate cyclobutylmethyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate cyclopentyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-pr opanoate cyclobutylmethyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

1-ethylpropyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate butyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclobut anecarboxylate 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate isobutyl l-[[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]methyl]cyclobut anecarboxylate

2,2-dimethylpropyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate 1-ethylpropyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-pr opanoate

(1-cyano-l-methyl-ethyl) l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate cyclohexyl l-[[2,3-dimethoxy-6-( l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate cyclopentyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

1-ethylpropyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate cyclohexyl 3-[2,3-dimethoxy-6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl-pr opanoate and cyclohexyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

In one or more embodiments of the present invention, the compounds of formula I as defined above are useful in therapy and in particular useful for the prophylaxis, treatment or amelioration of dermal diseases. In one or more embodiments of the present invention, the dermal disease or condition is selected from proliferative and inflammatory skin disorders, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis, and eczema.

The compounds of formula I may be obtained in crystalline form either directly by concentration from an organic solvent or by crystallisation or recrystallisation from an organic solvent or mixture of said solvent and a cosolvent that may be organic or inorganic, such as water. The crystals may be isolated in essentially solvent-free form or as a solvate, such as a hydrate. The invention covers all crystalline forms, such as polymorphs and pseudopolymorphs, and also mixtures thereof.

Compounds of formula I may or may not comprise asymmetrically substituted (chiral) carbon atoms which give rise to the existence of isomeric forms, e.g. enantiomers and possibly diastereomers. The present invention relates to all such isomers, either in pure form or as mixtures thereof (e.g. racemates). Pure stereoisomeric forms of the compounds and the intermediates of this invention may be obtained by the application of procedures known in the art. The various isomeric forms may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. liquid chromatography using chiral stationary phases. Enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active amines, such as l-ephedrine. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereoisomeric forms may also be derived from the corresponding pure stereoisomeric forms of the appropriate starting materials, provided that the reaction occurs

stereoselectively or stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereoselective or stereospecific methods of preparation. These methods will advantageously employ chiral pure starting materials.

Compounds of the present invention, optionally in combination with other active compounds, would be useful for the treatment of dermal diseases or conditions, or acute or chronic cutaneous wound disorders, in particular for the treatment of proliferative and inflammatory skin disorders, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis, and eczema. Besides being useful for human treatment, the compounds of the present invention may also be useful for veterinary treatment of animals including mammals such as horses, cattle, sheep, pigs, dogs, and cats.

For use in therapy, compounds of the present invention are typically in the form of a pharmaceutical composition. The invention therefore relates to a pharmaceutical composition comprising a compound of formula I, optionally together with one or more other therapeutically active compound(s), together with a pharmaceutically acceptable excipient, vehicle or carrier(s). The excipient must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

Conveniently, the active ingredient comprises from 0.05-99.9% by weight of the formulation.

In the form of a dosage unit, the compound may be administered one or more times a day at appropriate intervals, always depending, however, on the condition of the patient, and in accordance with the prescription made by the medical practitioner. Conveniently, a dosage unit of a formulation contain between 0.1 mg and 1000 mg, preferably between 1 mg and 100 mg, such as 5-50 mg of a compound of formula I.

A suitable dosage of the compound of the invention will depend, inter alia, on the age and condition of the patient, the seventy of the disease to be treated and other factors well known to the practising physician. The compound may be administered either orally, parenterally or topically according to different dosing schedules, e.g. daily or with weekly intervals. In general a single dose will be in the range from 0.01 to 400 mg/kg body weight. The compound may be administered as a bolus (i.e. the entire daily dosis is administered at once) or in divided doses two or more times a day.

In the context of topical treatment it may be more appropriate to refer to a "usage unit", which denotes a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers. The term "usage unit" in connection with topical use means a unitary, i.e. a single dose, capable of being administered topically to a patient in an application per square centimetre of the infected area of from 0.1 mg to 10 mg and preferably from 0.2 mg to 1 mg of the active ingredient in question.

It is also envisaged that in certain treatment regimes, administration with longer intervals, e.g. every other day, every week, or even with longer intervals may be beneficial. If the treatment involves administration of another therapeutically active compound it is recommended to consult Goodman & Gilman's The Pharmacological Basis of

Therapeutics, 9 ^th Ed., J.G. Hardman and L.E. Limbird (Eds.), McGraw-Hill 1995, for useful dosages of said compounds. The administration of a compound of the present invention with one or more other active compounds may be either concomitantly or sequentially.

The formulations include e.g. those in a form suitable for oral (including sustained or timed release), rectal, parenteral (including subcutaneous, intraperitoneal,

intramuscular, intraarticular and intravenous), transdermal, ophthalmic, topical, nasal or buccal administration.

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy, e.g. as disclosed in Remington, The Science and Practice of Pharmacy, 21ed ed., 2005. All methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid, such as ethanol or glycerol; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. Such oils may be edible oils, such as e.g. cottonseed oil, sesame oil, coconut oil or peanut oil. Suitable dispersing or suspending agents for aqueous suspensions include synthetic or natural gums such as tragacanth, alginate, acacia, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose, hydroxypropylmethylceilulose, hydroxypropylcellulose, carbomers and polyvinylpyrrolidone. The active ingredients may also be administered in the form of a bolus, electuary or paste.

A tablet may be made by compressing or moulding the active ingredient optionally with one or more accessory ingredients. Compressed tablets may be prepared by

compressing, in a suitable machine, the active ingredient(s) in a free-flowing form such as a powder or granules, optionally mixed by a binder, such as e.g. lactose, glucose, starch, gelatine, acacia gum, tragacanth gum, sodium alginate, carboxymethylcellulose, methylcellulose, hydroxypropylmethylceilulose, polyethylene glycol, waxes or the like; a lubricant such as e.g. sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride or the like; a disintegrating agent such as e.g. starch, methylcellulose, agar, bentonite, croscarmellose sodium, sodium starch glycollate, crospovidone or the like or a dispersing agent, such as polysorbate 80.

Moulded tablets may be made by moulding, in a suitable machine, a mixture of the powdered active ingredient and suitable carrier moistened with an inert liquid diluent. Formulations for rectal administration may be in the form of suppositories in which the compound of the present invention is admixed with low melting water soluble or insoluble solids such as cocoa butter, hydrogenated vegetable oils, polyethylene glycol or fatty acids esters of polyethylene glycols, while elixirs may be prepared using myristyl palmitate.

Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredients, which is preferably isotonic with the blood of the recipient, e.g. isotonic saline, isotonic glucose solution or buffer solution. The formulation may be conveniently sterilised by for instance filtration through a bacteria retaining filter, addition of sterilising agent to the formulation, irradiation of the formulation or heating of the formulation. Liposomal formulations as disclosed in e.g. Encyclopedia of Pharmaceutical Technology, vol.9, 1994, are also suitable for parenteral administration. Alternatively, the compounds of formula I may be presented as a sterile, solid

preparation, e.g. a freeze-dried powder, which is readily dissolved in a sterile solvent immediately prior to use. Transdermal formulations may be in the form of a plaster or a patch.

Formulations suitable ophthalmic administration may be in the form of a sterile aqueous preparation of the active ingredients, which may be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems e.g. as disclosed in Encyclopedia of Pharmaceutical Technology, vol.2, 1989, may also be used to present the active ingredient for ophthalmic administration.

Formulations suitable for topical or ophthalmic administration include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops. Compositions for ophthalmic treatment may preferably additionally contain a cyclodextrin.

For topical administration, the compound of formula I may typically be present in an amount of from 0.01 to 20% by weight of the composition, such as 0.1% to about 10 %, but may also be present in an amount of up to about 50% of the composition.

Formulations suitable for nasal or buccal administration include powder, self-propelling and spray formulations, such as aerosols and atomisers. Such formulations are disclosed in greater detail in e.g. Modern Pharmaceutics, 2 ^nd ed., G.S. Banker and C.T. Rhodes (Eds.), page 427-432, Marcel Dekker, New York; Modern Pharmaceutics, 3 ^th ed., G.S. Banker and C.T. Rhodes (Eds.), page 618-619 and 718-721, Marcel Dekker, New York and Encyclopedia of Pharmaceutical Technology, vol. 10, J. Swarbrick and J.C. Boylan (Eds), page 191-221, Marcel Dekker, New York.

In addition to the aforementioned ingredients, the formulations of a compound of formula I may include one or more additional ingredients such as diluents, buffers, flavouring agents, colourant, surface active agents, thickeners, preservatives, e.g.

methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.

When the active ingredient is administered in the form of salts with pharmaceutically acceptable non-toxic acids or bases, preferred salts are for instance easily water-soluble or slightly soluble in water, in order to obtain a particular and appropriate rate of absorption. The pharmaceutical composition may additionally comprise one or more other active components conventionally used in the treatment of dermal disease or conditions, e.g. selected from the group consisting of proliferative and inflammatory skin disorders, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis, and eczema.

Examples of such additional active components may for example be selected from the group consisting of glucocorticoids, vitamin D and vitamin D analogues, antihistamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methylxanthines, β- adrenergic agents, COX-2 inhibitors, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol lowering agents, retinoids, zinc salts and salicylazosulfapyridine. METHODS OF PREPARATION

The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of synthesis. The compounds of formula I may for example be prepared using the reactions and techniques outlined below together with methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are carried out in solvents appropriate to the reagents and materials employed and suitable for the transformations being effected. Also, in the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction

temperature, duration of experiment and work-up procedures, are chosen to be conditions of standard for that reaction, which should be readily recognized by one skilled in the art. Not all compounds falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods can be used. The compounds of the present invention or any intermediate may be purified if required using standard methods well known to a synthetic organist chemist, e.g. methods described in "Purification of Laboratory Chemicals", 5 ^th ed. 2003. Starting materials are either known compounds, commercially available, or they may be prepared by routine synthetic methods well known to a person skilled in the art.

GENERAL PROCEDURES, PREPARATIONS AND EXAMPLES H nuclear magnetic resonance (NMR) spectra were recorded at 300 MHz or 600MHz and ¹³ C NMR spectra at 75.6 MHz or 151 MHz. Chemical shift values (δ, in ppm) are quoted in the specified solvent relative to internal tetramethylsilane (δ = 0.00) or chloroform (δ = 7.25) or deuteriochloroform (δ = 76.81 for ¹³ C NMR) standards. The value of a multiplet, either defined (doublet (d), triplet (t), quartet (q)) or not (m) at the approximate mid point is given unless a range is quoted, (bs) indicates a broad singlet. The organic solvents used were usually anhydrous. Chromatography was performed on Merck silica gel 60 (0.040 - 0-063 mm). The solvent ratios indicated refer to v:v unless otherwise noted.

The following abbreviations have been used throughout:

Bu butyl

DCM dichloromethane

DMF Λ/,Λ/'-Dimethylformamide

DMSO dimethyl sulfoxide

EDC.HCI l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

Et ethyl

HOAt l-Hydroxy-7-azabenzotriazole

L litre

m milli

Me methyl

NMR nuclear magnetic resonance

PCy ₃ tricyclohexylphosphine

PdCI ₂ (dppf) ₂ [Dichloro-l-l'-bis(diphenylphosphino)ferrocene]palladium(II)

Pd ₂ (dba) ₃ Di-Palladium-tris(dibenzylideneacetone)

Pet ether Petroleum ether

Ph Phenyl

RT room temperature

THF tetrahydrofuran

v volume

Preparative HPLC/MS

Preparative HPLC/MS was performed on a Dionex APS-system with two Shimadzu PP150 prep, pumps and a Thermo MSQ Plus mass spectrometer. Column: Waters XTerra C-18, 150 mm x 19 mm, 5 pm; solventsystem : A = water (0.1 % formic acid) and B = acetonitrile (0.1 % formic acid); flow rate = 18 mL/min; method (10 min) : Linear gradient method going from 10 % B to 100 % B in 6 minutes and staying at 100 % B for another 2 minutes. The fractions were collected based on ion traces of relevant ions and PDA signal (240-400 nm).

Analytical UPLC/MS

Analytical UPLC/MS was performed on a system consisting of a Waters Premier XE mass spectrometer.

Column : Waters Acquity UPLC HSS T3 1.8μηη ; 2.1 x 50mm.

Solvent system : A: 10mM Ammonium acetate + 0.1% HCOOH; B: CH3CN + 0.1% HCOOH.

Flow rate 0.7 mL/min.

Method (4.8 min) : 0.0 min : 99% A and 1% B, 0.5 min : 94% A and 6% B, 1.0 min 94% A and 6% B, 2.6 min : 5% A and 95% B, 3.8 min : 5% A and 95% B, 3.81 min : 99% A and 1% B, 4.8min : 99% A and 1% B.

Column Temp: 40C.

General Methods and Examples:

The compounds of the invention may for example be prepared according to the following non-limiting general methods and examples. Rl, Rl, R3, X, Y and Zi-Z ₄ are as previously defined for the compounds of Formula I

Scheme 1

Method A:

Reaction of compounds of general formula a with halogenating agents such as Br _2/ NBS, I ₂ or NIS in a suitable solvent such as, but not limited to THF, DMF or HOAc at e.g minus 78°C to reflux to yield compounds of the general formula b. Reaction of compounds of general formula b with suitable alkyl or alkenyl chlorides, bromides, iodides, mesylates or tosylates in the presence of a suitable base, such as K ₂ C0 ₃ , NaOH or NaH in a suitable solvent such as CH ₃ CN, DMSO or DMF at temperatures from room temperature to 180°C (see also Protective Groups in Organic Chemistry, John Wiley & sons, Ed : T. Greene and P. G. Wuts, 3 ^rd edition ( 1999), p 249-72), or by reaction with suitable alcohols, e.g. alkyl alcohols, using Mitsunobu conditions (see Synthesis (1981), 1 ; Tet. Lett. (1993), 34, 1639-42 and Eur. J. Org. Chem. (2004), 2763-72), in a suitable solvent such as THF, benzene or DMF to yield compounds of the general formula c.

Reaction of a halogenide of the general formula c with a borylating agent to yield boronic acids or boronic acid esters of the general formula d. This may be accomplished by cross-coupling with a diboron, e.g. bis(pinacolato)diboron in the presence of a Pd catalyst such as PdCI ₂ (dppf) or Pd ₂ (dba) ₃ /PCy ₃ and in the presence of a suitable base such as KOAc in a suitable solvent such as 1,4-dioxan, THF or DMF at temperatures from room temperature to 180°C to yield boronic acid esters of the general formula d. (See Hall, D.G: Boronic Acids: Preparation, Applications in Organic Synthesis and Medicines, Wiley-VCH 2005, p 102-105). This may also be accomplished by transmetallation of c, with e.g n-butyllithium and trapping the arylmetal intermediate with a borate ester such as trimethyl borate in a suitable solvent such as THF at temperatures from -78°C to room temperature. The boronic acid ester may be hydrolysed to the corresponding boronic acid by reaction with aqueous HCI or aqueous NH ₄ CI to yield boronic acids of the general formula d. (See Hall, D.G : Boronic Acids: Preparation, Applications in Organic Synthesis and Medicines, Wiley-VCH 2005, p. 28-33)

Reaction of boronic acids or boronic acid esters of the general formula d with a halogenide h under Suzuki coupling conditions using a suitable catalyst (e.g.

tetrakistriphenylphosphinepalladium or Pd ₂ (dba) ₃ /PCy ₃ ), and a suitable base, such as cesium carbonate, potassium carbonate, sodium hydroxide, triethylamine, K ₃ P0 ₄ in a suitable solvent such as but not limited to DMF, NMP, 1,2-dimethoxyethane, THF, 1,4- dioxane, water or a mixture two or more of these, at temperatures from e.g. minus 78°C to 180°C to yield compounds of the general formula I. (For a general review on Suzuki coupling see Suzuki, A. in Hall, D.G : Boronic Acids: Preparation, Applications in Organic Synthesis and Medicines, Wiley-VCH 2005, p. 123 - 170)

Method B: Reaction of halogenides of the general formula c with boronic acids or boronic acid ester of the general formula j under Suzuki coupling conditions to yield compounds of the general formula I. Method C:

Reaction of halogenides of the general formula b with boronic acids or boronic acid ester of the general formula j under Suzuki coupling conditions to yield compounds of the general formula g, wherein R' is hydrogen. Reaction of compounds of general formula g with suitable alkyl or alkenyl chlorides, bromides, iodides, mesylates or tosylates in the presence of a suitable base, such as K ₂ C0 ₃ , NaOH or NaH in a suitable solvent such as CH ₃ CN, DMSO or DMF at temperatures from room temperature to 180°C, or by reaction with suitable alcohols, e.g. alkyl alcohols, using Mitsunobu conditions, in a suitable solvent such as THF, benzene or DMF to yield compounds of the general formula I.

Method D :

Protection of the phenol moiety of compounds of the general formula b with a suitable protecting group, such as but not limited to, methoxymethyl, by reaction with

methoxymethyl bromide in the presence of a suitable base such as triethyl amine in a suitable solvent such as methylene chloride (see Protective Groups in Organic Chemistry, John Wiley & sons, Ed : T. Greene and P. G. Wuts, 3 ^rd edition (1999), p 249-72), to yield compounds of the general formula e. Reaction of halogenides of the general formula e with a borylating agent to yield compounds of the general formula f. This may be accomplished by transmetallation of e, with e.g n-butyllithium and trapping the arylmetal intermediate with a borate ester such as trimethyl borate in a suitable solvent such as THF at temperatures from -78°C to room temperature. The boronic acid ester may be hydrolysed to the corresponding boronic acid by reaction with aqueous HCI or aqueous NH ₄ CI to yield boronic acids of the general formula f.

Reaction of boronic acids or boronic acid ester of the general formula f with a halogenide h under Suzuki coupling conditions to yield compounds of the general formula g, wherein R' is a protecting group. Removal of the protecting group to yield compounds of the general formula g, wherein R' is hydrogen may be accomplished by treating the methoxymethyl protected compound with HCI in MeOH (see also Protective Groups in Organic Chemistry, John Wiley & sons, Ed : T. Greene and P. G. Wuts, 3 ^rd edition (1999), p 249-72).

Reaction of compounds of general formula g wherein R' is hydrogen with suitable alkyl or alkenyl chlorides, bromides, iodides, mesylates or tosylates in the presence of a suitable base, such as K ₂ C0 ₃ , NaOH or NaH in a suitable solvent such as CH ₃ CIM, DMSO or DMF at temperatures from room temperature to 180°C, or by reaction with suitable alcohols, e.g. alkyl alcohols, using Mitsunobu conditions, in a suitable solvent such as THF, benzene or DMF to yield compounds of the general formula I.

The boronic acid esters of the general formula j may be synthesised from the halogenide h by cross-coupling with a diboron, e.g. bis(pinacolato)diboron in the presence of a Pd catalyst such as PdCI ₂ (dppf) or Pd ₂ (dba) ₃ /PCy ₃ and in the presence of a suitable base such as KOAc in a suitable solvent such as 1,4-dioxan, THF or DMF at temperatures from room temperature to 180°C.

Preparation 1

3 4-dimethoxy-2-imethoxymethynphenylboronic acid (compound 301)

To a stirring solution of 2,3-dimethoxy-phenol (6 g, 38.70 mmol) in tetrahydrofuran (30 ml.) at 25°C, was added N-bromosuccinimide (6.89 g, 38.70 mmol) and the resultant reaction mixture was stirred at RT for 1 h. The reaction mixture was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 6-Bromo-2,3-dimethoxyphenol as a solid.

To a stirring solution of 6-bromo-2,3-dimethoxyphenol (1 g, 4.31 mmol) in

dichloromethane (20 mL) at 0°C, were added triethyl amine (1.7 mL, 17.47 mmol) and methoxymethyl bromide (0.4 mL, 3.44 mmol) and the resultant reaction mixture was stirred at RT for 1 h. The reaction mixture was quenched with ice water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) afforded l-Bromo-3,4-dimethoxy-2-methoxymethoxy-benzene as a liquid.

To a stirring solution of l-bromo-3,4-dimethoxy-2-methoxymethoxy-benzene (1 g, 3.62 mmol) in tetrahydrofuran (15 mL) at -78°C, was added n-butyllithium (5.5 mL, 7.24 mmol) and stirred for 20 min to this trimethylborate (3.76 g, 36.23 mmol) was added and the resultant reaction mixture was stirred for 30 min at -78 °C. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 3,4- dimethoxy-2-(methoxymethyl)phenylboronic acid as a solid.

Preparation 2

3 4-dimethoxy-2-nsobutoxy ^' )phenylboronic acid (Compound 302)

Under an argon atmosphere 6-bromo-2,3-dimethoxyphenol (5.8 g, 25 mmol) was dissolved in acetone (40 mL). K ₂ C0 ₃ (5.2 g, 37.5 mmol) and isobutyl bromide (4.3g, 31.3 mmol) was added. DMF (20 mL) was added

and the suspension was stirred at 50°C over night. The suspension was partially concentrated in vacuo. H ₂ 0 was added and the mixture was extracted with EtOAc (x 2). The combined organic phases were washed with H20 and brine, dried (Na ₂ S0 ₄ ), filtered and concentrated in vacuo. The crude product was purified by flash chromatography using heptane : EtOAc 96 : 4 as the eluent to afford l-bromo-2-isobutoxy-3,4- dimethoxy-benzene as a liquid.

Under an argon atmosphere l-bromo-2-isobutoxy-3,4-dimethoxy-benzene (6.7 g, 23.2 mmol) was dissolved in dry THF (50 mL). The solution was cooled to -70°C while n-BuLi (2.0 M in pentane, 12.8 mL, 25.5 mmol) was added over 10 min. The solution was stirred for 20 min at -70°C after which trimethyl borate (5.2 mL, 46.4 mmol) was added over 10 min. The solution was kept at -70°C for 15 min after which it was heated to RT over 15 min and stirred at RT for 30 min. Saturated aq. NH ₄ CI (200 mL) was added and the solution was adjusted to pH 1 with 4N HCI (10 mL). The mixture was extracted with EtOAc (x 3). The combined organic phases were dried (Na ₂ S04), filtered and concentrated to afford an oil. The crude product was purified by flash chromatography using heptane : EtOAc 4 : 1 -> 3 : 1 as the eluent to afford a crystalline compound which was recrystallised from petroleum ether : Et ₂ 0 (90 : 10) to afford the title compound as a crystalline compound.

Preparation 3

4-(2-Hydroxy-3.4-dimethoxy-phenyl')-indan-l-one (Compound 303

To a stirring solution 3,4-dimethoxy-2-(methoxymethyl)phenylboronic acid (Compound

301)(1 g, 0.186 mmol) in dimethylformamide under nitrogen atmosphere, were added cesium carbonate (4.5 g, 13.84 mmol), tetrakis(triphenylphosphine)palladium(0) (269 mg, 0.232 mmol) and 4-bromo-indan-l-one (1.35 g, 5.57 mmol) and the resultant reaction mixture was heated to 90 °C for 4 h. The reaction mixture was filtered off and the filtrate was extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-35% ethyl acetate in pet ether) afforded 4-(3,4-Dimethoxy-2-methoxymethoxy-phenyl)-indan-l- one as a solid.

To a stirring solution of 4-(3,4-Dimethoxy-2-methoxymethoxy-phenyl)-indan-l-one ( 1.6 g, 4.87 mmol) in methanol (15 mL) at 0 °C, was added concentrated hydrochloride acid (3 mL) and the resultant reaction mixture was stirred at 50 °C for 15 min. The reaction mixture was concentrated under reduced pressure and basified with aq sodium

bicarbonate solution extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue was purified by washing with ether to afford the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.76 (dd, J = 7.5, 0.9 Hz, 1H), 7.56 (dd, J = 7.4, 1.2 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 6.58 (d, J = 8.6 Hz, 1H), 6.04 (s, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.11 - 3.02 (m, 2H), 2.71 - 2.63 (m, 2H).

Preparation 4 4-(2-h droxy-3 _f 4-dimethoxyphenyl)isobenzofuran-lf3HVone (Compound 304^

To a stirring solution of 3-bromo-2-methyl-benzoic acid (1 g) in methanol (10 mL), was added concentrated sulphuric acid (0.4 mL) and the resultant reaction mixture was heated to reflux for 16 h. The reaction mixture was concentrated under reduced pressure and the residue was diluted with water and washed with sodium bicarbonate solution and brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 3-bromo-2-methyl-benzoic acid methyl ester as a liquid. To a stirring solution of 3-Bromo-2-methyl-benzoic acid methyl ester (500 mg, 2.22 mmol) in carbon tetrachloride (6 mL) at 0°C, was added chromylchloride (0.36 mL, 4.45 mmol) and the reaction mixture was heated to reflux for 20 h. The reaction mixture was cooled to RT, added ice water and sat sodium bicarbonate solution at 0 °C. Extracted with ethyl acetate (3 x) the combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification by column chromatography (silica gel, 0-10% ethyl acetate in pet. ether) afforded 4-bromo-3H-isobenzofuran-l-one as a solid.

To a stirring solution of 3,4-dimethoxy-2-(methoxymethyl)phenylboronic acid

(compound 301)(2.3 g, 10.79 mmol) in dimethylformamide (25 mL) under nitrogen atmosphere, were added cesium carbonate (10.52 g, 32.31 mmol),

tetrakis(triphenylphosphine)palladium(0) (623 mg, 0.539 mmol) and 4- bromoisobenzofuran-l(3H)-one (5.2 g, 21.5 mmol) and the resultant reaction mixture was heated to 80 °C for 3 h. The reaction mixture was filtered off and the filtrate was extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) afforded 4-(3,4-dimethoxy-2-methoxymethoxy-phenyl)-3H-isobenzofuran-l -one as a solid. To a stirring solution of 4-(3,4-dimethoxy-2-(methoxymethoxy)phenyl)isobenzofuran- l(3H)-one (1.3 g, 3.9 mmol) in methanol (15 mL) at 0 °C, was added concentrated hydrochloride acid (3 mL) and the resultant reaction mixture was stirred at 50 °C for 15 min. The reaction mixture was concentrated under reduced pressure and basified with aq. sodium bicarbonate solution extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure and purification. The resulting residue purified by washings with pentane to afford the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.90 (d, J = 6.8 Hz, 1H), 7.65 (d, J - 6.5 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.60 (d, J = 8.7 Hz, 1H), 6.18 (s, 1H), 5.31 (s, 2H), 3.98 (S, 3H), 3.93 (s, 3H).

Preparation 5

5- 2-hydroxy-3 _f 4-dimethoxyphenvn-indan-l-one (Compound 305

To a stirring solution of 3,4-dimethoxy-2-(methoxymethyl)phenylboronic acid

(Compound 301) (3.5 g, 16.58 mmol) in dimethylformamide (50 mL) under nitrogen atmosphere, were added cesium carbonate (16.17 g, 49.75 mmol),

tetrakis(triphenylphosphine)palladium(0) (957 mg, 0.828 mmol) and 5-bromo-2,3- indan-l-one (8.02 g, 33.14 mmol) and the resultant reaction mixture was heated to 70 °C for 3 h. The reaction mixture was filtered off and the filtrate was extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) afforded 5-(3,4- dimethoxy-2-(methoxymethoxy)phenyl)-indan-l-one as a solid.

To a stirring solution of compound 5-(3,4-dimethoxy-2-(methoxymethoxy)phenyl)- indan-l-one (1.3 g, 3.9 mmol) in methanol (15 mL) at 0 °C, was added concentrated hydrochloride acid (3 mL) and the resultant reaction mixture was stirred at 50°C for 15 min. The reaction mixture was concentrated under reduced pressure and basified with aq sodium bicarbonate solution extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The resulting residue was purified by washings with pentane to afford the title compound as a solid.

1H IMMR (300 MHz, cdcl3) δ 7.79 (d, J = 8.0 Hz, 1H), 7.70 (s, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 6.59 (d, J = 8.8 Hz, 1H), 6.19 (s, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.23 - 3.11 (m, 2H), 2.77 - 2.67 (m, 2H).

Preparation 6

5-(2-h droxy-3,4-dimethoxypheny0isobenzofuran-l(3H)-one (Compound 306)

To a stirring solution of 3,4-dimethoxy-2-(methoxymethyl)phenylboronic acid

(Compound 301) (3.5 g, 16.58 mmol) in dimethylformamide (50 mL) under nitrogen atmosphere, were added cesium carbonate (16.17 g, 49.75 mmol),

tetrakis(triphenylphosphine) palladium(O) (957 mg, 0.828 mmol) and 5- bromoisobenzofuran-l(3H)-one (8.02 g, 33.14 mmol) and the resultant reaction mixture was heated to 70 °C for 3 h. The reaction mixture was filtered off and the filtrate was extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) afforded 5-(3,4-dimethoxy-2-(methoxymethoxy)phenyl)isobenzofuran-l(3H )-one as a solid.

To a stirring solution of 5-(3,4-dimethoxy-2-(methoxymethoxy)phenyl)isobenzofuran- l(3H)-one (1.4 g, 4.26 mmol) in methanol (20 mL) at 0 °C, was added concentrated hydrochloride acid (3 mL) and the resultant reaction mixture was stirred at 50°C for 15 min. The reaction mixture was concentrated under reduced pressure and basified with aq sodium bicarbonate solution extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The resulting residue was purified by washings with pentane to afford the title compound as a solid.

1H IMMR (300 MHz, cdcl3) δ 7.94 (d, J = 8.4 Hz, 1H), 7.73 (m, 2H), 7.08 (d, J = 8.8 Hz, 1H), 6.60 (d, J = 8.8 Hz, 1H), 6.22 (s, 1H), 5.35 (s, 2H), 3.96 (s, 3H), 3.93 (s, 3H). Preparation 7

5-(2-h droxy-3.4-dimethoxyphenyl)isoindolin- 1-one f Compound 307)

To a stirring solution of 3,4-dimethoxy-2-(methoxymethyl)phenylboronic acid

(compound 301) (400 mg, 1.88 mmol) in dimethylformamide (10 mL) under nitrogen atmosphere, were added cesium carbonate (1.8 g, 5.66 mmol),

tetrakis(triphenylphosphine)palladium(0) (100 mg, 0.09 mmol) and 5-bromoisoindolin- 1-one (913 mg, 3.77 mmol) and the resultant reaction mixture was heated to 90 °C for 6 h. The reaction mixture was filtered off and the filtrate was extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification was done by column chromatography (silica gel, 0-3% methanol in dichloromethane) afforded 5-(3,4-dimethoxy-2-(methoxymethoxy)phenyl)isoindolin-l-one as a solid.

To a stirring solution of _^ 5-(3,4-dimethoxy-2-(methoxymethoxy)phenyl)isoindolin-l -one (600 g, 1.81 mmol) in methanol (20 mL) at 0 °C, was added concentrated hydrochloride acid ( 1 mL) and the resultant reaction mixture was stirred at 50°C for 15 min. The reaction mixture was concentrated under reduced pressure and basified with aq sodium bicarbonate solution extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the resulting residue by washings with ether afforded the title compound as a solid.

1H NMR (400 MHz, dmso) δ 9.03 (s, 1H), 8.48 (s, 1H), 7.66 (m, 2H), 7.60 (d, J = 7.8 Hz, 1H), 7.03 (d, J = 8.6 Hz, 1H), 6.63 (d, J = 8.6 Hz, 1H), 4.39 (s, 2H), 3.83 (s, 3H), 3.73 (s, 3H).

Preparation 8

4-(4 _f 4,5,5-TetramethyHl _f 3,21dioxaborolan-2-yl ^' Hndan-l-one (Compound 308

In a screw cap vessel 4-Bromo-l-indanone (1.0 g, 4.9 mmol) was dissolved in 1,4- dioxan (40 ml_). Argon was purged through the solution. PdCI ₂ (dppf) ₂ *CH ₂ Cl ₂ (0.16g, 0.2 mmol) and bis(pinacolato)diborane (1.3g, 5.1 mmol) was added followed by addition of KOAc (l,4g, 14.6 mmol). The vessel was closed and the mixture was stirred at 80°C for 4 h. The mixture was cooled to RT and diluted with EtOAc (50ml_).The suspension was filtered and washed with EtOAc. The filtrate was concentrated and the crude product was purified by flash chromatography (heptane: EtOAc 100 : 0 -> 93 : 7) to afford the title compound as a solid.

1H NMR (300 MHz, CDCI3) δ 8.04 (d, J = 7.2 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 3.39 - 3.29 (m, 2H), 2.70 - 2.63 (m, 2H), 1.36 (s, 12H).

Preparation 9

5-f4.4,5.5-Tetramethyl-[l _f 3.21dioxaborolan-2-vn-3H-isobenzofuran-l-one (Compound

The title compound was prepared according to the procedure described in preparation 8, using 5-bromo-3H-isobenzofuran-l-one as the starting material.

1H NMR (300 MHz, CDCI3) δ 7.98 - 7.89 (m, 3H), 5.31 (s, 2H), 1.37 (s, 12H).

Preparation 10

5-(4.4,5,5-Tetramethyl- l,3,21dioxaborolan-2-yn-2,3-dihydro-isoindol-l-one

The title compound was prepared according to the procedure described in preparation 8, using 5-bromo-2,3-dihydro-isoindol-l-one as the starting material.

1H NMR (300 MHz, DMSO) δ 8.63 (s, 1H), 7.87 (s, 1H), 7.76 (d, J = 7.4 Hz, 1H), 7.70 - 7.64 (m, 1H), 4.38 (s, 2H), 1.31 (s, 12H). Example 1

Procedure for alk lation of phenols using parallel synthesis

Under an argon atmosphere the phenol (0.035 mmol) and the halogenide (0.07 mmol) were dissolved in DMF (0.5 mL) in a microwave vial. K ₂ C0 ₃ (0.012 g, 0.087 mmol) was added and the suspension was heated in a microwave oven at 120°C for 10 min. H ₂ 0 (2 mL) was added and the mixture was extracted with EtOAc (2 x 3 mL). The phases were separated using a phase separation cartridge (Chromabond, PTS). The organic phase was concentrated in vacuo and the residue was dissolved in DMSO (0.3 mL) and purified by preparative HPLC/MS.

Following this procedure starting from 4-(2-Hydroxy-3,4-dimethoxy-phenyl)-indan-l-one (compound 303) as the phenol compounds 101 - 114 were prepared : -[ ^" 3,4-Dimethoxy-2-( ^, 3-methyl-butoxy)-phenyl1-indan-l-one (Compound 1011

1H NMR (600 MHz, DMSO-SPE) δ 7.64 (dd, J = 7.6, 0.9 Hz, 1H), 7.55 (dd, J = 7.3, 1.1 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.01 (dd, J = 8.5, 3.3 Hz, 1H), 6.93 - 6.89 (m, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.64 (t, J = 6.2 Hz, 2H), 3.00 - 2.91 (m, 2H), 2.64 - 2.57 (m, 2H), 1.30 (dp, J = 13.3, 6.7 Hz, 1H), 1.18 (q, J = 6.4 Hz, 2H), 0.58 (s, 3H), 0.57 (s 3H).

4-(2-Cyclobutylmethoxy-3 _r 4-dimethoxy-phenyO-indan-l-one (Compound 102^

IH NMR (600 MHz, DMSO-SPE) δ 7.63 (dd, J = 7.6, 0.9 Hz, IH), 7.56 (dd, J = 7.4, 1.2 Hz, IH), 7.48 (t, 3 = 7.5 Hz, IH), 7.03 - 6.99 (m, IH), 6.92 - 6.89 (m, IH), 3.85 (s, 3H), 3.80 (s, 3H), 3.60 (d, J = 6.3 Hz, 2H), 2.96 (dd, J = 14.5, 8.5 Hz, 2H), 2.64 - 2.58 (m, 2H), 2.35 - 2.26 (m, IH), 1.70 - 1.61 (m, 3H), 1.57 - 1.49 (m, I H), 1.37 - 1.28 (m, 2H).

4-[2-(4-Methanesulfonyl-benzyloxyV3.4-dimethoxy-phenyl ^" |-indan- l-one (Compound 1

IH NMR (600 MHz, DMSO-SPE) δ 7.71 - 7.68 (m, 2H), 7.62 (dd, J = 7.6, 1.0 Hz, I H), 7.49 (dd, J = 7.3, 1.1 Hz, IH), 7.43 (t, J = 7.5 Hz, I H), 7.16 (d, J = 8.3 Hz, 2H), 7.05 - 7.02 (m, IH), 6.97 - 6.94 (m, I H), 4.87 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 3.16 (s, 3H), 2.88 - 2.83 (m, 2H), 2.58 - 2.52 (m, 2H).

4-r2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3.4-dimethoxy-p henyll-indan- l-one

)

IH NMR (600 MHz, DMSO-SPE) δ 7.64 (dd, J = 7.5, 0.9 Hz, IH), 7.55 (dd, J = 7.4, 1.2 Hz, I H), 7.48 (t, J = 7.5 Hz, I H), 7.03 (d, J = 8.6 Hz, IH), 6.96 - 6.92 (m, IH), 4.74 (t, J = 5.3 Hz, I H), 4.09 (d, J = 5.8 Hz, 2H), 3.90 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 3.81 (s, 2H), 3.29 (t, J = 3.8 Hz, 2H), 2.98 - 2.92 (m, 2H), 2.63 - 2.57 (m, 2H) . 4- r2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl ^" |-indan-l-one (Compound

1H NMR (600 MHz, DMSO-SPE) δ 7.65 (dd, J = 7.6, 0.8 Hz, 1H), 7.55 (dd, 3 = 7.3, 1.1 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.92 - 6.89 (m, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.69 - 3.62 (m, 2H), 2.97 - 2.91 (m, 2H), 2.63 - 2.56 (m, 2H), 1.22 (t, J = 7.2 Hz, 2H), 0.65 (s, 9H). - 2,3-Dimethoxy-6-(l-oxo-indan-4-yn-phenoxymethyll-benzamide (Compound 106)

1H NMR (600 MHz, DMSO-SPE) δ 7.89 (s, 1H), 7.64 (ddd, J = 4.2, 3.3, 1.4 Hz, 3H), 7.51 (dd, J = 7.3, 1.1 Hz, 1H), 7.45 (t, J = 7.5 Hz, 1H), 7.31 (s, 1H), 7.04 - 7.00 (m, 1H), 6.93 (dd, J = 8.4, 4.6 Hz, 3H), 4.81 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 3.32 (d, J = 10.7 Hz, 2H), 2.83 - 2.78 (m, 2H), 2.52 (dt, J = 5.9, 5.4 Hz, 2H). 4-[2-(3-Hydroxy-2 _r 2-dimethyl-propoxy 3.4-dimethoxy-phenyll-indan-l-one

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (dd, J = 7.5, 0.8 Hz, 1H), 7.54 (dd, J = 7.3, 1.1 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 6.91 - 6.87 (m, 1H), 4.28 (t, J = 5.4 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.40 (s, 2H), 2.98 - 2.93 (m, 2H), 2.90 (t, J = 3.7 Hz, 2H), 2.60 (dd, J = 6.8, 4.9 Hz, 2H).

4- 2.3-Dimethoxy-6-(l-oxo-indan-4-yn-phenoxymethyl1-N-methyl-be nzamide

(Compound 108

1H NMR (600 MHz, DMSO-SPE) δ 8.34 (q, J = 4.2 Hz, 1H), 7.64 (dd, J = 7.5, 0.8 Hz, 1H), 7.59 (d, J = 8.2 Hz, 2H), 7.51 (dd, J = 7.3, 1.0 Hz, 1H), 7.45 (t, J = 7.4 Hz, 1H), 7.04 - 7.00 (m, 1H), 6.93 (m, 3H), 4.80 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.85 - 2.79 (m, 2H), 2.75 (d, J = 4.6 Hz, 3H), 2.52 (m, 2H).

4- r2.3-Dimethoxy-6-( ^, l-oxo-indan-4-yl phenoxymethyl1-N,N-dirnethyl-benzamide (Compound 109

1H NMR (600 MHz, DMSO-SPE) δ 7.62 (dd, J = 7.5, 0.8 Hz, 1H), 7.50 (dd, J = 7.3, 1.1 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 8.6 Hz, 1H), 6.93 (m, 3H), 4.78 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.94 (s, 3H), 2.87 - 2.78 (m, 5H), 2.54 (dt, J = 12.9, 5.6 Hz, 2H). 3-[2 -Dimethoxy-6-f l-oxo-indan-4-ylVphenoxymethyll-N _r N-dimethyl-benzamide (Compound 110

1H NMR (600 MHz, DMSO-SPE) δ 7.61 (dd, J = 7.5, 0.7 Hz, 1H), 7.51 (dd, J = 7.3, 1.0 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.21 - 7.18 (m, 2H), 7.02 (d, J = 8.5 Hz, 1H), 6.99

(ddd, J = 8.8, 4.5, 1.6 Hz, 1H), 6.96 - 6.91 (m, 1H), 6.80 (s, 1H), 4.79 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.94 (s, 3H), 2.85 (dd, 3 = 17.9, 11.8 Hz, 2H), 2.71 (s, 3H), 2.56 - 2.52 (m, 2H). 3-[2 _f 3-Dimethoxy-6-(l-oxo-indan-4-yn-phenoxymethyl]-N,N-dim ethyl-

1H NMR (600 MHz, DMSO-SPE) δ 7.62 - 7.59 (m, 1H), 7.58 (d, 3 = 7.9 Hz, 1H), 7.50 (dd, J = 7.3, 0.8 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.37 (s, 1H), 7.25 (d, J = 7.7 Hz, 1H), 7.02 (d, J = 8.5 Hz, 1H), 6.96 - 6.93 (m, 1H), 4.87 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.87 - 2.82 (m, 2H), 2.57 - 2.53 (m, 2H), 2.48 (s, 6H).

4-[2 _f 3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyn-benzenesulfon amide

1H NMR (600 MHz, DMSO-SPE) δ 7.65 (dd, J = 7.4, 0.9 Hz, 1H), 7.59 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 7.3, 1.2 Hz, 1H), 7.45 (t, J = 7.4 Hz, 1H), 7.29 (s, 2H), 7.05 (d, J 8.3 Hz, 2H), 7.03 (d, J = 8.5 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 4.83 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.87 (dd, J = 13.9, 8.4 Hz, 2H), 2.58 (dd, J = 6.7, 4.9 Hz, 2H).

4- 2-(3-Methanesulfonyl-benzyloxy)-3 _f 4-dimethoxy-phenyll-indan-l-one (Compound

1H NMR (600 MHz, DMSO-SPE) δ 7.76 (d, J = 7.9 Hz, 1H), 7.62 - 7.59 (m, 1H), 7.57 (s, 1H), 7.51 (dd, J = 7.3, 0.9 Hz, 1H), 7.43 (m, 2H), 7.25 (d, J = 7.7 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.97 - 6.95 (m, 1H), 4.86 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 3.10 (s, 3H), 2.90 - 2.86 (m, 2H), 2.57 - 2.53 (m, 2H). 3-[2 _f 3-Dimethoxy-6-( l-oxo-indan-4-yn-phenoxymethyl1-benzamide (Compound 114)

1H NMR (600 MHz, DMSO-SPE) δ 7.84 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.59 (dd, J - 7.6, 0.6 Hz, 1H), 7.54 (s, 1H), 7.48 (dd, J = 7.3, 1.0 Hz, 1H), 7.41 (t, J = 7.5 Hz, 1H), 7.30 (s, 1H), 7.17 (dd, 3 = 9.5, 5.8 Hz, 1H), 7.01 (d, 3 = 8.5 Hz, 1H), 6.94 (m, 2H), 4.79 (s, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 2.84 - 2.78 (m, 2H), 2.55 - 2.51 (m, 2H).

Example 2

Following the procedure described in example 1 starting from 4-(2-hydroxy-3,4- dimethoxyphenyl)isobenzofuran-l(3H)-one (Compound 304) as the phenol, compounds 115 - 119 were prepared :

4-[2-(4-Methanesulfonyl-benzyloxy')-3,4-dimethoxy-phenyn- 3H-isobenzofuran-l-one (Compound 115)

1H NMR (600 MHz, DMSO-SPE) δ 7.82 (dd, 3 = 6.4, 2.2 Hz, 1H), 7.69 (d, 3 = 8.3 Hz, 2H), 7.61 - 7.57 (m, 2H), 7.19 (d, 3 = 8.3 Hz, 2H), 7.11 (t, 3 = 7.5 Hz, 1H), 6.97 (d, 3 = 8.7 Hz, 1H), 5.25 (s, 2H), 4.88 (s, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.17 (s, 3H).

4-r2,3-Dimethoxy-6-(l-oxo-l ,3-dihydro-isobenzofuran-4-yn-phenoxymethyl1-

1H NMR (600 MHz, DMSO-SPE) δ 7.88 (s, 1H), 7.84 (dd, 3 = 7.2, 1.2 Hz, 1H), 7.63 (ddd, 3 = 19.4, 12.8, 7.8 Hz, 4H), 7.31 (s, 1H), 7.11 (d, 3 = 8.5 Hz, 1H), 6.97 - 6.94 (m, 3H), 5.23 (s, 2H), 4.79 (s, 2H), 3.87 (s, 3H), 3.85 (d, 3 = 5.2 Hz, 3H). 4- r2 _f 3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-4-yn-ph enoxymethyll-N-methyl-

1H NMR (600 MHz, DMSO-SPE) δ 8.34 (d, 3 = 4.5 Hz, 1H), 7.84 (dd, 3 = 7.3, 1.1 Hz, 1H), 7.65 - 7.59 (m, 4H), 7.11 (d, J = 8.6 Hz, 1H), 6.96 (dd, J = 8.4, 4.1 Hz, 3H), 5.24 (s, 2H), 4.79 (d, J = 7.5 Hz, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 2.76 (d, J = 7.4 Hz, 3H).

4-[ ^" 2 _f 3-Dimethoxy-6-f l-oxo-l _f 3-dihydro-isobenzofuran-4- l phenoxymethyl1-N _f N-

dimethyl-benzamide (Compound 1181

1H NMR (600 MHz, DMSO-SPE) δ 7.82 (dd, J = 7.2, 1.2 Hz, 1H), 7.65 - 7.57 (m, 2H), 7.18 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 8.6 Hz, 1H), 6.96 (d, J = 8.4 Hz, 3H), 5.26 (s, 2H), 4.78 (d, J = 7.9 Hz, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 2.95 (s, 3H), 2.83 (s, 3H).

4-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy1-3,4-dimethoxy-p henyl1-3H-isobenzofuran- -one (Compound 119)

1H NMR (600 MHz, DMSO-SPE) δ 7.87 - 7.84 (m, 1H), 7.70 (dd, J = 7.4, 0.9 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.1.3 (d, J = 8.6 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 5.33 (s, 2H), 4.77 (t, J = 5.3 Hz, 1H), 4.10 (d, J = 5.8 Hz, 2H), 3.92 (d, J = 5.8 Hz, 2H), 3.86 (s, 3H), 3.84 (s, 2H), 3.82 (s, 3H).

Example 3

Following the procedure described in example 1 starting from 5-(2-Hydroxy-3,4- dimethoxy-phenyl)-indan-l-one (Compound 305) as the phenol, compounds 120 - 130 were prepared : 5-r3 ^, 4-Dimethoxy-2-(3-methyl-butoxyVphenyl1-indan-l-one (Compound 120)

1H NMR (600 MHz, DMSO-SPE) δ 7.67 - 7.63 (m, 2H), 7.53 - 7.49 (m, 1H), 7.12 (d, J = 8.7 Hz, 1H), 6.94 - 6.90 (m, 1H), 3.84 (s, 3H), 3.79 (d, J = 3.6 Hz, 3H), 3.74 (q, J = 6.6 Hz, 2H), 3.15 - 3.10 (m, 2H), 2.69 - 2.63 (m, 2H), 1.59 (dq, J = 13.4, 6.7 Hz, 1H), 1.36 (q, J = 6.5 Hz, 2H), 0.73 (d, J = 6.7 Hz, 6H).

5-r2-(2 _r 2-Dimethyl-propoxy>3,4-dimethoxy-phenyH-indan-l-one (Compound 1211

1H NMR (600 MHz, DMSO-SPE) δ 7.67 (s, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.13 (d, 3 = 8.6 Hz, 1H), 6.92 (d, J = 8.7 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.41 - 3.36 (s, 2H), 3.10 (dd, J = 15.3, 9.4 Hz, 2H), 2.70 - 2.63 (m, 2H), 0.80 (s, 9H). 5-(2-C clobutylmethoxy-3,4-dimethoxy-phenyl1-indan-l-one (Compound 1221

1H NMR (600 MHz, DMSO-SPE) δ 7.68 - 7.63 (m, 2H), 7.53 (d, J = 7.9 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 6.92 (d, J = 8.7 Hz, 1H), 3.84 (s, 3H), 3.80 (s, 3H), 3.71 (t, J = 6.4 Hz, 2H), 3.16 - 3.10 (m, 2H), 2.69 - 2.64 (m, 2H), 2.48 - 2.39 (m, 1H), 1.85 - 1.53 (m, 6H). 5- 2-f3 _f 3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl1-indan-l-one (Compound 123)

IH NMR (600 MHz, DMSO-SPE) δ 7.68 - 7.63 (m, 2H), 7.53 - 7.49 (m, IH), 7.11 (d, J = 8.6 Hz, IH), 6.94 - 6.90 (m, IH), 3.84 (s, 3H), 3.80 (s, 3H), 3.78 (t, J = 7.3 Hz, 2H), 3.17 - 3.10 (m, 2H), 2.70 - 2.64 (m, 2H), 1.45 (t, J = 7.3 Hz, 2H), 0.79 (s, 9H). -r2,3-Dimethoxy-6-f l-oxo-indan-5-yn-phenoxymethyll-benzamide (Compound 124)

IH NMR (600 MHz, DMSO-SPE) δ 7.93 (s, IH), 7.74 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 7.9 Hz, IH), 7.53 (s, IH), 7.50 - 7.46 (m, IH), 7.34 (s, IH), 7.20 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 8.7 Hz, IH), 6.99 - 6.95 (m, IH), 4.88 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.07 - 3.02 (m, 2H), 2.68 - 2.61 (m, 2H). 5-[2-(3-Hydroxy-2 _r 2-dimethyl-propoxy ^' )-3,4-dimethoxy-phenyl1-indan-l-one

IH NMR (600 MHz, DMSO-SPE) δ 7.66 (s, IH), 7.64 (d, J = 8.0 Hz, IH), 7.51 (d, J = 8.0 Hz, IH), 7.12 (d, J = 8.7 Hz, IH), 6.91 (d, J = 8.7 Hz, IH), 4.35 (t, J = 5.3 Hz, IH), 3.84 (s, 3H), 3.78 (s, 3H), 3.50 (s, 2H), 3.13 (dd, J = 16.5, 10.9 Hz, 2H), 3.08 (d, J = 5.4 Hz, 2H), 2.71 - 2.63 (m, 2H), 0.74 (s, 6H). 4- [2 _f 3-Dimethoxy-6-Q-oxo-indan-5-yn-phenoxymethyl1-N-methyl -benzamide

1 H NMR (600 MHz, DMSO-SPE) δ 8.39 (q, J = 4.3 Hz, 1 H), 7.70 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 7.9 Hz, 1 H), 7.54 (s, IH), 7.51 - 7.46 (m, 1H), 7.21 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 8.6 Hz, IH), 6.99 - 6.94 (m, IH), 4.87 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 3.07 - 3.03 (m, 2H), 2.77 (d, J = 4.5 Hz, 3H), 2.68 - 2.62 (m, 2H).

4-r2,3-Dimethoxy-6-( l-oxo-indan-5-yl -phenoxymethyl1-N.N-dimethyl-benzamide (Compound 127)

I H NMR (600 MHz, DMSO-SPE) δ 7.63 - 7.58 (m, 2H), 7.48 (d, J = 8.0 Hz, I H), 7.28 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.6 Hz, IH), 6.98 - 6.95 (m, IH), 4.86 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.09 - 3.04 (m, 2H), 2.96 (s, 3H), 2.86 (s, 3H), 2.67 - 2.63 (m, 2H) .

3-r2 _r 3-Dimethoxy-6-( ^' l-oxo-indan-5-yl)-phenoxymethyl1-N.N-dimethyl-benzamide (Com ound 1281

IH NMR (600 MHz, DMSO-SPE) δ 7.61 - 7.58 (m, 2H), 7.48 - 7.45 (m, IH), 7.31 (dd, 3 = 9.4, 5.6 Hz, I H), 7.29 - 7.25 (m, I H), 7.23 (t, J = 7.3 Hz, I H), 7.11 (t, J = 6.9 Hz, IH), 7.06 (s, IH), 6.96 (d, J = 8.7 Hz, I H), 4.87 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.08 - 3.02 (m, 2H), 2.94 (s, 3H), 2.77 (s, 3H), 2.68 - 2.60 (m, 2H) . 5-[2-(3-Hvdroxymethyl-oxetan-3-ylmethoxy)-3.4-dimethoxy-phen yn-indan-l-one

1H NM (300 MHz, CDCI3) δ 7.80 (d, J = 8.0 Hz, 1H), 7.62 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8.7 Hz, 1H), 6.82 (d, J = 8.7 Hz, 1H), 4.38 (d, J = 6.4 Hz, 2H), 4.23 (d, J = 6.4 Hz, 2H), 3.95 (m, 10H), 3.22 - 3.14 (m, 2H), 2.81 - 2.68 (m, 2H), 2.35 (s, 1H). 5- 2-(4-Methanesulfonyl-benzyloxy)-3 _f 4-dimethoxy-phenyll-indan-l-one (Compound 1301

1H NMR (300 MHz, CDCI3) δ 7.79 - 7.70 (m, 3H), 7.48 (dd, J = 10.3, 2.3 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 7.06 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 8.7 Hz, 1H), 4.92 (s, 2H), 3.95 (s, 3H), 3.94 (s, 3H), 3.15 - 3.06 (m, 2H), 3.01 (s, 3H), 2.74 (ddd, J = 6.7, 5.8, 4.6 Hz, 2H).

Example 4

Following the procedure described in example 1 starting from 5-(2-hydroxy-3,4- dimethoxyphenyl)isobenzofuran-l(3H)-one (compound 306) as the phenol, compounds 131 - 146 were prepared :

5-[3,4-Dimethoxy-2-i3-methyl-butoxy1-phenyl1-3H-isobenzof uran-l-one (Compound 1311

1H NMR (600 MHz, DMSO-SPE) δ 7.87 (d, J = 7.9 Hz, 1H), 7.74 (s, 1H), 7.67 (dd, J = 7.9, 1.1 Hz, 1H), 7.15 - 7.10 (m, 1H), 6.96 - 6.92 (m, 1H), 5.43 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.77 - 3.68 (m, 2H), 1.55 (dh, J = 13.4, 6.7 Hz, 1H), 1.35 (q, J = 6.5 Hz, 2H), 0.71 (d, J = 6.7 Hz, 6H).

5-r2-(2.2-Dimethyl-propoxy ^' )-3,4-dimethoxy-phenyll-3H-isobenzofuran-l-one

(Compound 132)

1H NMR (600 MHz, DMSO-SPE) δ 7.85 (d, J = 7.9 Hz, 1H), 7.75 (s, 1H), 7.68 (dd, J = 8.0, 1.0 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.96 - 6.92 (m, 1H), 5.42 (s, 2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.38 (s, 2H), 0.79 (s, 9H).

5-(2-Cyclobutylmethoxy-3 _r 4-dimethoxy-phenyn-3H-isobenzofuran-l-one iCompound 133

1H NMR (600 MHz, DMSO-SPE) δ 7.86 (d, J = 8.0 Hz, 1H), 7.74 (s, 1H), 7.68 (dd, J = 7.9, 1.1 Hz, 1H), 7.15 - 7.11 (m, 1H), 6.96 - 6.91 (m, 1H), 5.44 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.71 (d, J = 6.5 Hz, 2H), 2.47 - 2.38 (m, 1H), 1.85 - 1.49 (m, 6H). 5-r2-r3-Hvdroxymethyl-oxetan-3-ylmethoxyV3,4-dimethoxy-pheny l1-3H-isobenzofuran- -one (Compound 1341

IH NMR (600 MHz, DMSO-SPE) δ 7.86 (d, J = 8.0 Hz, IH), 7.74 (s, IH), 7.65 (dd, J = 8.0, 1.1 Hz, IH), 7.17 - 7.14 (m, IH), 6.99 - 6.95 (m, IH), 5.43 (s, 2H), 4.80 (t, J = 5.2 Hz, IH), 4.22 (t, J = 6.8 Hz, 2H), 4.14 (d, J = 5.8 Hz, 2H), 3.92 (d, J = 10.1 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 3.47 (d, J = 5.2 Hz, 2H).

5-r2-(3,3-Dimethyl-butoxy ^' )-3,4-dimethoxy-phenvn-3H-isobenzofuran- 1-one CCompound 1351

IH NMR (600 MHz, DMSO-SPE) δ 7.88 (d, J = 7.9 Hz, IH), 7.73 (s, IH), 7.68 (dd, J = 8.0, 1.3 Hz, IH), 7.12 (d, J = 8.7 Hz, IH), 6.95 - 6.92 (m, IH), 5.44 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.79 - 3.74 (m, 2H), 1.44 (dd, J = 9.8, 4.9 Hz, 2H), 0.78 (s, 9H).

4-[ ^" 2 _r 3-Dimethoxy-6-(l-oxo-1.3-dihvdro-isobenzofuran-5-vn-ph enoxymethyll-

IH NMR (600 MHz, DMSO-SPE) δ 7.93 (s, IH), 7.84 - 7.80 (m, IH), 7.75 - 7.71 (m, 2H), 7.64 - 7.60 (m, 2H), 7.34 (s, IH), 7.18 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 8.6 Hz, IH), 7.00 - 6.96 (m, IH), 5.37 (s, 2H), 4.89 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H). S- r - S-Hvdroxy- ^-dimethyl-propoxy ^' i-S^-dimethoxy-phenyn-SH-isobenzofuran- l-one

1 H NMR (600 MHz, DMSO-SPE) δ 7.85 (d, J = 8.0 Hz, 1H), 7.74 (s, 1H), 7.67 (dd, J = 8.0, 1.1 Hz, 1H), 7.13 (d, J = 8.7 Hz, 1H), 6.95 - 6.91 (m, IH), 5.42 (s, 2H), 4.35 (t, J = 5.3 Hz, I H), 3.85 (s, 3H), 3.78 (s, 3H), 3.50 (s, 2H), 3.06 (d, J = 5.3 Hz, 2H), 0.73 (s, 6H) .

4-r2 _r 3-Dimethoxy-6-( ^' l-oxo- l ,3-dihydro-isobenzofuran-5-yl ^" )-phenoxymethyll-N-methyl-

IH NMR (600 MHz, DMSO-SPE) δ 8.39 (q, J = 4.3 Hz, IH), 7.84 - 7.80 (m, IH), 7.72 - 7.67 (m, 2H), 7.65 - 7.61 (m, 2H), 7.19 (d, J = 8.2 Hz, 2H), 7.15 - 7.10 (m, I H), 6.98 (d, J = 8.7 Hz, I H), 5.37 (s, 2H), 4.88 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 2.77 (d, J = 4.5 Hz, 3H).

4-r2.3-Dimethoxy-6-i l-oxo-l ,3-dihydro-isobenzofuran-5-vn-phenoxymethyn-N,N- dimethyl-benzamide (Compound 139)

IH NMR (600 M Hz, DMSO-SPE) δ 7.80 (d, J = 7.9 Hz, IH), 7.65 - 7.59 (m, 2H), 7.26 (d, J = 8.1 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 8.7 Hz, IH), 6.98 (d, J = 8.7 Hz, I H), 5.39 (s, 2H), 4.87 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.96 (s, 3H), 2.85 (s, 3H). 3-r2,3-Dimethoxy-6- i-oxo-l,3-dihydro-isobenzofuran-5-yl)-phenoxymethyl]-N _r N- dimeth l-benzamide (Compound 140

IH NMR (600 MHz, DMSO-SPE) δ 7.80 (d, J = 7.9 Hz, IH), 7.67 (s, IH), 7.60 (d, J = 7.9 Hz, IH), 7.32 - 7.24 (m, 2H), 7.22 - 7.19 (m, IH), 7.12 (d, J = 8.6 Hz, IH), 7.03 (s, IH), 6.99 - 6.95 (m, IH), 5.38 (s, 2H), 4.88 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.95 (s, 3H), 2.77 (s, 3H). 4- 2.3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)-pheno xymethvn-

IH NMR (600 MHz, DMSO-SPE) δ 7.85 - 7.82 (m, IH), 7.71 - 7.67 (m, 2H), 7.62 (d, J 6.8 Hz, 2H), 7.33 (s, 2H), 7.31 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 8.6 Hz, IH), 7.00 - 6.97 (m, IH), 5.39 (s, 2H), 4.92 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H).

5-r2-(4-Methanesulfonyl-benzyloxy)-3 _f 4-dimethoxy-phenyl]-3H-isobenzofuran-l-one

IH NMR (600 MHz, DMSO-SPE) δ 7.81 (m, 3H), 7.65 (s, IH), 7.61 (d, J = 8.0 Hz, IH), 7.40 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 8.6 Hz, IH), 7.01 - 6.98 (m, IH), 5.39 (s, 2H), 4.95 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.18 (s, 3H). 5- [2-(3-Methanesulfonyl-benzyloxy)-3 _r 4-dimethoxy-phenyll-3H-isobenzofuran- l-one (Compound 143)

IH NMR (600 MHz, DMSO-SPE) δ 7.83 - 7.78 (m, 2H), 7.66 (s, 2H), 7.60 (d, J = 7.8 Hz, IH), 7.53 (t, J = 7.6 Hz, IH), 7.49 (d, J = 7.7 Hz, I H), 7.14 - 7.11 (m, IH), 6.99 (d, J = 8.7 Hz, I H), 5.38 (s, 2H), 4.96 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 3.14 (s, 3H) .

3-r2.3-Dimethoxy-6-f l-oxo- l .S-dihydro-isobenzofuran-S-yn-phenoxymethyll-

I H NMR (600 MHz, DMSO-SPE) δ 7.82 (d, J = 7.9 Hz, IH), 7.72 (t, J = 7.4 Hz, IH), 7.68 (m, 2H), 7.65 - 7.62 (m, IH), 7.45 (t, J = 7.7 Hz, I H), 7.37 - 7.33 (m, 3H), 7.14 (t, J = 6.8 Hz, IH), 7.01 - 6.98 (m, IH), 5.38 (s, 2H), 4.90 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H) . 3-[2 _f 3-Dimethoxy-6-i l -oxo-l ,3-dihydro-isobenzofuran-5-y))-phenoxymethyl]-N,N-

I H NMR (600 MHz, DMSO-SPE) δ 7.79 (d, J = 7.9 Hz, IH), 7.65 - 7.60 (m, 2H), 7.60 - 7.57 (m, I H), 7.54 - 7.50 (m, IH), 7.49 - 7.44 (m, 2H), 7.11 (d, J = 8.6 Hz, IH), 7.00 - 6.97 (m, I H), 5.38 (s, 2H), 4.97 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 2.51 (s, 6H) .

3-[2.3-Dimethoxy-6-( l-oxo-l ,3-dihydro-isobenzofuran-5-ylVp enoxymethyll- benzamide (Compound 146)

1H NMR (600 MHz, DMSO-SPE) δ 7.90 (s, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.77 - 7.73 (m, 1H), 7.64 (m, 2H), 7.59 (dd, J = 10.5, 2.6 Hz, 1H), 7.34 (s, 1H), 7.31 (dd, J = 9.5, 5.7 Hz, 1H), 7.26 (d, J - 7.6 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 5.38 (s, 2H), 4.87 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H).

Example 5

Following the procedure described in example 1 starting from 5-(2-hydroxy-3,4- dimethoxyphenyl)isoindolin-l-one (Compound 307) as the phenol, compounds 147 - 161 were prepared :

5-[3,4-Dimethoxy-2-f3-methyl-butoxy)-phenyl1-2.3-dihydro- isoindol-l-one (Compound

1H NMR (600 MHz, DMSO-SPE) δ 8.53 (s, 1H), 7.70 - 7.66 (m, 1H), 7.63 (s, 1H), 7.55 (dd, J = 7.9, 1.0 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.93 - 6.88 (m, 1H), 4.39 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 3.71 (t, J = 6.3 Hz, 2H), 1.60 - 1.48 (m, 1H), 1.33 (q, J = 6.5 Hz, 2H), 0.70 (d, J = 6.6 Hz, 6H). 5-[2-(2 _r 2-Dimethyl-propoxy ^' )-3.4-dimethoxy-phenyll-2 _f 3-dihydro-isoindol-l-one

1H NMR (600 MHz, DMSO-SPE) δ 8.53 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.64 (s, 1H), 7.56 (dd, J = 7.9, 1.1 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 6.91 (d, J = 8.7 Hz, 1H), 4.37 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 3.36 (s, 2H), 0.78 (s, 9H). 5-(2-Cyclobutylmethoxy-3.4-dimethoxy-phenyn-2.3-dihydro-isoi ndol-l-one (Compound

1H NMR. (600 MHz, DMSO-SPE) δ 8.54 (s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.64 (s, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 6.91 (d, J = 8.7 Hz, 1H), 4.39 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 3.68 (d, J = 6.4 Hz, 2H), 2.47 - 2.36 (m, 1H), 1.86 - 1.48 (m, 6H). 5-[2-(4-Methanesulfonyl-benzyloxy ^' )-3.4-dimethoxy-phenyll-2,3-dihydro-isoindol-l-one

1H NMR (600 MHz, DMSO-SPE) δ 8.54 (s, 1H), 7.82 - 7.77 (m, 2H), 7.65 (d, J = 7.8 Hz, 1H), 7.56 (d, J = 9.4 Hz, 1H), 7.52 (dd, J = 7.9, 1.2 Hz, 1H), 7.42 (t, J = 9.0 Hz, 2H), 7.12 (dd, J = 7.9, 4.6 Hz, 1H), 6.99 - 6.95 (m, 1H), 4.93 (d, J = 7.8 Hz, 2H), 4.34 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 3.18 (s, 3H).

5-f2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3.4-dimethoxy-p henyl1-2,3-dihydro-

1H NMR (600 MHz, DMSO-SPE) δ 8.55 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.64 (s, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1H), 6.95 (dd, J = 8.7, 3.4 Hz, 1H), 4.81 (t, J = 5.2 Hz, 1H), 4.39 (s, 2H), 4.20 (t, J = 4.3 Hz, 2H), 4.13 (t, J = 5.3 Hz, 2H), 3.88 (s, 2H), 3.85 (d, J = 10.6 Hz, 3H), 3.81 (s, 3H), 3.47 (t, J = 5.7 Hz, 2H). 5- 2-f3 ^, 3-Dimethyl-butoxyV3 _f 4-dimethoxy-phenyll-2.3-dihydro-isoindol-l-one

1H NMR (600 MHz, DMSO-SPE) δ 8.54 (s, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.63 (s, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.09 (t, J = 6.9 Hz, 1H), 6.93 - 6.88 (m, 1H), 4.40 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 3.78 - 3.70 (m, 2H), 1.42 (t, J = 7.4 Hz, 2H), 0.77 (s, 9H).

4-r2 _r 3-Dimethoxy-6-f l-oxo-2,3-dihydro-lH-isoindol-5-yn-phenoxymethvn-benzamide

1H NMR (600 MHz, DMSO-SPE) δ 8.54 (s, 1H), 7.92 (s, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 5.8 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.33 (s, 1H), 7.20 (d, J = 8.2 Hz, 2H), 7.10 (d, J = 8.6 Hz, 1H), 6.98 - 6.93 (m, 1H), 4.86 (s, 2H), 4.33 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H).

5-r2-( ^' 3-Hydroxy-2 _r 2-dimethyl-propoxy ^' )-3.4-dimethoxy-phenyl1-2.3-dihydro-isoindol-l-

1H NMR (600 MHz, DMSO-SPE) δ 8.53 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.64 (s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.90 (dd, J = 8.7, 3.4 Hz, 1H), 4.38 (s, 2H), 4.34 (t, J = 5.3 Hz, 1H), 3.84 (s, 3H), 3.78 (d, J = 6.5 Hz, 3H), 3.48 (d, J = 5.4 Hz, 2H), 3.06 (d, J = 5.4 Hz, 2H), 0.71 (s, 6H).

4-r2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-ylVph enoxymethyl]-N-methyl- benzamide (Compound 155)

1H NMR (600 MHz, DMSO-SPE) δ 8.54 (s, 1H), 8.39 (q, J = 4.2 Hz, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 8.2 Hz, 2H), 7.10 (d, J = 8.6 Hz, 1H), 6.96 (dd, J = 8.5, 4.2 Hz, 1H), 4.86 (s, 2H), 4.33 (s, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 2.77 (d, J = 4.6 Hz, 3H).

4- 2 _r 3-Dimethoxy-6-(l-oxo-2.3-dihydro-lH-isoindol-5-yl)-phe noxymethyl1-N.N-

1H NMR (600 MHz, DMSO-SPE) δ 8.52 (s, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.54 - 7.50 (m, 1H), 7.27 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 8.6 Hz, 1H), 6.96 (dd, J = 8.6, 4.3 Hz, 1H), 4.84 (s, 2H), 4.34 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 2.93 (d, J = 35.2 Hz, 3H), 2.87 (d, J = 20.8 Hz, 3H). 3-r2,3-Dimethoxy-6-(l-oxo-2 _f 3-dihydro-lH-isoindol-5-vn-phenoxymethyl]-N _r N-

1H NMR (600 MHz, DMSO-SPE) δ 8.54 (s, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.51 (dt, J = 8.0, 4.1 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.26 (dt, J = 7.4, 1.2 Hz, 1H), 7.21 (d, J = 7.5 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 7.06 (s, 1H), 6.95 (d, J = 8.7 Hz, 1H), 4.85 (s, 2H), 4.33 (s, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 2.95 (s, 3H), 2.75 (s, 3H).

3- 2 _r 3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yn-phen oxymethyl1- benzenesulfonamide (Compound 158)

IH NMR (600 MHz, DMSO-SPE) δ 8.52 (s, IH), 7.76 - 7.71 (m, 2H), 7.65 (t, J = 6.5 Hz, IH), 7.64 (d, J = 7.4 Hz, IH), 7.55 (dd, J = 7.8, 1.2 Hz, IH), 7.46 (t, J = 7.7 Hz, IH), 7.36 (m, 3H), 7.13 (t, J = 6.1 Hz, IH), 6.97 (dd, J = 8.7, 4.4 Hz, IH), 4.86 (s, 2H), 4.35 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H).

3-[2 _F 3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl1-phe noxymethyl1-benzamide

IH NMR (600 MHz, DMSO-SPE) δ 8.52 (s, IH), 7.93 (s, IH), 7.76 (m, 2H), 7.64 (d, J = 7.8 Hz, IH), 7.60 (s, IH), 7.55 - 7.51 (m, IH), 7.35 - 7.30 (m, 2H), 7.28 (d, J = 7.6 Hz, IH), 7.11 (d, J = 8.6 Hz, IH), 6.96 (d, J = 8.7 Hz, IH), 4.85 (s, 2H), 4.35 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H). 5-[2-('3-Methanesulfonyl-benzyloxy)-3 _f 4-d)methoxy-phenyl1-2 _f 3-dihydro-i

IH NMR (600 MHz, DMSO-SPE) δ 8.52 (s, IH), 7.84 - 7.79 (m, IH), 7.74 (s, IH), 7.64 (d, J = 7.9 Hz, IH), 7.59 (s, IH), 7.55 - 7.47 (m, 3H), 7.11 (d, J = 8.7 Hz, IH), 6.98 (dd, J = 8.7, 3.4 Hz, IH), 4.93 (s, 2H), 4.35 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.13 (s 3H).

4- r2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl ^' )-phenoxymethyl1- benzenesulfonamide (Compound 161)

1H NMR (600 MHz, DMSO-SPE) δ 8.54 (s, 1H), 7.72 - 7.68 (m, 2H), 7.66 (d, J = 7.9 Hz, 1H), 7.56 (s, 1H), 7.53 (t, J = 8.4 Hz, 1H), 7.31 (m, 4H), 7.10 (t, J - 7.7 Hz, 1H), 6.97 (d, J = 8.7 Hz, 1H), 4.88 (s, 2H), 4.35 (s, 2H), 3.86 (s, 3H), 3.83 (s, 3H).

Example 6

General Procedure for Mitsunobu reaction :

In a screw cap vessel under an argon atmosphere the phenol (0.035 mmol) and the alcohol (0.07 mmol) were dissolved in dry THF (2 mL). Triphenyl phosphine resin (0.05 mmol, 0.036 g, 1.5 mmol/g) was added. The mixture was shaken at RT for 30 min after which diethyl azodicarboxylate (40% in toluene, 0.023 mL, 0.07 mmol) was added. The mixture was shaken at RT over night after which it was filtrated and evaporated in vacuo. The crude product was re-dissolved in DMSO (0.3 mL) and purified by

preparative HPLC.

Following this procedure starting from 4-(2-Hydroxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 303) as the phenol compounds 162 - 163 were prepared : 3-r2 _f 3-Dimethoxy-6-f l-oxo-indan-4-yn-phenoxy1-2,2-dimethyl-propionic acid methyl ester CCompound 162)

1H NMR (600 MHz, DMSO-SPE) δ 7.65 - 7.62 (m, 1H), 7.52 (dd, J = 7.3, 1.1 Hz, 1H), 7.47 (t, J = 7.4 Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 3.85 (s, 3H), 3.77 (s, 3H), 3.67 (s, 2H), 3.30 (s, 3H), 2.93 - 2.88 (m, 2H), 2.62 - 2.56 (m, 2H), 0.86 (s, 6H) .

4-r3,4-Dimethoxy-2-(3-methyl-oxetan-3-ylmethoxy ^' )-phenyn-indan-l-one (Compound

1H NMR (600 MHz, DMSO-SPE) δ 7.64 (dd, J = 7.5, 0.7 Hz, 1H), 7.56 (dd, J = 7.3, 1.0 Hz, 1H), 7.48 (t, J - 7.5 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.97 - 6.93 (m, 1H), 4.02 - 3.97 (m, 4H), 3.86 (s, 3H), 3.82 (s, 3H), 3.70 (s, 2H), 2.98 - 2.92 (m, 2H), 2.62 - 2.57 (m, 2H), 0.97 (s, 3H).

Example 7

Following the procedure described in example 6 starting from 4-(2-hydroxy-3,4- dimethoxyphenyl)isobenzofuran-l(3H)-one (Compound 304) as the phenol, compound 164 was prepared :

4-[3 _f 4-Dimethoxy-2- 3-methyl-oxetan-3-ylmethoxy)-phenyl1-3H-isobenzofuran-l-one (Com ound 1641

1H NMR (300 MHz, CDCI3) δ 7.91 (dd, J = 7.0, 1.5 Hz, 1H), 7.66 - 7.53 (m, 2H), 6.99 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.6 Hz, 1H), 4.14 (q, J = 5.9 Hz, 4H), 3.93 (s, 6H), 3.82 (s, 2H), 1.08 (s, 3H).

Example 8 Following the procedure described in example 6 starting from 5-(2-Hydroxy-3,4- dimethoxy-phenyl)-indan-l-one (compound 305) as the phenol, compound 165 was prepared : 3- 2,3-Dimethoxy-6-(l-oxo-indan-5-yl phenoxyl-2,2-dimethyl-propionic acid methyl ester (Compound 165)

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (d, J = 7.9 Hz, 1H), 7.61 (s, 1H), 7.46 (d, J = 7. Hz, 1H), 7.11 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 3.85 (s, 3H), 3.78 (s, 2H), 3.76 (s, 3H), 3.40 (d, J = 6.8 Hz, 3H), 3.16 - 3.09 (m, 2H), 2.69 - 2.64 (m, 2H), 1.04 (2s, 6H).

Example 9

General Procedure for parallel Suzuki coupling.

In a microwave vessel under an argon atmosphere 3,4-dimethoxy-2- (isobutoxy)phenylboronic acid (Compound 302) (0.04 g, 0.15 mmol) was dissolved in degassed 1,4-dioxan (0.4 mL). Argon was purged through the solution. The bromide (0.15 mmol) was added. Pd ₂ (dba) ₃ (0.002 g, 0.002 mmol) and tricyclohexylphosphine (0.001 g, 0.004 mmol) was added. K ₃ P0 ₄ (0.04g, 0.5 mmol) in degassed H ₂ 0 (0.2 mL) was added. The suspension was heated in a microwave oven at 145°C for 15 min. The mixture was filtrated, concentrated in vacuo, re-dissolved in DMSO and purified by preparative HPLC .

Following this procedure compounds 166 - 173 were prepared :

4-(2-Isobutoxy-3 _r 4-dimethoxy-phenyn-indan-l-one (Compound 166

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (dd, J = 7.6, 1.0 Hz, 1H), 7.55 (dd, J = 7.3, 1.1 Hz, 1H), 7.47 (dd, 3 = 13.2, 5.8 Hz, 1H), 7.02 - 6.99 (m, 1H), 6.92 - 6.89 (m, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.42 (d, J = 6.0 Hz, 2H), 2.98 - 2.92 (m, 2H), 2.61 (dd, J = 6.8, 5.0 Hz, 2H), 1.58 (dp, J = 12.9, 6.6 Hz, 1H), 0.57 (d, J = 6.7 Hz, 6H) .

4- 2-Isobutoxy-3 _f 4-dimethoxy-phenyh-6,7-dimethoxy-indan- l-one (Compound 167)

1H NMR (300 MHz, CDCI3) δ 7.13 (s, 1H), 6.93 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 4.02 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 3.89 (s, 3H), 3.49 (d, J = 6.1 Hz, 2H), 2.91 (dd, J = 7.2, 4.9 Hz, 2H), 2.65 (dd, J = 7.0, 5.1 Hz, 2H), 1.71 (td, J = 13.0, 6.5 Hz, 1 H), 0.70 (t, J = 8.6 Hz, 6H).

4-(2-Isobutox -3 _f 4-dimethoxy-phenyO-7-methoxy-indan-l-one (Compound

1 H NMR (300 MHz, CDCI3) δ 7.44 (d, J = 8.3 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1 H), 6.83 (d, J = 8.4 Hz, 1 H), 6.73 (d, J = 8.5 Hz, 1 H), 3.99 (s, 3H), 3.92 (s, 3H), 3.91 (s, 3H), 3.46 (d, J = 6.2 Hz, 2H), 3.02 - 2.85 (m, 2H), 2.69 - 2.55 (m, 2H), 1.78 - 1.57 (m, 1 H), 0.66 (d, J = 6.6 Hz, 6H).

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 169)

1H NMR (300 MHz, CDCI3) δ 7.76 (d, J = 8.0 Hz, 1H), 7.64 (s, 1H), 7.57 - 7.50 (m, 1H), 7.06 (d, J = 8.6 Hz, 1H), 6.79 - 6.71 (m, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.54 (d, J = 6.2 Hz, 2H), 3.22 - 3.10 (m, 2H), 2.82 - 2.63 (m, 2H), 1.81 (dp, J = 13.1, 6.6 Hz, 1H), 0.81 (d, J = 6.6 Hz, 6H).

5-f2-Isobutox -3,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (Compound 170)

1H NMR (300 MHz, CDCI3) δ 7.92 (d, J = 8.0 Hz, 1H), 7.69 (dd, J = 4.7, 4.1 Hz, 1H), 7.65 (s, 1H), 7.06 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 5.34 (s, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.55 (d, J = 6.3 Hz, 2H), 1.78 (td, J = 13.2, 6.6 Hz, 1H), 0.80 (d, J = 6.6 Hz, 6H).

5-(2-Isobutoxy-3 _r 4-dimethoxy-phenyn-2.3-dimethyl-2.3-dihydro-isoindol-l -one

(Com ound 171)

1H NMR (300 MHz, DMSO) δ 7.66 (d, J = 8.1 Hz, 2H), 7.52 (dd, J = 7.8, 1.2 Hz, 1H), 7.09 (d, J = 8.7 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H), 4.56 (q, J = 6.6 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.58 - 3.43 (m, 2H), 3.00 (d, J = 8.0 Hz, 3H), 1.72 (dp, J = 13.1, 6.5 Hz, 1H), 1.45 (d, J = 6.7 Hz, 3H), 0.74 (dd, J = 6.7, 3.5 Hz, 6H) . 5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2-methyl-2.3-dihydro-is oindol-l-one (Compound 172)

1H NMR (300 MHz, CDCI3) δ 7.84 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 7.6 Hz, 2H), 7.05 (d, J = 8.7 Hz, 1H), 6.79 - 6.71 (m, 1H), 4.39 (s, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 3.52 (d, J = 6.3 Hz, 2H), 3.22 (s, 3H), 1.88 - 1.69 (m, 1H), 0.78 (d, J = 6.6 Hz, 6H). -(2-Isobutoxy-3 _f 4-dimethoxy-phenyn-2.3-dihydro-isoindol-l-one (Compound 173

1H NMR (300 MHz, CDCI3) δ 7.85 (dt, J = 7.9, 4.0 Hz, 1H), 7.56 - 7.45 (m, 2H), 6.96 (d, J = 8.6 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 6.55 (s, 1H), 4.41 (s, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.44 (d, J = 6.1 Hz, 2H), 1.6 (m, 1H), 0.61 (d, J = 6.8 Hz, 6H).

Example 10

eneral procedure for Suzuki coupling

In a screw cap vial under an argon atmosphere 3,4-dimethoxy-2- (isobutoxy)phenylboronic acid (Compound 302) (0.015g, 0.06mmol) and the bromide (0.066 mmol) was dissolved in dimethoxyethane (0.35 mL). K ₂ C0 ₃ (1M solution, 0.12 mL, 0.12 mmol) and Pd(PPh ₃ ) ₄ (0.004g, 0.003mmol) was added. The suspension was shaken at 80°C for 72h. Brine (2 mL) was added and the mixture was extracted with CH ₂ CI ₂ (3 mL). The phases were separated using a phase separation cartridge (Chromabond, PTS) . The organic phase was concentrated in vacuo and the residue was dissolved in DMF (0.3 mL) and purified by preparative HPLC/MS.

Compounds 174 - 176 were prepared according to this procedure: -i2-Isobutoxy-3 _r 4-dimethoxy-phenyl)-2,3-dihydro-isoindol-l-one iCompound 174)

1H NM (600 MHz, DMSO-SPE) δ 8.53 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.64 (s, 1H), 7.56 (dd, J = 7.9, 1.2 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.93 - 6.88 (m, 1H), 4.39 (s, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.48 (d, J = 14.4 Hz, 2H), 1.78 - 1.67 (m, 1H), 0.75 (d, J = 6.7 Hz, 6H).

4-(2-Isobutox -3,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (Compound 175)

1H NMR (600 MHz, DMSO-SPE) δ 7.85 (dd, J = 7.4, 0.9 Hz, 1H), 7.71 (dd, J = 7.6, 1.0 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.10 (t, J = 6.9 Hz, 1H), 6.94 - 6.90 (m, 1H), 5.34 (s, 2H), 3.85 (s, 3H), 3.81 (s, 3H), 3.42 (dd, J = 19.8, 14.7 Hz, 4H), 1.68 - 1.50 (m, 1H), 0.60 (d, J = 6.8 Hz, 6H).

6-(2-Isobutoxy-3.4-dimethoxy-phenyl)-benzofuran-3-one (Compound 176)

1H NMR (300 MHz, CDCI3) δ 7.66 (dd, J = 7.6, 1.2 Hz, 1H), 7.32 - 7.26 (m, 2H), 7.06 (d, J = 8.6 Hz, 1H), 6.75 (d, J = 8.6 Hz, 1H), 4.67 (s, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 3.57 (d, J = 6.2 Hz, 2H), 1.84 (tt, J = 13.2, 6.6 Hz, 1H), 0.84 (d, J = 6.7 Hz, 6H). Example 11

4-r2-(l-Hydroxymethyl-cyclopropylmethoxy)-3 _F 4-dimethoxY-phenyll-indan-l-one

To a stirring solution of (l-hydroxymethyl-cyclopropyl)-methanol (20 g, 197.05 mmol) in dichloromethane (200 mL) at 0 °C, were added N,N-diisopropylethylamine (70 mL,

393.79 mmol) and tert-butyl(chloromethyl)diphenylsilane (15 g, 58.17 mmol) and the resultant reaction mixture was stirred at RT for 16 h. The resultant reaction mixture was quenched with ice water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-5% ethyl acetate in pet ether) afforded (l-((tert- butyldiphenylsilyl)methoxy)cyclopropyl)methanol as a yellow liquid.

To a stirring solution of 4-(2-hydroxy-3,4-dimethoxy-phenyl)-indan-l-one_(Compound 303) ( 5 g, 17.60 mmol) in tetrahydrofuran (50 mL), were added triphenylphosphine (9.2 g, 35.21 mmol) and diisopropylazodicarboxylate (7.11 g, 35.21 mmol) and {1- [(tert-Butyl-diphenyl-silanyl)-methoxy]-cyclopropyl>-meth anol (7.18 g, 21.12 mmol) and the resultant reaction mixture was stirred at RT for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x).The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) afforded 4-(2-((l-((tert- butyldiphenylsilyl)methoxy)cyclopropyl)methoxy)-3,4-dimethox yphenyl)-2,3-dihydro- lH-inden-l-one as a liquid.

To a stirring solution of 4-(2-((l-((tert- butyldiphenylsilyl)methoxy)cyclopropyl)methoxy)-3,4-dimethox yphenyl)-2,3-dihydro- lH-inden-l-one (5 g, 6.25 mmol) in tetrahydrofuran, was added tetrabutylammonium fluoride trihydrate (33 mL, 33 mmol) and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification was done by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford the title compound as a yellow solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.64 (dd, J = 7.6, 0.9 Hz, 1H), 7.54 (dd, J = 7.3, 1.1 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.90 - 6.88 (m, 1H), 4.22 (t, J = 5.5 Hz, 1H), 3.84 (s, 3H), 3.80 (s, 3H), 3.58 (d, J = 10.9 Hz, 2H), 2.97 (t, J = 6.1 Hz, 4H), 2.61 (dd, J = 6.7, 5.0 Hz, 2H), 0.23 - 0.16 (m, 2H), 0.0 (m, 2H)

Example 12

4-r3 _r 4-Dimethoxy-2-(l-methoxymethyl-cyclopropylmethoxy ^' )-phenyll-indan-l-one

To a stirring solution of cyclopropane-l, l-diyldimethanol (2 g, 19.60 mmol) in dimethylformamide (30 mL) at 0 °C, was added potassium tertiarybutoxide (1.095 g, 9.73 mmol) and stirred for 1 h. To this methyl iodide (5.5 g, 38.73 mmol) was added to the above reaction mixture and the resultant reaction mixture was stirred at 0 °C for 45 min. The reaction mixture was diluted with water and extracted with ethylacetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) afforded 1- (methoxymethyl)cyclopropyl)methanol as a solid. To a stirring solution of 4-(2-hydroxy-3,4-dimethoxy-phenyl)-indan-l-one_(Compound 303) (100 mg, 0.3521 mmol) in tetrahydrofuran (15 mL), were added

diisopropylazodicarboxylate (142 mg, 0.702 mmol) and triphenylphosphine (184 mg, 0.702 mmol) and (l-(methoxymethyl)cyclopropyl)methanol (122 mg, 1.051 mmol) and the resultant reaction mixture was heated to 70 °C. After completion of reaction (by TLC), the reaction mixture was quenched with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) afforded the title compound as a solid. 1H NMR (400 MHz, cdcl3) δ 7.77 (d, J = 7.5 Hz, 1H), 7.54 (dd, J = 7.4, 1.1 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 3.95 (s, 3H), 3.90 (s, 3H), 3.60 (d, J = 5.3 Hz, 2H), 3.11 - 3.06 (m, 2H), 3.05 (s, 3H), 2.88 (s, 2H), 2.72 - 2.64 (m, 2H), 0.31 (t, J = 5.3 Hz, 2H), 0.22 (t, J = 5.3 Hz, 2H).

Example 13

Ethyl-carbamic acid l- 2.3-dimethoxy-6-(l-oxo-indan-4-yl1-phenoxymethyl1-

To a stirring solution of 4-[2-( l-Hydroxymethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 177) (150 mg, 0.407 mmol) in dichioromethane (15 mL), were added triethylamine (123 mg, 1.22 mmol) and ethyl isocyanate (86 mg, 1.22 mmol) and the resultant reaction mixture was heated to 50 °C for 16 h. The reaction mixture was quenched with sodium bicarbonate solution and extracted with

dichioromethane (3 x). The combined dichioromethane layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (400 MHz, cdcl3) δ 7.76 (d, J = 7.5 Hz, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.42 (t, J = 7.3 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.77 (d, J = 7.5 Hz, 1H), 4.40 (s, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.73 (s, 2H), 3.52 (s, 2H), 3.17 (s, 2H), 3.12 - 3.01 (m, 2H), 2.74 - 2.63 (m, 2H), 1.13 (t, J = 16.8 Hz, 3H), 0.37 (d, J = 19.4 Hz, 2H), 0.21 (d, J = 19.1 Hz, 2H). Example 14

Isopropyl-carbamic acid l-r2 _f 3-dimethoxy-6-d-oxo-indan-4-yh-phenoxymethyl1-

To a stirring solution of 4-[2-(l-Hydroxymethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 177) (200 mg, 0.543 mmol) in dichioromethane (20 mL), were added triethylamine ( 164 mg, 1.623 mmol) and 2-isocyanatopropane ( 184 mg, 2.164 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 179 to afford the title compound as a solid .

1H NMR (600 MHz, DMSO-SPE) δ 7.62 (d, J = 7.5 Hz, 1H), 7.54 (d, J = 7.1 Hz, 1 H), 7.46 (t, J = 7.5 Hz, 1 H), 7.02 (d, J = 8.5 Hz, 1H), 6.92 - 6.89 (m, 1 H), 6.84 (d, J = 7.5 Hz, 1 H), 3.84 (s, 3H), 3.80 (s, 3H), 3.56 - 3.47 (m, 5H), 3.00 - 2.94 (m, 2H), 2.61 (dd, J = 6.7, 5.0 Hz, 2H), 1.06 - 0.98 (m, 6H), 0.29 (d, J = 19.0 Hz, 2H), 0.13 (m, 2H) .

Example 15

Benzyl-carbamic acid l-r2 _f 3-dimethoxy-6-C l-oxo-indan-4-yl)-phenoxymethyll-

To a stirring solution of 4-[2-(l-Hydroxymethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 177) (150 mg, 0.407 mmol) in dichloromethane (15 mL), were added triethylamine ( 123 mg, 1.222 mmol) and benzyl isocyanate ( 105 mg, 0.812 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 179 to afforded the title compound as a solid .

1H NMR (600 MHz, DMSO-SPE) δ 7.63 - 7.59 (m, 1H), 7.55 - 7.51 (m, 2H), 7.43 (t, J = 7.4 Hz, 1 H), 7.33 - 7.28 (m, 2H), 7.23 (t, J = 6.7 Hz, 3H), 7.01 (d, J = 8.5 Hz, 1 H), 6.93 - 6.89 (m, 1H), 4.12 (t, J = 10.3 Hz, 2H) , 3.84 (s, 3H), 3.77 (s, 3H), 3.55 (m, 4H), 3.00 - 2.91 (m, 2H), 2.59 (dd, J = 24.5, 18.8 Hz, 2H), 0.34 - 0.28 (m, 2H), 0.17 - 0.11 (m, 2H) .

Example 16

4-f2-il-Aminomethyl-cyclopropylmethoxy)-3 _f 4-dimethoxy-phenyn-indan-l-one

To a stirring solution of 4-[2-( l-Hydroxymethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan- l-one (Compound 177) (2.5 g, . 6.79 mmol) in dichloromethane (30 mL) at 0 °C, was added triethylamine (2.7 mL, 20.29 mmol) and methanesulfonyl chloride ( 1.16 g, 10.19 mmol) and the resultant reaction mixture was stirred at RT for 1 h. The reaction mixture was quenched with water and extracted with dichloromethane (3 x) . The combined dichloromethane layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford l-((2,3-dimethoxy- 6-( l-oxo-2,3-dihydro- l H-inden-4-yl)phenoxy)methyl)cyclopropyl methanesulfonate as a liquid .

To a stirring solution of l-((2,3-dimethoxy-6-(l-oxo-2,3-dihydro- l H-inden-4- yl)phenoxy)methyl)cyclopropyl methanesulfonate (3 g, 6.72 mmol) in

dimethylformamide (20 mL), was added sodium azide (2.18 g, 33.63 mmol) and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with ice water and extracted with ethyl acetate (3 x) . The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-5% ethyl acetate in pet ether) to afforded 4-(2-(( l-

(azidomethyl)cyclopropyl)methoxy)-3,4-dimethoxyphenyl)-2, 3-dihydro- l H-inden- l-one as a liquid .

To a stirring solution of 4-(2-((l-(azidomethyl)cyclopropyl)methoxy)-3,4- dimethoxyphenyl)-2,3-dihydro- lH-inden-l-one ( 1.5 g, 3.947 mmol) in tetrahydrofu ran (50 mL), were added triphenylphosphine (4.14 g, 15.78 mmol) and the reaction mixture was stirred at RT for 2 h . water ( 5 mL) was added to the above reaction mixture and the resultant reaction was heated to 80 °C for 1 h. The reaction mixture was

concentrated under reduced pressure and the obtained residue was acidified with IN hydrochloric acid solution. Then extracted with ethyl acetate (3 x) and the aq layer was basified with sodium bicarbonate solution and extracted with ethyl acetate and the combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afforded the title compound as a liquid.

Example 17

N--T l- 2,3-Dimethoxy-6-f l-oxo-indan-4-yh-phenoxymethyl1-cyclopropylmethyl>-

To a stirring solution of 4-[2-(l-aminomethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 182) (100 mg, 0.272 mmol) in dichloromethane (10 mL), were added diisopropylethylamine (0.034 g, 0.272 mmol) and isobutyryl chloride (29 mg, 0.272 mmol) and the resultant reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) to afforded the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (dd, J = 7.5, 0.7 Hz, 1H), 7.57 - 7.53 (m, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.35 (t, J = 5.7 Hz, 1H), 7.01 (d, J = 8.5 Hz, 1H), 6.92 - 6.89 (m, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.49 (s, 2H), 3.01 - 2.95 (m, 2H), 2.82 (d, J = 5.8 Hz, 2H), 2.66 - 2.60 (m, 2H), 2.27 (hept, J = 6.8 Hz, 1H), 0.92 (d, 3 = 6.8 Hz, 6H), 0.22 - 0.16 (m, 2H), 0.00 - -0.05 (m, 2H).

Example 18

N-{ l-r2 _i 3-Dimethoxy-6-f l-oxo-indan-4-yn-phenoxymethyl1-cyclopropylmethyl>-

To a stirring solution of 4-[2-(l-Aminomethy!-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 182) (100 mg, 0.272 mmol) in dichloromethane (10 mL), were added diisopropylethylamine (0.034 g, 0.272 mmol) and butyryl chloride (29 mg, 0.272 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of compound 183 to afford the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.65 - 7.59 (m, 1H), 7.57 - 7.52 (m, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.42 - 7.35 (m, 1H), 7.01 (d, J = 8.5 Hz, 1H), 6.92 - 6.89 (m, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.50 (s, 2H), 3.01 - 2.95 (m, 2H), 2.80 (d, J = 5.8 Hz, 2H), 2.65 - 2.59 (m, 2H), 1.95 (t, J = 7.3 Hz, 2H), 1.44 (h, J = 7.4 Hz, 2H), 0.80 (t, J = 7.4 Hz, 3H), 0.24 - 0.17 (m, 2H), 0.0 (m, 2H).

Example 19

N--( ^" l- 2.3-Dimethoxy-6-f l-oxo-indan-4-vn-phenoxymethyll-cyclopropylmethyl - acetamide (Compound 185)

To a stirring solution of 4-[2-(l-aminomethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 182) (100 mg, 0.272 mmol) in dichloromethane (10 mL), were added triethylamine (0.082 g, 0.811 mmol) and acetyl chloride (42 mg, 0.544 mmol) and the resultant reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-2% methanol in dichloromethane) afforded the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (dd, J = 7.6, 0.7 Hz, 1H), 7.55 (dd, J = 7.3, 1.0 Hz, 1H), 7.46 (m, 2H), 7.00 (d, J = 8.5 Hz, 1H), 6.92 - 6.88 (m, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.49 (s, 2H), 3.00 - 2.94 (m, 2H), 2.76 (d, J = 5.7 Hz, 2H), 2.65 - 2.59 (m, 2H), 1.71 (s, 3H), 0.23 - 0.16 (m, 2H), 0.02 (q, J = 4.5 Hz, 2H). Example 20

•T l- 2,3-Dimethoxy-6-C l-oxo-indan-4-ylVphenoxymethyn-cyclopropylmethyl Vcarbamic

To a stirring solution of 4-[2-(l-Aminomethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 182) (110 mg, 0.272 mmol) in dichloromethane (10 mL), were added triethylamine (0.082 g, 0.811 mmol) and ethyl carbonochloridate (59 mg, 0.544 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 183 and Purification by column chromatography (silica gel, 0-25% ethyl acetate in pet ether) to afford the title compound as a solid. 1H NMR (600 MHz, DMSO-SPE) δ 7.65 - 7.60 (m, 1H), 7.54 (dd, J = 7.4, 1.1 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.02 - 6.98 (m, 1H), 6.92 - 6.89 (m, 1H), 6.69 (t, J = 5.6 Hz, 1H), 3.95 - 3.87 (m, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.47 (d, J = 15.7 Hz, 2H), 3.01 - 2.94 (m, 2H), 2.71 (d, J = 5.8 Hz, 2H), 2.65 - 2.60 (m, 2H), 1.15 - 1.08 (m, 3H), 0.24 - 0.16 (m, 2H), 0.0 (m, 2H). Example 21

■ri-r2.3-Dimethoxy-6-( ^' l-oxo-indan-4-yn-phenoxymetriyl1-cyclopropylmethyl -carbamic acid isopropyl ester (Compound 187)

To a stirring solution of 4-[2-(l-Aminomethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 182) (150 mg, 0.272 mmol) in dichloromethane (10 mL), were added triethylamine (0.082 g, 0.811 mmol) and isopropyl carbonochloridate (66 mg, 0.544 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 183 to afford the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (d, J = 7.3 Hz, 1H), 7.54 (dt, J = 7.9, 4.0 Hz,

1H), 7.47 (t, J = 7.5 Hz, 1H), 7.00 (t, J = 6.8 Hz, 1H), 6.92 - 6.88 (m, 1H), 6.63 (t, J =

5.7 Hz, 1H), 4.71 - 4.62 (m, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.47 (d, J = 14.1 Hz, 2H), 3.02 - 2.95 (m, 2H), 2.71 (d, J = 5.8 Hz, 2H), 2.61 (dd, J = 14.0, 8.3 Hz, 2H), 1.16 -

1.08 (m, 6H), 0.24 - 0.16 (m, 2H), 0.04 - 0.07 (m, 2H).

Example 22

{ l-r2.3-Dimethoxy-6-Cl-oxo-indan-4-yl')-phenoxymethyll-cyclop ropylmethyl>-carbamic acid 2-methoxy-ethyl ester (Compound 188^

To a stirring solution of 4-[2-(l-Aminomethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 182} (150 mg, 0.272 mmol) in dichloromethane (10 mL), were added triethylamine (0.082 g, 0.811 mmol) and 2-methoxyethyl

carbonochloridate (68 mg, 0.544 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 183 to afford the title compound as a solid

1H NMR (600 MHz, DMSO-SPE) δ 7.65 - 7.61 (m, 1H), 7.54 (dt, J = 7.6, 3.8 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.02 - 6.98 (m, 1H), 6.92 - 6.89 (m, 1H), 6.88 - 6.83 (m, 1H), 3.99 (dd, J = 5.3, 4.1 Hz, 2H), 3.85 (d, J = 5.8 Hz, 3H), 3.80 (s, 3H), 3.49 (s, 2H), 3.47 - 3.42 (m, 2H), 3.23 (s, 3H), 3.00 - 2.95 (m, 2H), 2.72 - 2.69 (m, 2H), 2.64 - 2.59 (m, 2H), 0.22 (t, J = 5.0 Hz, 2H), 0.02 - -0.02 (m, 2H). Example 23

Ethyl-carbamic acid 3- r2,3-dimethoxy-6-f l-oxo-indan-4-yn-phenoxymethyn-oxetan-3-

To a stirring solution of 4-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 104)(100 mg, 0.2604 mmol) in dichloromethane (15 mL), were added triethylamine (0.1 mL, 0.772 mmol) and ethyl isocyanate (55 mg, 0.78 mmol) and the resultant reaction mixture was heated to 50 °C for 16 h. The reaction mixture was quenched with sodium bi carbonate solution and extracted with

dichloromethane (3 x). The combined dichloromethane layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification by column chromatography (silica gel, 0-25% ethyl acetate in pet ether) to afforded the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.62 (t, J = 9.6 Hz, 1H), 7.55 (d, J = 7.0 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.05 (t, J = 6.9 Hz, 2H), 6.96 (d, J = 8.6 Hz, 1H), 4.12 (d, J = 6.1 Hz, 2H), 3.93 (d, J = 6.1 Hz, 2H), 3.88 (m, 7H), 3.81 (s, 3H), 3.00 - 2.90 (m, 4H), 2.65 - 2.56 (m, 2H), 1.01 - 0.96 (tr, 3H). Example 24

4-r3 _f 4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy ^' )-phenyl1-indan-l-one

To a stirring solution of (3-Bromomethyl-oxetan-3-yl)-methanol (200 mg, 1.104 mmol) in tetrahydrofuran (15 mL) at 0 °C, was added sodium hydride (63 mg, 2.65 mmol) and stirred for 15 min. To this methyl iodide (629 mg, 4.419 mmol) was added to the above reaction mixture and the resultant reaction mixture was warmed to RT and stirred for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 3- (bromomethyl)-3-(methoxymethyl)oxetane as a liquid (120 mg, 55%).

To a stirring solution of 4-(2-Hydroxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 303) (100 mg, 0.352 mmol) in acetonitrile (15 ml_), were added potassium carbonate (145 mg, 1.056 mmol) and 3-(bromomethyl)-3-(methoxymethyl)oxetane (102 mg, 0.528 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column

chromatography (silica gel, 0-25% ethyl acetate in pet ether) to afforded the title compound as a colorless liquid.

1H NMR (600 MHz, DMSO-SPE) δ 7.66 (dd, J = 7.5, 0.8 Hz, 1H), 7.55 (dd, J = 7.3, 1.1 Hz, 1H), 7.49 (dd, J = 9.2, 5.7 Hz, 1H), 7.05 - 7.02 (m, 1H), 6.97 - 6.93 (m, 1H), 4.11 (d, J = 6.0 Hz, 2H), 3.95 (t, J = 7.8 Hz, 2H), 3.86 (s, 3H), 3.83 (s, 2H), 3.82 (s, 3H), 3.17 (s, 2H), 3.08 (s, 3H), 2.94 (dd, J = 11.6, 6.0 Hz, 2H), 2.64 - 2.58 (m, 2H).

Example 25

4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy ^' )-3.4-dimethoxy-phenyn-indan-l-one

To a stirring solution of 4-(2-Hydroxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 303) (500 mg, 1.76 mmol) in acetonitrile, were added potassium carbonate (728 mg, 5.28 mmol) and (3-Bromomethyl-oxetan-3-yl)-methanol (764 mg, 4.28 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and

concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-70% ethyl acetate in pet ether) afforded 4-(2-((3-(hydroxymethyl)oxetan-3- yl)methoxy)-3,4-dimethoxyphenyl)-indan-l-one (Compound 104) as a white solid.

To a stirring solution of 4-(2-((3-(hydroxymethyl)oxetan-3-yl)methoxy)-3,4- dimethoxyphenyl)-indan-l-one (4 g, 10.41 mmol) in dichloromethane (70 mL) at 0 °C, were added triethylamine (3.15 g, 31.25 mmol) and mesyl chloride (1.78 g, 15.614 mmol), the resultant reaction mixture was warmed to RT and stirred for 30 min. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford (3-((2,3-dimethoxy- 6-(l-oxo-2,3-dihydro-lH-inden-4-yl)phenoxy)methyl)oxetan-3-y l)methyl

methanesulfonate as a solid.

To a stirring solution of (3-((2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-inden-4- yl)phenoxy)methyl)oxetan-3-yl)methyl methanesulfonate (5 g, 10.82 mmol) in dimethylformamide (40 mL), was added sodium azide (3.5 g, 54.11 mmol) and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with ice water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 4-(2-((3-(azidomethyl)oxetan-3- yl)methoxy)-3,4-dimethoxyphenyl)-indan-l-one as a solid.

To a stirring solution of 4-(2-((3-(azidomethyl)oxetan-3-yl)methoxy)-3,4- dimethoxyphenyl)-indan-l-one (3 g, 7.57 mmol) in in tetrahydrofuran (30 mL), were added triphenylphosphine (7.6 g, 29.28 mmol) and the reaction mixture was stirred at RT for 2 h. Water (3 mL) was added to the above reaction mixture and the resultant reaction mixture was heated to 80 °C for 1 h. The reaction mixture was concentrated under reduced pressure and the obtained residue was acidified with IN hydrochloric acid solution. Then extracted with ethyl acetate (3 x) and the aq layer was basified with sodium bicarbonate solution and extracted with ethyl acetate and the combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford the title compound as a liquid.

Example 26

N-- 3-[2,3-Dimethoxy-6-d-oxo-indan-4-yl)-phenoxymethyn-oxetan-3- ylmethyl>-

To a stirring solution of 4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 191) (150 mg, 0.391 mmol) in dichloromethane (15 mL), were added triethylamine (118 mg, 1.174 mmol) and acetyl chloride (61 mg, 0.777 mmol) and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-2% methanol in dichloromethane) afforded the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.82 (t, J = 6.0 Hz, 1H), 7.64 (t, J = 6.1 Hz, 1H), 7.56 (dd, J = 7.3, 1.0 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.06 - 7.03 (m, 1H), 6.97 - 6.94 (m, 1H), 4.08 (d, J = 6.0 Hz, 2H), 3.90 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 3.74 (s, 2H), 3.05 (d, J = 6.0 Hz, 2H), 2.99 - 2.93 (m, 2H), 2.62 (dd, J = 11.4, 6.3 Hz, 2H), 1.77 (s, 3H).

Example 27

N-- 3-[ ^" 2,3-Dimethoxy-6-f l-oxo-indan-4-yn-phenoxymethyl1-oxetan-3-ylmethyl - isobutyramide (Compound 193)

To a stirring solution of 4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 191) (150 mg, 0.3916 mmol) in dichloromethane (15 ml_), were added diisopropylethylamine (50 mg, 0.390 mmol) and isobutyryl chloride (41 mg, 0.391 mmol) and the resultant reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x) . The combined dichloromethane layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column

chromatography (silica gel, 0-2% methanol in dichloromethane) afforded the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.75 (t, J = 6.1 Hz, 1H), 7.65 - 7.62 (m, 1H), 7.56

(dd, J = 7.3, 1.0 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.97 - 6.95 (m, 1H), 4.09 (d, J = 6.0 Hz, 2H), 3.89 (t, J = 6.1 Hz, 2H), 3.87 (s, 3H), 3.81 (s, 3H), 3.73 (d, J = 11.6 Hz, 2H), 3.06 (d, J = 6.1 Hz, 2H), 2.99 - 2.95 (m, 2H), 2.61 (dd, J = 6.7, 4.9 Hz, 2H), 2.32 (dq, J = 13.5, 6.8 Hz, 1H), 0.96 (s, 3H), 0.95 (s, 3H).

Example 28

N--r3- r2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl1-oxetan-3- ylmethyl - butyramide f Compound 194)

To a stirring solution of 4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan- l-one (Compound 191) ( 150 mg, 0.3916 mmol) in dichloromethane ( 15 mL), were added diisopropylethylamine ( 50 mg, 0.390 mmol) and butyryl chloride (41 mg, 0.391 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 193 and purification by column chromatography (silica gel, 0-3% methanol in dichloromethane) afforded the title compound as a solid. 1 H NMR (600 MHz, DMSO-SPE) δ 7.79 (t, J = 6.0 Hz, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.58 - 7.53 (m, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1 H), 6.96 (d, J = 8.6 Hz, 1H), 4.09 (d, J = 6.0 Hz, 2H), 3.90 (d, J = 6.0 Hz, 2H), 3.85 (s, 3H), 3.81 (s, 3H), 3.73 (s, 2H), 3.05 (d, J = 6.1 Hz, 2H), 3.01 - 2.92 (m, 2H), 2.65 - 2.57 (m, 2H), 2.01 (t, J = 7.3 Hz, 2H), 1.53 - 1.40 (m, 2H), 0.83 (dt, J = 14.8, 4.8 Hz, 3H).

Example 29

N-{3- r2 _i 3-Dimethoxy-6-( l-oxo-indan-4-yn-phenoxymethyl1-oxetan-3-ylmethyl>-2-

To a stirring solution of 4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan- l-one (150 mg, 0.391 mmol) in dichloromethane (15 mL), methoxy- acetic acid ( 142 mg, 1.56 mmol), l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC. HCI) ( 112 mg, 0.587 mmol) and l-Hydroxy-7-azabenzotriazole (HOAt) ( 106 mg, 0.78 mmol) and triethylamine were added and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-3% methanol in dichloromethane) afforded the title compound as a solid .

1H NMR (600 MHz, DMSO-SPE) δ 7.84 (t, J = 6.3 Hz, 1 H), 7.63 (td, J = 7.9, 2.2 Hz, 1H), 7.57 (dd, J = 7.3, 1.0 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1 H), 7.05 (d, J = 8.5 Hz, 1H), 6.98 - 6.95 (m, 1 H), 4.15 (d, J = 6.1 Hz, 2H), 3.88 (d, J = 6.1 Hz, 2H), 3.87 (s, 3H), 3.82 (s, 3H), 3.78 (s, 2H), 3.75 - 3.67 (m, 2H), 3.28 (s, 3H), 3.12 (d, J = 6.3 Hz, 2H), 2.99 - 2.92 (m, 2H), 2.61 (dd, J = 6.7, 5.0 Hz, 2H).

Example 30

■r3-r2 _f 3-Dimethoxy-6-(l-oxo-indan-4-yl ^' )-phenoxymethyll-oxetan-3-ylmetriyl ^' }-carbamic

To a stirring solution of 4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 191) (150 mg, 0.3916 mmol) in dichloromethane (15 mL), were added triethylamine (118 mg, 1.174 mmol) and ethyl carbonochloridate (84 mg, 0.783 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 192 to afford the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (t, J = 6.6 Hz, 1H), 7.55 (dd, J = 7.3, 1.0 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.14 (t, J = 6.0 Hz, 1H), 7.06 - 7.02 (m, 1H), 6.98 - 6.94 (m, 1H), 4.10 (d, J = 6.1 Hz, 2H), 3.98 - 3.92 (m, 2H), 3.89 (d, J = 6.1 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 3.75 (s, 2H), 2.96 (dd, J = 12.6, 6.0 Hz, 4H), 2.64 - 2.58 (m, 2H), 1.17 - 1.11 (m, 3H).

Example 31

• 3-( ^" 2,3-Dimethoxy-6-Cl-oxo-indan-4-ylVphenoxymethyll-oxeta n-3-ylmethyl -carbamic

To a stirring solution of 4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 191) (150 mg, 0.3916 mmol) in dichloromethane (15 mL), were added triethylamine (118 mg, 1.174 mmol) and isopropyl carbonochloridate (95 mg, 0.783 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 192 to afford the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.63 (d, J = 7.3 Hz, 1H), 7.55 (dd, J = 7.3, 0.9 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.09 (t, J = 6.1 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.95 (dd, J = 8.6, 4.3 Hz, 1H), 4.70 (hept, J = 6.2 Hz, 1H), 4.10 (d, J = 6.1 Hz, 2H), 3.91 - 3.85 (m, 5H), 3.81 (s, 3H), 3.75 (s, 2H), 2.95 (t, J = 5.5 Hz, 4H), 2.61 (dd, J = 6.5, 5.1 Hz, 2H), 1.18 - 1.12 (m, 6H).

Example 32

-{ ^" 3- 2 _f 3-Dimethoxy-6-(l-oxo-indan-4-yn-phenoxymethyn-oxetan-3 -ylmethyl -carbamic

To a stirring solution of 4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 191) (150 mg, 0.3916 mmol) in dichloromethane (15 ml_), were added triethylamine (118 mg, 1.174 mmol) and 2-methoxyethyl

carbonochloridate (99 mg, 0.783 mmol) and the resultant reaction mixture was subjected to the conditions used in the preparation of Compound 192 to afford the title compound as a solid.

1H NMR (600 MHz, DMSO-SPE) δ 7.62 (dd, J = 13.5, 7.6 Hz, 1H), 7.55 (d, J = 6.8 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.29 (t, J = 6.1 Hz, 1H), 7.06 - 7.02 (m, 1H), 6.97 - 6.93 (m, 1H), 4.10 (d, J = 6.1 Hz, 2H), 4.04 (dd, J = 11.7, 7.1 Hz, 2H), 3.89 (d, J = 6.1 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 3.76 (s, 2H), 3.46 (dd, J = 10.3, 5.8 Hz, 2H), 3.24 (s, 3H), 3.00 - 2.90 (m, 4H), 2.61 (dd, J = 12.1, 7.2 Hz, 2H). Example 33

3-[2 _r 3-Dimethoxy-6-( l-oxo-indan-4-ylVphenoxy1-2.2-dimethyl-propionic

To a stirring solution of 4-(2-Hydroxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 303) (1.3 g, 4.57 mmol), triphenylphosphine (3.5 g, 13.35 mmol),

diethylazodicarboxylate (2.4 g, 13.40 mmol) in tetrahydrofuran (30 mL) methyl 3- hydroxy-2,2-dimethylpropanoate (1.2 g, 9.09 mmol) was added portion wise and the resultant reaction mixture was heated to 70 °C. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) afforded Methyl 3-(2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-inden- 4-yl) phenoxy)-2,2-dimethyl propanoate as a solid. To a stirring solution of methyl 3-(2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-inden-4-yl) phenoxy)-2,2-dimethyl propanoate (650 mg, 1.641 mmol) in THF (15 mL) lithium hydroxide (689 mg, 16.41 mmol) and water (5 mL) were added and the resultant reaction mixture was stirred for 2 h at room temperature. The reaction mixture was concentrated under reduced pressure and purification by column chromatography (silica gel, 0-60% ethyl acetate in pet ether) afforded the title compound as a solid.

Example 34

3-[2,3-Dimethoxy-6-f l-oxo-indan-4-yn-phenoxyl-2,2 _f N-trimethyl-propion

To a stirring solution of 3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 199) (30 mg, 0.078 mmol) in dichloromethane, were added l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCI) (22 mg, 0.117 mmol), 1-Hydroxybenzotriazole hydrate (HOBT) (23 mg, 0.156 mmol) and triethylamine (0.1 mL, 0.234 mmolo) and 1M methylamine solution (0.15 mL, 0.156 mmol) and the resultant reaction mixture was stirred at 16 h at RT. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine and dried over anhydrous sodium sulphate and

concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-60% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (400 MHz, cdcl3) δ 7.79 (d, J = 7.1 Hz, 1H), 7.54 (dd, J = 7.3, 0.9 Hz, 1H), 7.45 (t, J = 7.5 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.82 (m, 2H), 3.95 (s, 3H), 3.95 (s, 3H), 3.53 (s, 2H), 3.05 - 2.98 (m, 2H), 2.73 (d, J = 7.5 Hz, 3H), 2.66 (dd, J = 12.3, 7.0 Hz, 2H), 0.87 (s, 6H).

Example 35

3-r2,3-Dimethoxy-6-(l-oxo-indan-4-yn-phenoxy1-N-ethyl-2.2-di methyl-propionamide (Compound 2011

From 3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 199) and 2M ethylamine solution following the procedure for the preparation of Compound 200. Purification by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (400 MHz, cdcl3) δ 7.76 (d, J = 7.5 Hz, 1H), 7.52 (dd, J = 7.3, 0.9 Hz, 1H), 7.42 (dd, J = 9.4, 5.5 Hz, 1H), 6.94 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 6.73 (s, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.53 (s, 2H), 3.24 - 3.12 (m, 2H), 3.03 - 2.94 (m, 2H), 2.69 - 2.59 (m, 2H), 1.11 - 1.02 (m, 3H), 0.82 (s, 6H).

Example 36

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy1-2.2 _r N _f N-tetramethyl-propionamide

From 3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 199) and 2M dimethylamine solution following the procedure for the preparation of Compound 200. Purification by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.75 (d, J = 6.8 Hz, 1H), 7.52 (dd, J = 7.3, 1.0 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.5 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.77 (s, 2H), 3.02 (d, J = 6.1 Hz, 2H), 2.71 - 2.63 (m, 2H), 1.07 (s, 6H).

Example 37

N-Cyclopropyl-3-r2.3-dimethoxy-6-< ^' l-oxo-indan-4-yl)-phenoxy1-2,2-dimethyl-

From 3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 199) and cyclopropylamine following the procedure for the preparation of Compound 200. Purification by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.77 (d, J = 7.4 Hz, 1H), 7.52 (dd, J = 7.3, 1.1 Hz, 1H), 7.43 (t, J = 7.4 Hz, 1H), 6.94 (m, 2H), 6.81 (d, J = 8.6 Hz, 2H), 3.96 (s, 3H), 3.94 (s, 3H), 3.49 (s, 2H), 3.05 - 2.95 (m, 2H), 2.72 - 2.64 (m, 2H), 0.79 (d, J - 8.0 Hz, 6H), 0.77 - 0.71 (m, 2H), 0.44 (m, 2H) . Example 38

4-r2-(2,2-Dimethyl-3-morpholin-4-yl-3-oxo-propoxy')-3,4-dime thoxy-phenyn-indan-l-

From 3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 199) and morpholine following the procedure for the preparation of

Compound 200. Purification by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.76 (d, J = 7.5 Hz, 1H), 7.52 (d, J = 6.3 Hz, 1H), 7.41 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.5 Hz, 1H), 6.78 (d, J = 8.5 Hz, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.74 (s, 2H), 3.59 - 3.51 (m, 4H), 3.45 - 3.36 (m, 4H), 3.08 - 2.97 (m, 2H), 2.72 - 2.63 (m, 2H), 1.04 (s, 6H).

Example 39

3-r2.3-Dimethoxy-6-(l-oxo-indan-5-yn-phenoxy1-2,2-dimethyl-p ropionic

To a stirring solution of 5-(2-hydroxy-3,4-dimethoxyphenyl)-indan-l-one (Compound 305) ( 1.3 g, 4.57 mmol) in tetrahydrofuran (30 mL), were added triphenylphosphine (3.5 g, 13.35 mmol) and diethylazodicarboxylate (2.4 g, 13.40 mmol) and methyl 3- hydroxy-2,2-dimethylpropanoate (1.2 g, 9.09 mmol) was added portion wise and the resultant reaction mixture was heated to 70 °C. The reaction mixture was quenched with water and extracted with ethyl acetate (3 x).The combined ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) afforded methyl 3-(2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-inden- 5-yl)phenoxy)-2,2-dimethyl propanoate as a solid.

To a stirring solution of methyl 3-(2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-inden-5- yl)phenoxy)-2,2-dimethyl propanoate (650 mg, 1.641 mmol) in THF (15 ml_), were added lithium hydroxide (689 mg, 16.41 mmol) and water (5 mL) and the resultant reaction mixture was stirred for 2 h. The reaction mixture was concentrated under reduced pressure and purification by column chromatography (silica gel, 0-60% ethyl acetate in pet ether) afforded the title compound as a solid.

Example 40

3- 2.3-Dimethoxy-6-f l-oxo-indan-5-yl1-phenoxyl-2.2 _r N-trimethyl-propion

To a stirring solution of 3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 205) ( 100 mg, 0.260 mmol) in dichloromethane, were added l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCI) (75 mg, 3.90 mmol), 1-Hydroxybenzotriazole hydrate (HOBT) (80 mg, 0.520 mmol) and triethylamine (0.1 mL, 0.9814 mmol) and 1M methylamine solution (0.4 mL, 0.520 mmol) and the resultant reaction mixture was stirred at 16 h at room temperature. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.79 (d, J = 7.9 Hz, 1H), 7.62 (s, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.09 (m, 2H), 6.82 (d, J = 8.6 Hz, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.56 (s, 2H), 3.23 - 3.11 (m, 2H), 2.85 - 2.67 (m, 5H), 1.03 (s, 6H). Example 41

3-[2.3-Dimetrioxy-6-(l-oxo-indan-5-yl)-phenoxyl-2.2 _r N _r N-tetramethyl-propionamide

)

This was obtained from 3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 205) and dimethylamine following the procedure for preparation of Compound 206. Purification by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.75 (d, J = 7.9 Hz, 1H), 7.62 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 6.77 (d, J - 8.6 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.81 (s, 2H), 3.24 - 3.11 (m, 2H), 2.90 (s, 5H), 2.79 - 2.66 (m, 2H), 1.22 (s, 6H).

Example 42

3-[2,3-Dimethoxy-6-f l-oxo-indan-5-yn-phenoxy1-N-isopropyl-2.2-dimethyl-

From 3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 205) and isopropylamine following the procedure for preparation of

Compound 206. Purification by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (300 MHz, cdcl3) δ 7.77 (d, J = 7.9 Hz, 1H), 7.59 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.05 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 8.7 Hz, 1H), 6.52 (d, J = 7.0 Hz, 1H), 4.05 (td, J = 13.4, 6.7 Hz, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.64 (s, 2H), 3.21 - 3.12 (m, 2H), 2.78 - 2.66 (m, 2H), 1.14 (d, J = 6.6 Hz, 6H), 0.99 (s, 6H).

Example 43

3-r2 _r 3-Dimethoxy-6-(l-oxo-indan-5-yl ^' )-phenoxy1-2.2-dimethyl-N-propyl-propionamide (Compound 209)

From 3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 205) and propan-l-amine following the procedure for preparation of Compound 206. Purification by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) afforded the title compound as a solid.

1H NMR (400 MHz, cdcl3) δ 7.78 (d, J = 7.9 Hz, 1H), 7.61 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 6.95 (s, 1H), 6.81 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.61 (s, 2H), 3.18 (dd, J = 13.3, 6.9 Hz, 4H), 2.78 - 2.68 (m, 2H), 1.6 (s, 6H), 1.50 (m, 2H), 1.02 (s, 6H), 0.90 (t, 3 = 7.4 Hz, 3H).

Example 44

Ethyl-carbamic acid 3-r2 _r 3-dimethoxy-6-(l-oxo-1.3-dihydro-isobenzofura

-5-yn-phenoxy ^" l-2 _f 2-dimethyl-propyl ester (Compound 210)

In a screw cap vessel Compound 306 (0.017g, 0.06 mmol) and 3-bromo-2,2-dimethyl- 1-propanol (0.2g, 0.12 mmol) were dissolved in DMF (0.5 mL) and K ₂ C0 ₃ (0.02g, 0.15 mmol) was added. The suspension was heated at 100°C for 20h. 3-Bromo-2,2-dimethyl- 1-propanol (0.2g, 0.12 mmol) and K ₂ C0 ₃ (0.02g, 0.15 mmol) was added and the suspension was heated at 100°C for 4 h. H ₂ 0 (3 mL) was added and the suspension was extracted with EtOAc (3 x 3 mL). The combined organic phases were washed with brine, dried (Na ₂ S04), filtered and concentrated.

In a screw cap vessel the crude product was dissolved in CH ₃ CN (0.2 mL). triethyl amine (0.003 mL) and Ethyl isocyanate (0.049 mL, 0.6 mmol) were added. The mixture was heated at 50°C for 18 h and the solvent was evaporated. The crude product was purified by flash chromatography using toluene : EOAc 3 : 1 as the eluent. This afforded the title compound as an oil.

1H NMR (300 MHz, DMSO) δ 7.84 (d, J = 7.9 Hz, 1H), 7.72 (s, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.88 (s, 1H), 5.42 (s, 2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.62 (s, 2H), 3.56 - 3.44 (m, 2H), 3.01 - 2.88 (m, 2H), 1.01 - 0.93 (m, 3H) , 0.79 (s, 6H) .

Example 45

Ethyl-carbamic acid 3-r2,3-dimethoxy-6-( l-oxo-indan-4-yl)-phenoxy ^" l-2,2

The compound was prepared according to the procedure described in example 44 using compound 303 as the starting material .

1H NMR (300 MHz, DMSO) δ 7.62 (dd, J - 7.4, 1.2 Hz, 1H), 7.53 (dd, J = 7.3, 1.3 Hz, 1H), 7.47 (d, J = 7.4 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1 H), 6.93 - 6.84 (m, 2H), 3.85 (s, 3H), 3.78 (s, 3H), 3.46 (s, 2H), 3.44 (s, 2H), 2.98 - 2.90 (m, 4H), 2.61 (dd, J = 6.8, 4.7 Hz, 2H), 0.97 (t, J = 7.3 Hz, 3H), 0.58 (s, 6H) . Example 46

Ethyl-carbamic acid 3-f2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol- -y0-phenoxy ^" l-2,2-dimethyl-propyl ester (Compound 212)

The compound was prepared according to the procedure for the preparation of

Compound 210 using compound 307 as the starting material .

1 H NMR (300 MHz, DMSO) δ 8.50 (t, J = 5.7 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1 H), 7.74 (s, 1 H), 7.61 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1 H), 6.94 (d, J = 8.8 Hz, 1 H), 6.85 (s, 1H), 4.81 (s, 2H), 3.85 (s, 3H), 3.79 (d, J = 3.0 Hz, 3H), 3.59 (d, J = 11.6 Hz, 2H), 3.52 (d, J = 11.8 Hz, 2H), 3.00 - 2.85 (m, 2H), 1.20 - 1.10 (m, 3H), 0.78 (s, 6H).

Example 47

Ethyl-carbamic acid 3-[ ^" 2,3-dimethoxy-6-( l-oxo- 1.3-dihvdro-isobenzofura

n-5-yl)-phenoxymethyl ^" l-oxetan-3-ylmethyl ester (Compound 213)

In a screw cap vessel Compound 306 (0.017g, 0.06 mmol) and 3-bromomethyl-3- hydroxymethyl-oxetane (0.22g, 0.12 mmol) were dissolved in DMF (0.5 mL) and K ₂ C0 ₃ (0.02g, 0.15 mmol) was added. The suspension was heated at 100°C for 3h. H ₂ 0 (3 mL) was added and the suspension was extracted with EtOAc (3 x 3 mL). The combined organic phases were washed with brine, dried (Na ₂ S04), filtered and concentrated.

In a screw cap vessel the crude product was dissolved in CH ₃ CN (0.2 mL). Triethyl amine (0.003 mL) and Ethyl isocyanate (0.044 mL, 0.6 mmol) were added. The mixture was heated at 50°C for 18 h and the solvent was evaporated. The crude product was purified by flash chromatography using toluene: EOAc 60:40 -> 40: 60 as the eluent. This afforded the title compound as an oil.

1H NMR (300 MHz, DMSO) δ 7.85 (d, J = 8.0 Hz, 1H), 7.72 (s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.16 (d, J = 8.7 Hz, 1H), 7.07 (t, J = 5.5 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 5.43 (s, 2H), 4.25 (t, J = 7.3 Hz, 2H), 4.17 (d, J = 6.1 Hz, 2H), 4.08 - 3.98 (m, 2H), 3.94 (s, 2H), 3.87 (s, 3H), 3.81 (s, 3H), 3.03 - 2.92 (m, 2H), 1.03 - 0.92 (m, 3H).

Example 48

Ethyl-carbamic acid 3-r2 _f 3-dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol- -yh-phenoxymethyll-oxetan-3-ylmethyl ester (Compound 214)

The title compound was prepared following the procedure described in example 47, using compound 307 as the starting material.

1H NMR (300 MHz, DMSO) δ 8.50 (t, J = 5.7 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.73 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.00 (m, 2H), 4.82 (s, 2H), 4.25 (d, J = 6.1 Hz, 2H), 4.17 (d, J = 6.1 Hz, 2H), 4.02 (dd, J = 8.5, 5.7 Hz, 2H), 3.94 (s, 2H), 3.87 (s, 3H), 3.82 (s, 3H), 3.02 - 2.85 (m, 2H), 1.15 (dd, J = 11.3, 4.1 Hz, 3H).

Example 49 5-[3 _f 4-Dimethoxy-2-f 3-methoxymethyl-oxetan-3-ylmethoxy ^' l-prienyl1-3H-

3-(bromomethyl)-3-(methoxymethyl)oxetane (0.35g, 0.18 mmo,) preparation described in example 24) and 6-bromo-2,3-dimethoxyphenol (0.21g, 0.9 mmol)(preparation described in Preparation 1) were dissolved in DMF (8 mL). K ₂ C0 ₃ (0.31g, 2.2 mmol) was added. The suspension was heated in a microwave oven at 100°C for 10 min. H ₂ 0 was added and the mixture was extracted with EtOAc (x 2). The combined organic phases were washed with brine, dried (Na ₂ S0 ₄ ), filtered and concentrated. Purification by flash chromatography (Heptane: EtOAc 100: 0 -> 75 : 25) yielded 3-(6-Bromo-2,3-dimethoxy- phenoxymethyl)-3-methoxymethyl-oxetane as an oil.

3-(6-Bromo-2,3-dimethoxy-phenoxymethyl)-3-methoxymethyl-o xetane (0.02g, 0.06 mmol) and 5-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-3H-isobenzo furan-l-one (Compound 309) (0.039 g, 0.14 mmol) were dissolved in 1,4-dioxan (0.6 mL). Argon was purged through the solution. Pd ₂ (dba) ₃ O.OOlg, O.OOlmmol) and PCy ₃ (0.0008g, 0.003 mmol) were added followed by addition of K ₃ P0 ₄ (0.043g, 0.2 mmol) in H ₂ 0 (0.3 mL). The reaction mixture was heated in a microwave oven at 120°C for 10 min. The mixture was filtrated, concentrated, redissolved in DMSO and purified by preparative HPLC to afford the title compound.

1H NMR (600 MHz, DMSO-SPE) δ 7.88 (d, J = 8.0 Hz, 1H), 7.73 (s, 1H), 7.67 - 7.63 (m, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.00 - 6.95 (m, 1H), 5.44 (s, 2H), 4.25 - 4.19 (m, 2H), 4.15 (d, J = 6.0 Hz, 2H), 3.91 (s, 2H), 3.87 (s, 3H), 3.82 (s, 3H), 3.38 (s, 2H), 3.16 (s, 3H).

Example 50

5-r3.4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy ^' )-phenyll-2.3-dihydro-

The title compound was prepared following the procedure described in example 49, using 5-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-2,3-dihydro -isoindol-l-one (Compound 310) as the boronic acid ester.

1H NM (600 MHz, DMSO-SPE) δ 8.55 (s, 1H), 7.69 (d, J - 7.8 Hz, 1H), 7.62 (d, J = 8.2 Hz, 1H), 7.53 (dd, J = 11.6, 3.7 Hz, 1H), 7.11 (d, J = 8.6 Hz, 1H), 6.96 (dd, J = 10.0, 5.5 Hz, 1H), 4.40 (d, J = 9.4 Hz, 2H), 4.21 (d, J = 6.0 Hz, 2H), 4.13 (d, J = 6.0 Hz, 2H), 3.89 (s, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 3.36 (s, 2H), 3.15 (s, 3H).

Example 51

4-[3,4-Dimethoxy-2-(3-methoxy-2 _r 2-dimethyl-propoxy phenyl ^" l-indan-l-one

Under an argon atmosphere 3-Bromo-2,2-dimethyl-propan-l-ol (l. lg, 6.9 mmol) was dissolved in dry THF (50ml_) and cooled to 0°C. NaH (0.4g, 16.5 mmol) was added and the suspension was stirred at 0°C for 15 min. Mel (1.7 ml_, 27.6 mmol) was added at 0°C. The reaction mixture was allowed to stir at RT for 2 h. H ₂ 0 (100 mL) was added and the aqueous phase was extracted with EtOAc (x 2). The combined organic phases were washed with brine, dried (Na ₂ S0 ₄ ), filtered and concentrated to afford l-bromo-3- methoxy-2,2-dimethyl-propane as an oil.

Compound 303 (0.02g, 0.07 mmol) and l-bromo-3-methoxy-2,2-dimethyl-propane (0.12g, 0.56mmol) were dissolved in dry DMF (0.8 mL). K ₂ C0 ₃ (O. lg, 0.68mmol) were added. The suspension was heated at 100°C for 18h. H ₂ 0 was added and the mixture was extracted with EtOAc (x 2). The combined organic phases were washed with brine, dried (Na ₂ S0 ₄ ), filtered and concentrated. Purification by preparative HPLC afforded the title compound as an oil.

1H NMR (300 MHz, CDCI3) δ 7.76 (d, J = 7.6 Hz, 1H), 7.52 (dd, J = 7.4, 1.2 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.75 (d, J = 8.5 Hz, 1H), 3.92 (s, 6H), 3.49 (s, 2H), 3.11 - 3.01 (m, 5H), 2.81 (s, 2H), 2.73 - 2.61 (m, 2H), 0.66 (s, 6H).

Example 52

5-r3 _f 4-Dimethoxy-2-(3-methoxy-2 _r 2-dimethyl-propoxyVphenyll-3H-isobenzofuran-l- one (Compound 218)

The title compound was prepared following the procedure described in example 51, using compound 306 as the starting material.

1H NMR (300 MHz, CDCI3) δ 7.93 (d, J = 8.0 Hz, 1H), 7.71 - 7.65 (m, 1H), 7.62 (s, 1H), 7.04 (d, J = 8.7 Hz, 1H), 6.76 (d, J = 8.7 Hz, 1H), 5.34 (s, 2H), 3.91 (s, 6H), 3.56 (s, 2H), 3.15 (s, 3H), 3.00 (s, 2H), 0.81 (s, 6H).

Example 53

5-[3 _i 4-Dimethoxy-2-(3-methoxy ^, -2 _r 2-dimethyl-propoxy ^' )-phenyn-2,3-dihvdro-isoindol-l-

The title compound was prepared following the procedure described in example 51, using compound 307 as the starting material.

1H NMR (300 MHz, CDCI3) δ 7.89 (d, J = 8.3 Hz, 1H), 7.62 (d, J = 6.5 Hz, 2H), 7.04 (d, J = 8.7 Hz, 1H), 6.75 (d, J = 8.7 Hz, 1H), 6.29 (s, 1H), 4.48 (s, 2H), 3.91 (s, 6H), 3.54 (s, 2H), 3.15 (s, 3H), 2.99 (s, 2H), 0.80 (s, 6H).

Example 54

3-(2,3-dimethoxy-6-f l-oxo-1.3-dihydroisobenzofuran-5-ynphenoxy)-2 _i 2- dimethylpropanoic acid (Compound 220^

To a stirring solution of methyl 3-hydroxy-2,2-dimethylpropanoate (2.76 g, 20.94 mmol, in portions) in tetrahydrofuran (25 mL) was added diethylazodicarboxylate (2.43 g, 13.96 mmol), triphenylphosphine (3.59 g, 13.96 mmol) and 5-(2-hydroxy-3,4- dimethoxyphenyl) isobenzofuran-l(3H)-one (2 g, 6.98 mmol) and the resultant reaction mixture was heated to 70 °C for 6 h. The reaction mixture was diluted with ethyl acetate layer, washed with water, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by flash, column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford Methyl 3-(2,3-dimethoxy-6-(l- oxo-l,3-dihydroisobenzofuran-5-yl)phenoxy)-2,2-dimethylpropa noate as a solid (800 mg, 28.6%)

To a stirring solution of methyl 3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5- yl) phenoxy)- 2,2-dimethylpropanoate (200 mg, 0.49 mmol) in tetrahydrofuran (15 mL) was added lithium hydroxide (102.5 mg, 2.45 mmol) in water (5 mL) and the resultant reaction mixture was stirred at RT for 4 h. The reaction mixture was concentrated under reduced pressure, the residue was acidified using IN HCI solution to pH 5 and then extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (120 mg, 63%).

Example 55

3-f2.3-dimethoxy-6-f l-oxo-l ,3-dihydroisobenzofuran-5-ynphenoxyV/V.2 _r 2- trimeth lpropanamide (Compound 221 ^' )

To a stirring solution of 3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5- yl)phenoxy)-2,2-dimethylpropanoic acid (100 mg, 0.259 mmol) in dichloromethane (10 mL) was added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCI) (74 mg, 0.388 mmol), triethylamine (0.1 mL, 0.77 mmol) and 1-hydroxybenzotriazole hydrate (HOBt) (79 mg, 0.518 mmol) and stirred for 10 min. To this methyl amine solution in THF (0.518 mmol) was added and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-80% ethyl acetate in pet ether) afforded the title compound as a solid (50 mg, 50%).

UPLC-MS (M + l): 400.16; UPLC-MS RT (min) : 2.2 Example 56

3-(2,3-dimethoxy-6-f l-oxo-l,3-dihydroisobenzofuran-5- nphenoxyV/V./V _f 2.2-

tetramethylpropanamide (Compound 222)

To a stirring solution of 3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5- yl)phenoxy)-2,2-dimethylpropanoic acid (100 mg, 0.259 mmol) in dichloromethane (10 mL) was added l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCI) (74.1 mg, 0.388 mmol), triethylamine (1 mL, 0.77 mmol) and 1-hydroxybenzotriazole hydrate (HOBt) (79.2 mg, 0.518 mmol) and stirred for 10 min. To this dimethylamine (23 mg, 0.518 mmol) was added and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-45% ethyl acetate in pet ether) afforded the title compound as a solid (30 mg, 30%).

UPLC-MS (M + l) : 414.19 ; UPLC-MS RT (min) : 2.3

Example 57

3-i2,3-dimethoxy-6-il-oxo-l,3-dihydroisobenzofuran-5-ynpheno xy)-N-isopropyl-2.2- dimeth lpropanamide (Compound 223)

To a stirring solution of 3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5- yl)phenoxy)-2,2-dimethylpropanoic acid (100 mg, 0.25 mmol) in dichloromethane (10 mL) was added l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC. HCI) (71.6 mg, 0.375 mmol), triethylamine (1 mL, 0.75 mmol) and 1-hydroxybenzotriazole hydrate (HOBT) (76.5 mg, 0.50 mmol) and stirred for 10 min. To this isopropyl amine (59 mg, 1.00 mmol) was added and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) afforded the title compound as a solid (27 mg, 27%).

UPLC-MS (M + l) : 428.19 ; UPLC-MS RT (min) : 2.4

Example 58

3-(2,3-dimethoxy-6-(l-oxo-l _f 3-dihydroisobenzofuran-5-yl)phenoxy)-2 _f 2-dimethyl-N- ropylpropanamide (Compound 224)

To a stirring solution of 3-(2,3-dimethoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5- yl)phenoxy)-2,2-dimethylpropanoic acid (100 mg, 0,25 mmol) in dichloromethane (10 mL) was added l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCI) (71.6 mg, 0.375 mmol), triethylamine (0.1 mL, 0.75 mmol) and 1-hydroxybenzotriazole hydrate (HOBT) (76.5 mg, 0.50 mmol) and stirred for 10 min. To this propylamine (59 mg, 1.0 mmol) was added and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) afforded the title compound as a solid (40 mg, 36%).

UPLC-MS (M + l) : 428.19 ; UPLC-MS RT (min) : 2.4

Preparation 11

4-(4-f DifluoromethoxyV2-hydroxy-3-methoxyphenyl)-2 _r 3-dihydro-lH-inden-l-one (Compound 311)

To a stirring solution of benzene-l,2,3-triol (2 g, 15.87 mmol) in acetone was added potassium bicarbonate (1.90 g, 19.04 mmol) and methyl iodide (3.38 g, 23.80 mmol) and the resultant reaction mixture was heated to reflux for 16 h. The reaction mixture was cooled to RT and filtered through celite bed. The filtrate was concentrated under reduced pressure, triturated with diethyl ether and the obtained solid was separated and the filtrate was concentrated under reduced pressure. Purification of the residue by flash chromatography (silica gel, 0-15% ethyl acetate in pet ether) afforded 2- Methoxybenzene-l,3-diol as a solid (600 mg, 27.2%).

4-Bromo-2-methoxybenzene-l,3-diol : To a stirring solution of 2-methoxybenzene-l,3- diol (3.0 g, 21.42 mmol) in tetrahydrofuran (30 mL) at -78 °C was added N- bromosuccinimide (4.57 g, 25.71 mmol) and the reaction mixture was stirred at -78 °C for 2 h. The reaction mixture was diluted with ice-cold water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The obtained residue has mixture of products (mono and dibromo) which was used as such for further reactions (4.2 g).

To a stirring solution of 4-bromo-2-methoxybenzene-l,3-diol (4.5 g, 20.54 mmol) in acetone (40 mL) at 0 °C was added potassium carbonate (2.83 g, 20.54 mmol) and methoxymethyl chloride (1.32 mg, 16.43 mmol) and the resultant reaction mixture was stirred at RT for 7 h. The reaction mixture was quenched with ice-cold water, filtered and the filtrate was concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) afforded 4-Bromo- 2-methoxy-3-(methoxymethoxy)phenol as a liquid (2 g, 37%).

To a stirring solution of 4-bromo-2-methoxy-3-(methoxymethoxy)phenol (700 mg, 2.66 mmol) in Λ/,/V-dimethylformamide (15 mL) was added potassium carbonate (734 mg, 5.32 mmol) cooled to -45 °C and chlorodifluoromethane (gas) was passed for 10 min and the resultant reaction mixture was heated to 80 °C for 2 h. The reaction mixture was quenched with ice-cold water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were dried over anhy. sodium sulphate and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-5% ethyl acetate in pet ether) afforded l-Bromo-4-(difluoromethoxy)-3-methoxy-2- (methoxymethoxy)benzene as a liquid (250 mg, 30%).

A stirring solution of l-bromo-4-(difluoromethoxy)-3-methoxy-2- (methoxymethoxy)benzene (3.0 g, 9.58 mmol) in Λ/,/V-dimethylformamide (30 mL) was purged with argon for 1 h, to this cesium carbonate (9.34 g, 28.74 mmol),

tetrakis(triphenylphosphine) palladium(O) (553 mg, 0.48 mmol) and 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l- one (2.96 g, 11.50 mmol) were added and the resultant reaction mixture was heated to 90 °C for 4 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 4-(4-(difluoromethoxy)-3-methoxy-2-(methoxymethoxy)phenyl)- 2,3-dihydro-lH-inden-l-one as a solid (1.5 g, 43%).

To a stirring solution of 4-(4-(difluoromethoxy)-3-methoxy-2-

(methoxymethoxy)phenyl)-2,3-dihydro-lH-inden-l-one (1 g, 2.74 mmol) in methanol (75 ml_) was added concentrated hydrochloride (5 mL) and the reaction mixture was heated to 50 °C for 1 h. The reaction mixture was cooled to RT and concentrated under reduced pressure and the obtained residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (700 mg, 80%).

Example 59

4-(4-Difluoromethoxy-2-ethoxy-3-methoxy-phenyl')-indan-l-one (Compound 225^

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (75 mg, 0.234 mmol) in acetonitrile (10 mL) was added potassium carbonate (96 mg, 0.702 mmol) and ethyl iodide (109 mg, 0.702 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 24%).

UPLC-MS (M + l) : 349.13 ; UPLC-MS RT (min) : 2.6 Example 60

4- 4-Difluoromethoxy-3-methoxy-2-propoxy-phenyl1-indan-l-one (Compound 2261

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (104 mg, 0.75 mmol) and propyl bromide (92 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 3 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford title compound as a solid (30 mg, 33.3%).

UPLC-MS (M + l) : 363.14 ; UPLC-MS RT (min) : 2.7

Example 61

-(4-Difluoromethoxy-2-isobutoxy-3-methoxy-phenyl)-indan-l-on e (Compound 2271

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (104 mg, 0.75 mmol) and isobutyl bromide (102 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford title compound as a solid (40 mg, 43%).

UPLC-MS (M + l) : 377.16 ; UPLC-MS RT (min) : 2.8 Example 62 4- r4-Difluoromethoxy-2-(3-hydroxy-2,2-dimethyl-propoxy)-3-metr ioxy-phenyll-indan- l- one (Compound 228)

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate ( 104 mg, 0.75 mmol) and followed by 3-bromo-2,2-dimethyl- propan-l-ol ( 125 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h . The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressu re. The residue was purified by column chromatography (silica gel, 0-70% ethyl acetate in pet ether) to afford title compound as a solid (30 mg, 30%) .

Example 63

4-r4-Difluoromethoxy-3-methoxy-2-(3-methoxy-2.2-dimethyl-pro poxy ^' )-phenyl1-indan- 1-one Compound 229

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro- l H-inden- l-one (75 mg, 0.234 mmol) in acetonitrile (10 mL) was added potassium carbonate (96.8 mg, 0.702 mmol) and 3-bromomethyl-3-methyl-oxetane ( 115 mg, 0.702 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column

chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford title compound as a solid (25 mg, 26%) .

UPLC-MS (M + l) : 405.15 ; UPLC-MS RT (min) : 2.5 Example 64

4-[4-Difluoromethoxy-2-(3-rivdroxymethyl-oxetan-3-ylmethoxy) -3-methoxy-phenyll-

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (103.5 mg, 0.75 mmol) and (3-bromomethyl-oxetan-3-yl)- methanol (135.7 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford title compound as a solid (40 mg, 38%).

Example 65

4-r4-Difluoromethoxy-3-methoxy-2-i3-methoxymethyl-oxetan- 3-ylmethoxyVphenyl1- indan-l-one (Compound 231)

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (103.5 mg, 0.75 mmol) and 3-bromomethyl-3-methoxymethyl- oxetane (146 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford title compound as a solid (25 mg, 23%).

UPLC-MS (M + l) : 435.16 ; UPLC-MS RT (min) : 2.5 Example 66

4- r3-Difluoromethoxy-2-methoxy-6-ri-oxo-indan-4-yn-phenoxymeth yl1- benzenesulfonamide (Compound 232)

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 ml_), was added potassium carbonate (104 mg, 0.75 mmol) and 4-bromomethyl-benzenesulfonamide (125 mg, 0.5 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column

chromatography (silica gel, 0-70% ethyl acetate in pet ether) to afford title compound as a solid (40 mg, 33%).

UPLC-MS (M + l) : 490.11 ; UPLC-MS RT (min) : 2.4

Example 67

4- 4-Difluoromethoxy-2-(4-methanesulfonyl-benzyloxy)-3-methoxy- phenyll-indan-l- one (Compound 233

To a stirring solution of 4-(4-(difluoromethoxy)-2-hydroxy-3-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 ml_), was added potassium carbonate (103.5 mg, 0.75 mmol) and l-bromomethyl-4-methanesulfonyl- benzene (186 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford title compound as a solid (40 mg, 24%) .

UPLC-MS (M + l) : 489.1 ; UPLC-MS RT (min) : 2.5 Example 68

4-f f 3-fdifluoromethoxy)-2-methoxy-6-f l-oxo-2,3-dihydro- lH-inden-4- vnphenoxylmethyObenzamide (Compound 234)

To a stirring solution of l-bromo-4-(difluoromethoxy)-3-methoxy-2- (methoxymethoxy)benzene ( 1 g, 3.19 mmol) in methanol ( 15 mL) was added

concentrated hydrochloride (2 mL) and the reaction mixture was heated to 50 °C for 1 h. The reaction mixture was cooled to RT, concentrated under reduced pressure and the obtained residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x) . The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford 6-Bromo- 3-(difluoromethoxy)-2-methoxyphenol as a solid (800 mg, 93%) .

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (1.0 g, 3.71 mmol) in acetonitrile ( 10 mL), was added potassium carbonate ( 1.53 g, 11.08 mmol) and followed by 4-(bromomethyl)benzamide (795 mg, 3.71 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure to afford 4-((6-Bromo-3-(difluoromethoxy)-2-methoxyphenoxy)methyl)benz amide as a solid ( 1 g, 67%).

A stirring solution of 4-((6-bromo-3-(difluoromethoxy)-2- methoxyphenoxy)methyl)benzamide (500 mg, 1.24 mmol) in dimethylformamide ( 10 mL) was purged with argon for 1 h, to this cesium carbonate ( 1.2 g, 3.73 mmol), tetrakis (triphenylphosphine) palladium(O) (72 mg, 0.06 mmol) and 4-(4,4,5,5- tetramethyl- l,3,2-dioxaborolan-2-yl)-2,3-dihydro- l H-inden- l-one (641 mg, 2.48 mmol) was added and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-80% ethyl acetate in pet ether) to afford title compound as a solid (150 mg, 26.7%) . UPLC-MS (M + l ) : 454.13 ; UPLC-MS T (min) : 2.3 Preparation 12

5-f4-fdifluoromethoxy ^' )-2-hydroxy-3-methoxyphenynisobenzofuran-l(3HVone

(Compound 312) :

A stirring solution of l-bromo-4-(difluoromethoxy)-3-methoxy-2-

(methoxymethoxy)benzene (3 g, 9.58 mmol) in /V _/ W-dimethylformamide (30 mL) was purged with argon for 1 h, to this cesium carbonate (9.36 g, 28.74 mmol),

tetrakis(triphenylphosphine) palladium(O) (553 mg, 0.479 mmol) and 5-(4,4,5,5- tetramethyl- l,3,2-dioxaborolan-2-yl)isobenzofuran- l(3H)-one (2.98 g, 11.49 mol) were added and the resultant reaction mixture was heated to 90 °C for 4 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 5-(4-(difluoromethoxy)-3-methoxy-2-

(methoxymethoxy)phenyl)isobenzofuran- l(3H)-one as a solid ( 1.5 g, 42%) .

To a stirring solution of 5-(4-(difluoromethoxy)-3-methoxy-2-(methoxymethoxy)phenyl) isobenzofuran- l(3H)-one ( 1 g, 2.73 mmol) in methanol (75 mL) was added concentrated hydrochloride (5 mL) and the reaction mixture was heated to 50 °C for 1 h. The reaction mixture was cooled to RT and concentrated under reduced pressure. The obtained residue was basified with sodium bicarbonate solution and extracted with

dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (800 mg, 91%) . Example 69

5-(4-Difluoromethoxy-2-ethoxy-3-methoxy-phenylV3H-isobenzofu ran- l-one (Compound 235

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (103.5 mg, 0.75 mmol) and ethyl iodide (0.1 mL, 0.75 mmol) and the resultant reaction mixture was heated to 70 °C for 3 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 100- 200 mesh, 0-30% ethyl acetate in pet ether) to afford title compound as a solid (50 mg, 58%). Example 70

5-(4-Difluoromethoxy-3-methoxy-2-propoxy-phenylV3H-isobenzof uran-l-one

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (103.5 mg, 0.75 mmol) and propyl bromide (92.2 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 3 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 22%). UPLC-MS (M + l) : 365.13 ; UPLC-MS RT (min) : 2.6

Example 71

5-(4-Difluoromethoxy-2-isobutoxy-3-methoxy-phenyl)-3H-isoben zofu ran-l-one

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran- l(3H)-one (80 mg, 0.25 mmol) in acetonitrile ( 10 mL) was added potassium carbonate ( 103 mg, 0.75 mmol) and isobutyl bromide ( 102 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h . The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column

chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford title compound as a solid (30 mg, 32%) .

UPLC-MS (M + l) : 379.14 ; UPLC-MS RT (min) : 2.7

Example 72

5-[4-Difluoromethoxy-2-i3-hydroxy-2.2-dimethyl-propoxyV3-met hoxy-phenyn-3H- isobenzofuran- l-one (Compound 238)

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran- l(3H)-one (100 mg, 0.31 mmol) in acetonitrile (10 mL) was added potassium carbonate ( 128 mg, 0.930 mmol) and 3-bromo-2,2-dimethyl- propan- l-ol ( 155 mg, 0.930 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h . The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by prep TLC to afford title compound as a solid (10 mg, 8%).

Example 73

5-r4-Difluoromethoxy-3-methoxy-2-(3-methoxy-2,2-dimethyl- propoxy)-phenyll-3H- isobenzofuran-l-one (Compound 239)

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.25 mmol) in acetonitrile (10 ml_), was added potassium carbonate (103.5 mg, 0.75 mmol) and and 3-bromomethyl-3- methyl-oxetane (123 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 3 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford title compound as a solid (30 mg, 30%).

UPLC-MS (M + l) : 407.13 ; UPLC-MS RT (min) : 2.5

Example 74

5- 4-Difluoromethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethoxy ^' )-3-methoxy-phenyl1- -isobenzofuran-l-one ( ^" Compound 240)

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.25 mmol) in acetonitrile (10 imL), was added potassium carbonate (103.5 mg, 0.75 mmol) and (3-bromomethyl-oxetan-3- yl)-methanol ( 135.7 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) to afford title compound as a solid (30 mg, 28.8%).

Example 75

4- r3-Difluoromethoxy-2-hydroxy-6-(l-oxo-l _f 3-dihvdro-isobenzofuran-5-yn- phenoxymethyll-benzenesulfonamide (Compound 241)

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran-l(3H)-one (100 mg, 0.310 mmol) in acetonitrile (20 mL), was added potassium carbonate (128.3 mg, 0.930 mmol) and 4-bromomethyl- benzenesulfonamide (155.2 mg, 0.620 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-70% ethyl acetate in pet ether) to afford title compound as a solid (70 mg, 46%).

UPLC-MS (M + l) : 492.96 ; UPLC-MS RT (min) : 2.3 Example 76

5-r4-Difluoromethoxy-3-hydroxy-2-(4-methanesulfonyl-benzylox y ^' )-phenyl1-3H- isobenzofuran-l-one (Compound 2421

To a stirring solution of 5-(4-(difluoromethoxy)-2-hydroxy-3- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.25 mmol) in acetonitrile (5 mL), was added potassium carbonate (103.5 mg, 0.75 mmol) and l-bromomethyl-4- methanesulfonyl-benzene (186.8 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 100-200 mesh, 0-20% ethyl acetate in pet ether) to afford title compound as a solid (50 mg, 41%).

UPLC-MS (M + l) : 491.09 ; UPLC-MS RT (min) : 2.4

Example 77

5-(4-fdifluoromethoxy)-3-methoxy-2-((3-(methoxymethyhoxet an-3-

To a stirring solution of l-bromo-4-(difluoromethoxy)-3-methoxy-2- (methoxymethoxy)benzene (1 g, 3.19 mmol) in methanol (15 mL) was added

concentrated hydrochloride (2 mL) and the reaction mixture was heated to 50 °C for 1 h. The reaction mixture was cooled to RT, concentrated under reduced pressure and the obtained residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford 6-Bromo- 3-(difluoromethoxy)-2-methoxyphenol as a solid (800 mg, 93%).

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (0.3 g, 1.11 mmol) in acetonitrile (10 mL) was added potassium carbonate (0.46 g, 3.34 mmol) and followed by 3-(bromomethyl)-3-(methoxymethyl)oxetane (0.43 g, 2.22 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 3-((6-bromo-3-(difluoromethoxy)-2-methoxyphenoxy)methyl)-3- (methoxymethyl)oxetane as a solid (0.3 g, 70%). A stirring solution of 3-((6-bromo-3-(difluoromethoxy)-2-methoxyphenoxy)methyl)-3- (methoxymethyl)oxetane (220 mg, 0.574 mmol) in dimethylformamide (10 mL) was purged with argon for 1 h, to this cesium carbonate (561 mg, 1.72 mmol), tetrakis (triphenylphosphine) palladium(O) (19 mg, 0.017 mmol) and 5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)isobenzofuran-l(3H)-one (178 mg, 0.686 mmol) was added and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-80% ethyl acetate in pet ether) to afford title compound as a solid (30 mg, 12%).

Preparation 13

6-Bromo-3-fdifluoromethoxy ^' )-2-methoxyphenol (Compound 313 :

To a stirring solution of l-bromo-4-(difluoromethoxy)-3-methoxy-2- (methoxymethoxy)benzene (1 g, 3.19 mmol) in methanol (15 mL) was added

concentrated hydrochloride (2 mL) and the reaction mixture was heated to 50 °C for 1 h. The reaction mixture was cooled to RT, concentrated under reduced pressure and the obtained residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (800 mg, 93%).

Preparation 14

5-(4 4 _r 5.5-tetramethyl-l,3,2-dioxaborolan-2-ynisoindolin-l-on e:

To a stirring solution of 4-bromo-2-methylbenzoic acid (3 g) in methanol (70 mL) was added concentrated hydrochloric acid (5 mL) and the reaction mixture was heated to 60 °C for 16 h. The reaction mixture was concentrated under reduced pressure, the residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford Methyl 4-bromo-2- methylbenzoate as a solid (2 g , 62%). To a stirring solution of methyl 4-bromo-2-methylbenzoate (600 mg, 2.62 mmol) in carbon tetrachloride (70 mL) was added /V-bromo succinimide (466 mg, 2.62 mmol) and benzoyl peroxide (12 mg) and the resultant reaction mixture was stirred in presence of sodium lamp at RT for 4 h. The reaction mixture was filtered through celite and washed with 2N sodium hydroxide solution, dried over sodium sulphate and concentrated under reduced pressure to afford Methyl 4-bromo-2-(bromomethyl)benzoate as a solid (300 mg, 37.5%).

Ammonia gas was purged to a stirring solution of methyl 4-bromo-2- (bromomethyl)benzoate (200 mg, 0.649 mmol) in methanol at 0 °C for 10 min. To the resulting reaction mixture ammonium hydroxide (0.5 mL) was added and the reaction mixture was stirred at RT for 16 h. The obtained solid was separated by filtration and dried to afford 5-Bromoisoindolin-l-one as a solid (100 mg, 72%). Argon was purged to a stirring solution of 5-bromoisoindolin-l-one (200 mg, 0.943 mmol) in dimethylformamide for 30 min, to this bis(pinacolato)diboron (477 mg, 1.886 mmol) and tetrakis(triphenylphosphine) palladium(O) (13 mg, 0.018 mmol) and potassium acetate (277 mg, 2.829 mmol) were added and the reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (100 mg, 41 %).

Example 78

-( ^, 4- Difluoromethoxy')-2-ethoxy-3-methoxyphenyl ^' )isoindolin-l-one (Compound 244)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (200 mg, 0.74 mmol) in acetonitrile (10 mL) was added potassium carbonate (307 mg, 2.23 mmol) and ethyl bromide (0.6 mL, 2.23 mmol) and the resultant reaction mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 200 mg of crude product, 1- Bromo-4-difluoromethoxy-2-ethoxy-3-methoxy-benzene, as a solid.

A stirring solution of l-bromo-4-(difluoromethoxy)-2-ethoxy-3-methoxybenzene (200 mg, 0.673 mmol) in /V,/V-dimethylformamide (5 mL) was purged with argon for 1 h, to this cesium carbonate (656 mg, 2.019 mmol), tetrakis(triphenylphosphine) palladium(O) (38 mg, 0.033 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l- one (209 mg, 0.807 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and

concentrated under reduced pressure. Purification of the residue by column

chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (30 mg, 13%).

UPLC-MS (M + l) : 408.16 ; UPLC-MS RT (min) : 2.2

Example 79

-(4-(Difluoromethoxy ^' )-3-methoxy-2-propoxyphenyl)isoindolin-l-one (Compound 245)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (300 mg, 1.115 mmol) in acetonitrile (10 mL) was added potassium carbonate (495 mg, 2.334 mmol) and propyl bromide (411 mg, 3.34 mmol) and the resultant reaction mixture was heated to 80 °C for 3 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 300 mg of 1-Bromo- 4-(difluoromethoxy)-3-methoxy-2-propoxybenzene (Intl4-F2) as a solid.

A stirring solution of l-bromo-4-(difluoromethoxy)-3-methoxy-2-propoxybenzene (300 mg, 0.964 mmol) in dimethylformamide (5 mL) was purged with argon for 1 h, to this cesium carbonate (625 mg, 1.926 mmol), tetrakis(triphenylphosphine) palladium(O) (37 mg, 0.032 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin- l-one (199 mg, 0.771 mmol) were added and the resultant reaction mixture was heated to 80- 90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0- 20% ethyl acetate in pet ether) afforded the title compound as a solid (40 mg, 11%). Example 80

-(4-(Difluoromethoxy)-2-isobutoxy-3-methoxyphenyl)isoindolin -l-one (Compound 246)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (100 mg, 0.371 mmol) in acetonitrile (10 ml_), was added potassium carbonate (153.8 mg, 1.114 mmol) and isobutyl bromide (152.6 mg, 1.114 mmol) and the resultant reaction mixture was heated to 80 °C for 3 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 300 mg of l-Bromo-4-(difluoromethoxy)-2-isobutoxy-3-methoxybenzene as a solid.

To a stirring solution of l-bromo-4-(difluoromethoxy)-2-isobutoxy-3-methoxybenzene (200 mg, 0.615 mmol) in dimethylformamide (5 mL) was purged with argon for 1 h. To this cesium carbonate (599 mg, 1.84 mmol), tetrakis(triphenylphosphine) palladium(O) (35 mg, 0.030 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l- one (191 mg, 0.738 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and

concentrated under reduced pressure. Purification of the residue by column

chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a (30 mg, 13%).

UPLC-MS (M + l) : 378.16 ; UPLC-MS RT (min) : 2.5

Example 81

5-r4-Difluoromethoxy-3-methoxy-2-(3-hydroxy-2,2-dimethyl-pro poxy)-phenyl1-2.3- dihydro-isoindol-l-one (Compound 247)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (200 mg, 0.743 mmol) in dimethylformamide (10 ml_) was added potassium carbonate (307 mg, 2.229 mmol) and 3-bromo-2,2-dimethylpropan-l-ol (248 mg, 1.486 mmol) and the resultant reaction mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 200 mg of 3-(6-Bromo-3-(difluoromethoxy)-2-methoxyphenoxy)-2,2-dimethy lpropan-l- ol as a solid.

To a stirring solution of 3-(6-bromo-3-(difluoromethoxy)-2-methoxyphenoxy)-2,2- dimethylpropan-l-ol (200 mg, 0.563 mmol) in dimethylformamide (10 ml_) was purged with argon for 1 h. To this cesium carbonate (548 mg, 1.689 mmol),

tetrakis(triphenylphosphine) palladium(O) (32 mg, 0.028 mmol) and 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l-one (175 mg, 0.675 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a (50 mg, 22%).

UPLC-MS (M + l) : 408.16 ; UPLC-MS RT (min) : 2.2

Example 82

5-[4-Difluoromethoxy-3-methoxy-2-(3-methyl-oxetan-3-ylmethox y)-phenyn-2.3- dihydro-isoindol-l-one (Compound 248)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (200 mg, 0.743 mmol) in acetonitrile (10 mL) was added potassium carbonate (307 mg, 2.229 mmol) and followed by 3-(bromomethyl)-3-methyloxetane (244 mg, 1.48 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 200 mg 3-((6-Bromo-3-(difluoromethoxy)-2- methoxyphenoxy)methyl)-3-methyloxetane (Intl4-F6) as a solid.

To a stirring solution of 3-((6-bromo-3-(difluoromethoxy)-2-methoxyphenoxy)methyl)- 3-methyloxetane (200 mg, 0.566 mmol) in dimethylformamide (10 mL) was purged with argon for 1 h. To this cesium carbonate (551 mg, 1.698 mmol), tetrakis

(triphenylphosphine) palladium(O) (32 mg, 0.028 mmol) and 5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)isoindolin-l-one (176 mg, 0.679 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (50 mg, 22%).

UPLC-MS (M + l) : 406.13 ; UPLC-MS RT (min) : 2.2

Example 83

5-| ^" 4-Difluoromethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethox y)-3-methoxy-phenyl1- 2,3-dihydro-isoindol-l-one (Compound 249)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (200 mg, 0.743 mmol) in acetonitrile (10 mL) was added potassium carbonate (307 mg, 2.23 mmol) and (3-(bromomethyl)oxetan-3-yl)methanol (267 mg, 1.48 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 30 mg of (3-((6-Bromo-3-(difluoromethoxy)-2-methoxyphenoxy)methyl)oxe tan-3- yl)methanol_ as a solid. To a stirring solution of (3-((6-bromo-3-(difluoromethoxy)-2- methoxyphenoxy)methyl)oxetan-3-yl)methanol (200 mg, 0.541 mmol) in

dimethylformamide ( 10 ml.) was purged with argon for 1 h. To this cesium carbonate (527 mg, 1.623 mmol), tetrakis(triphenylphosphine) palladium(O) (31 mg, 0.027 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l- one (168 mg, 0.650 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (50 mg, 21%).

UPLC-MS ( + l) : 422.14 ; UPLC-MS RT (min) : 2.0

Example 84

5-[4-Difluoromethoxy-3-methoxy-2-( ^, 3-methoxymethyl-oxetan-3-ylmethoxy ^' )-phenyl1- -dihydro-isoindol-l-one (Compound 250Ί

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (200 mg, 0.743 mmol) in acetonitrile (10 mL) was added potassium carbonate (307 mg, 2.228 mmol) and 3-(bromomethyl)-3-(methoxymethyl)oxetane (288 mg, 1.48 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 200 mg of 3-((6-Bromo-3-(difluoromethoxy)-2- methoxyphenoxy)methyl)-3-(methoxymethyl)oxetane as a solid.

To a stirring solution of 3-((6-bromo-3-(difluoromethoxy)-2-methoxyphenoxy)methyl)- 3-(methoxymethyl)oxetane (200 mg, 0.521 mmol) in dimethylformamide (10 mL) was purged with argon for 1 h. To this cesium carbonate (507 mg, 1.563 mmol),

tetrakis(triphenylphosphine) palladium(O) (30 mg, 0.026 mmol) and 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l-one (162 mg, 0.626 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (50 mg, 22%).

UPLC-MS (M + l) : 436.15 ; UPLC-MS RT (min) : 2.2

Example 85

4-r3-Difluoromethoxy-2-methoxy-6-(l-oxo-2,3-dihydro-lH-isoin dol-5-ylV

phenoxymethyll-benzenesulfonamide (Compound 251^

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (200 mg, 0.743 mmol) in acetonitrile (10 ml.) was added potassium carbonate (307 mg, 2.228 mmol) and 4-(bromomethyl)benzenesulfonamide (370 mg, 1.48 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 300 mg of 4-((6-Bromo-3-(difluoromethoxy)-2- methoxyphenoxy)methyl)benzenesulfonamide crude product as a solid.

To a stirring solution of 4-((6-bromo-3-(difluoromethoxy)-2- methoxyphenoxy)methyl)benzenesulfonamide (200 mg, 0.456 mmol) in

dimethylformamide (10 mL) was purged with argon for 1 h. To this cesium carbonate

(444 mg, 1.368 mmol), tetrakis (triphenylphosphine) palladium(O) (26 mg, 0.022 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l- one (141 mg, 0.547 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (40 mg, 18%).

UPLC-MS (M + l) : 491.09 ; UPLC-MS RT (min) : 2.2

Example 86 5- 4-Difluoromethoxy-2-(4-methanesulfonyl-benzyloxy ^' )-3-metrioxy-phenyll-2,3- dihydro-isoindol-l-one (Compound 252^

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (200 mg, 0.743 mmol) in acetonitrile (10 mL) was added potassium carbonate (307 mg, 2.228 mmol) and l-(bromomethyl)-4-(methylsulfonyl)benzene (368.6 mg, 1.48 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 300 mg of l-Bromo-4-(difluoromethoxy)-3-methoxy-2-(4- (methylsulfonyl)benzyloxy)benzene crude product as a solid.

To a stirring solution of l-bromo-4-(difluoromethoxy)-3-methoxy-2-(4- (methylsulfonyl)benzyloxy)benzene (200 mg, 0.457 mmol) in dimethylformamide (10 mL) was purged with argon for 1 h. To this cesium carbonate (445 mg, 1.371 mmol), tetrakis (triphenylphosphine) palladium(O) (26 mg, 0.022 mmol) and 5-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l-one (142 mg, 0.548 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (50 mg, 22%).

UPLC-MS (M + l) : 490.08 ; UPLC-MS RT (min) : 2.2

Example 87 4-((3-(difluoromethoxy;)-2-methoxy-6-f l-oxoisom^

(Compound 253)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol ( 1.0 g, 3.71 mmol) in acetonitriie ( 10 mL) was added potassium carbonate ( 1.53 g, 11.08 mmol) and 4-(bromomethyl)benzamide (795 mg, 3.71 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 4-((6-bromo-3- (difluoromethoxy)-2-methoxyphenoxy)methyl)benzamide as a solid (1 g, 67%) .

To a stirring solution of 4-((6-bromo-3-(difluoromethoxy)-2- methoxyphenoxy)methyl)benzamide (500 mg, 1.24 mmol) in dimethylformamide ( 10 mL) was purged with argon for 1 h. To this cesium carbonate ( 1.2 g, 3.73 mmol), tetrakis (triphenylphosphine) palladium(O) (72 mg, 0.06 mmol) and 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin- l-one (386 mg, 1.49 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h . The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (100 mg, 17.7%) .

UPLC-MS (M+ l) :455.13 ; UPLC-MS RT (min) : 2.3

Example 88

2-[3-Difluoromethoxy-2-methoxy-6-( l-oxo-2,3-dihydro-lH-isoindol-5-yl)-phenoxyl-N- propyl-acetamide (Compound 254)

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (500 mg, 1.858 mmol) in acetonitrile (20 mL) was added potassium carbonate (769 mg, 5.57 mmol) and ethyl 2-bromoacetate (568 mg, 3.71 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 300 mg of Ethyl 2-(6- bromo-3-(difluoromethoxy)-2-methoxyphenoxy)acetate as solid.

To a stirring solution of ethyl 2-(6-bromo-3-(difluoromethoxy)-2- methoxyphenoxy)acetate (300 mg, 0.845 mmol) in tetrahydrofuran was added lithium hydroxide in water and the reaction mixture was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure and the obtained residue was acidified to pH 2 and then extracted with ethyl acetate. The combined ethyl acetate layers were dried over sodium sulphate and concentrated under reduced pressure to afford 2-(6-Bromo-3-(difluoromethoxy)-2-methoxyphenoxy)acetic acid as a solid (180 mg, 66%).

To a stirring solution of 2-(6-bromo-3-(difluoromethoxy)-2-methoxyphenoxy)acetic acid (420 mg, 1.284 mmol) in dichloromethane (20 mL) at 0 °C was added triethylamine (0.54 mL, 5.20 mmol), EDC.HCI (369 mg, 1.921 mmol), HOBt (393 mg, 2.56 mmol) and propylamine (227 mg, 3.85 mmol) and the reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over anhydrous sodium sulpahte and concentrated under reduced pressure to afford 2-(6-Bromo-3- (difluoromethoxy)-2-methoxyphenoxy)-N-propylacetamide as a liquid (300 mg, 63%).

A stirring solution of 2-(6-bromo-3-difluoromethoxy-2-methoxy-phenoxy)-/V-propyl- acetamide ( 100 mg, 0.271 mmol) in dimethylformamide (10 mL) was purged with argon for 1 h, to this cesium carbonate (266 mg, 0.813 mmol), tetrakis(triphenylphosphine) palladium(O) (22 mg, 0.019 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)isoindolin-l-one ( 105.5 mg, 0.407 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid. (20 mg, 18%).

UPLC-MS (M + l) : 421.16 ; UPLC-MS RT (min) : 2.1 Preparation 15

4-f4-Ethoxy-2-hvdroxy-3-methoxyphenylV2,3-dihvdro-lH-inden-l -one (Compound

To a stirring solution of benzene-l,2,3-triol (2 g, 15.87 mmol) in acetone was added potassium bicarbonate (1.9 g, 19.04 mmol) and methyl iodide (3.3 g, 23.8 mmol) and the resultant reaction mixture was heated to reflux for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was diluted with ether, solid separated out was filtered and the filtrate was concentrated under reduced pressure to afford the crude product. The crude product was purified by flash column chromatography (silica gel, 0-15% ethyl acetate in pet ether) to afford 2-Methoxybenzene-l,3-diol as a solid (600 mg, 27%). To a stirring solution of 2-methoxybenzene-l,3-diol (3 g, 21.42 mmol) in THF (30 mL) at -78 °C was added /V-bromosuccinimide (4.5 g, 25.71 mmol) and the resultant reaction mixture was stirred at -78 °C for 2 h. The reaction mixture was diluted with ice-cold water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The obtained residue has mixture of products (4-Bromo-2- methoxybenzene-l,3-diol) which was used as such for further reactions (4.2 g).

To a stirring solution of 4-bromo-2-methoxybenzene-l,3-diol (4.5 g, 20.54 mmol) in acetone (40 mL) at 0 °C was added potassium carbonate (2.83 g, 20.54 mmol) and methoxymethyl chloride (1.32 g, 17.39 mmol). The resultant reaction mixture was stirred at RT for 7 h. The reaction mixture was quenched with ice-cold water, the solid was filtered and the filtrate was concentrated under reduced pressure to leave a residue having the crude product. The crude product was purified by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) to afford 4-Bromo-2-methoxy-3- (methoxymethoxy)phenol as a liquid (2 g, 37%). To a stirring solution of 4-bromo-2-methoxy-3-(methoxymethoxy)phenol (600 mg, 2.28 mmol) in acetonitrile (20 mL) was added potassium carbonate (944 mg, 6.84 mmol) and ethyl iodide (711 mg, 4.56 mmol) and the resultant reaction mixture was heated to 70 °C for 3 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-7% ethyl acetate in pet ether) to afford l-Bromo-4- ethoxy-3-methoxy-2-(methoxymethoxy)benzene as a solid (525 mg, 79%).

A stirring solution of l-bromo-4-ethoxy-3-methoxy-2-(methoxymethoxy)benzene (300 mg, 1.030 mmol) in dimethylformamide (10 mL) was purged with argon for 1 h, to this cesium carbonate (1 g, 3.092 mmol), Pd(PPh ₃ ) (59 mg, 0.051 mmol) and 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l- one (265 mg, 1.030 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 2 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0- 10% ethyl acetate in pet ether) afforded 4-(4-Ethoxy-3-methoxy-2- (methoxymethoxy)phenyl)-2,3-dihydro-lH-inden-l-one as a solid (200 mg, 56%).

To a stirring solution of 5-(4-ethoxy-3-methoxy-2-(methoxymethoxy)phenyl)-2,3- dihydro-lH-inden-l-one ( 1 g, 2.92 mmol) in methanol (20 mL) was added cone, hydrochloric acid (3 mL) and heated to 60 °C for 1 h. The reaction mixture was cooled to RT and concentrated under reduced pressure. The residue was basified with sodium bicarbonate solution and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (850 mg, 97.7%).

Example 89

4-i2,4-Diethoxy-3-methoxyphenylV2 _r 3-dihydro-lH-inden-l-one

To a stirring solution of 4-(4-ethoxy-2-hydroxy-3-methoxyphenyl)-2,3-dihydro-lH- inden-l-one (90 mg, 0.302 mmol) in acetonitrile was added potassium carbonate (126 mg, 0.906 mmol) and ethyl iodide (141 mg, 0.906 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded title compound as a solid (45 mg, 46%).

UPLC-MS (M + l) : 327.16 ; UPLC-MS RT (min) : 2.5

Example 90

4-(4-Ethoxy-3-methoxy-2-propoxyphenylV2,3-dihydro-lH-inden-l -one (Compound 256

To a stirring solution of 4-(4-ethoxy-2-hydroxy-3-methoxyphenyl)-2,3-dihydro-lH- inden-l-one (80 mg, 0.268 mmol) in acetonitrile was added potassium carbonate (111 mg, 0.805 mmol) and propyl bromide (99 mg, 0.805 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded title compound as a solid (7 mg, 7.7%). Example 91

4-i4-Ethoxy-2-isobutoxy-3-methoxyphenyn-2,3-dihydro-lH-inden -l-one (Compound 257

To a stirring solution of 4-(4-ethoxy-2-hydroxy-3-methoxyphenyl)-2,3-dihydro-lH- inden-l-one (80 mg, 0.268 mmol) in acetonitrile was added potassium carbonate (111 mg, 0.805 mmol) and isobutyl bromide (110 mg, 0.805 mmol) and the resultant reaction mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure.

Purification of the residue by flash column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded title compound as a solid (20 mg, 21%).

UPLC-MS (M + l) : 355.19 ; UPLC-MS RT (min) : 2.8

Example 92

4-i4-Ethoxy-2-(3-hydroxy-2,2-dimethylpropoxy)-3-methoxypheny n-2.3-dihydro-lH- inden-l- n und 258)

To a stirring solution of 4-(4-ethoxy-2-hydroxy-3-methoxyphenyl)-2,3-dihydro-lH- inden-l-one (80 mg, 0.268 mmol) in acetonitrile (7 mL) was added potassium carbonate (110 mg, 0.80 mmol) and 3-bromo-2,2-dimethylpropan-l-ol (133 mg, 0.80 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-25% ethyl acetate in pet ether) afforded title compound as a solid (20 mg, 19%).

Example 93

4-f4-Ethoxy-3-methoxy-2-(f3-methyloxetan-3-yl)methoxy^phenyn -2.3-dihydro-lH- inden-l-one (Compound 259)

To a stirring solution of 4-(4-ethoxy-2-hydroxy-3-methoxyphenyl)-2,3-dihydro-lH- inden-l-one (80 mg, 0.268 mmol) in acetonitrile (7 mL) was added potassium carbonate (111 mg, 0.80 mmol) and 3-(bromomethyl)-3-methyloxetane ( 132 mg, 0.80 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-25% ethyl acetate in pet ether) afforded title compound as a solid (20 mg, 19%) .

UPLC-MS (M + l ) : 383.18 ; UPLC-MS RT (min) : 2.5

Example 94

4-(4-Ethoxy-2-((3-(hydroxymethyl)oxetan-3-yl)methoxyV3-metho xyphenyl)-2 _r 3- dihydro- l H-inden-l-one (Compound 260)

To a stirring solution of 4-(4-ethoxy-2-hydroxy-3-methoxyphenyl)-2,3-dihydro- lH- inden-l-one (80 mg, 0.268 mmol) in acetonitrile (7 mL) was added potassium carbonate ( 111 mg, 0.80 mmol) and (3-(bromomethyl)oxetan-3-yl)methanol (97 mg, 0.536 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-25% ethyl acetate in pet ether) afforded title compound as a solid (20 mg, 19%) . UPLC-MS (M + l) : 399.18 ; UPLC-MS RT (min) : 2.2

Example 95

4-f4-Ethoxy-3-methoxy-2-f4-(methylsulfonyl ^' )benzyloxy ^' )phenyl ^' )-2.3-dihydro- l H-inden- 1-one (Com ound 261)

To a stirring solution of 4-(4-ethoxy-2-hydroxy-3-methoxyphenyl)-2,3-dihydro- lH- inden- l-one (80 mg, 0.268 mmol) in acetonitrile (7 mL) was added potassium carbonate ( 111 mg, 0.80 mmol) and l-(bromomethyl)-4-(methylsulfonyl)benzene ( 100 mg, 0.402 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-30% ethyl acetate in pet ether) afforded title compound as a solid (30 mg, 24%).

UPLC-MS (M + l) : 467.14 ; UPLC-MS RT (min) : 2.5

Preparation 16

5-(4-Ethox -2-hydroxy-3-methoxyphenynisobenzofuran-l(3H)-one (Compound 316)

A stirring solution of l-bromo-4-ethoxy-3-methoxy-2-(methoxymethoxy)benzene (200 mg, 0.722 mmol) in dimethylformamide (5 mL) was purged with argon for 1 h, to this cesium carbonate (700 mg, 2.166 mmol), Pd(PPh ₃ ) ₄ (41 mg, 0.036 mmol) and 5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isobenzofuran-l (3H)-one (280 mg, 1.08 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 5-(4-Ethoxy-3-methoxy-2- (methoxymethoxy)phenyl)isobenzofuran-l(3H)-one as a solid (100 mg, 40%).

To a stirring solution of 5-(4-ethoxy-3-methoxy-2-

(methoxymethoxy)phenyl)isobenzofuran-l(3H)-one (100 mg, 0.292 mmol) in methanol (5 mL) was added cone, hydrochloric acid (0.5 mL) and heated to 50 °C for 1 h. The reaction mixture was concentrated under reduced pressure; the residue was basified with sodium bicarbonate solution and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over sodium sulphate and

concentrated under reduced pressure to afford the title compound as a solid (60 mg, 68%). Example 96

5-(2,4-Diethoxy-3-methoxyphenyl)isobenzofuran-l(3H1-one (Compound 262)

To a stirring solution of 5-(4-ethoxy-2-hydroxy-3-methoxyphenyl)isobenzofuran- l (3H)- one (30 mg, 0.1 mmol) in acetonitrile (5 mL) was added potassium carbonate (41 mg, 0.30 mmol) and ethyl iodide (62 mg, 0.40 mmol) and the resultant reaction mixture was heated to 75 °C for 2 h . The reaction mixture was cooled to T, filtered through celite and the filtrate was concentrated under reduced pressu re. Purification of the residue by flash column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (20 mg, 61%) .

UPLC-MS (M + l) : 329.14 ; UPLC-MS RT (min) : 2.4

Example 97

5- 4-Ethoxy-3-methoxy-2-propoxyphenvnisobenzofuran- l(3l-0-one (Compound 263)

To a stirring solution of 5-(4-ethoxy-2-hydroxy-3-methoxyphenyl)isobenzofuran-l (3H)- one (80 mg, 0.266 mmol) in acetonitrile was added potassium carbonate ( 110 mg, 0.798 mmol) and propyl bromide ( 130 mg, 1.066 mmol) and the resultant reaction mixture was heated to 70 °C for 2 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-25% ethyl acetate in pet ether) afforded the title compound as a solid (20 mg, 22%).

UPLC-MS (M + l) : 343.15 ; UPLC-MS RT (min) : 2.6

Example 98

5-f4-Ethoxy-2-isobutoxy-3-methoxypheny0isobenzofuran-l(3l-0- one (Compound 264)

To a stirring solution of 5-(4-ethoxy-2-hydroxy-3-methoxyphenyl)isobenzofuran- l(3H)- one (80 mg, 0.266 mmol) in acetonitrile was added potassium carbonate (110 mg, 0.798 mmol) and isobutyl bromide ( 146 mg, 1.064 mmol) and the resu ltant reaction mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a solid (20 mg, 21%) .

UPLC-MS (M + l) : 357.17; UPLC-MS RT (min) : 2.7

Example 99

5-f4-Ethoxy-2-(3-hydroxy-2,2-dimethylpropoxy 3-methoxyphenyl)isobenzofuran- l -one (Compound 265)

To a stirring solution of 5-(4-ethoxy-2-hydroxy-3-methoxyphenyl)isobenzofuran- l(3H)- one (80 mg, 0.266 mmol) in acetonitrile (7 ml_) was added potassium carbonate ( 110 mg, 0.798 mmol) and 3-bromo-2,2-dimethylpropan-l-ol (134 mg, 0.798 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-25% ethyl acetate in pet ether) afforded title compound as a solid (15 mg, 14.7%) .

Example 100

5-(4-Ethoxy-3-methoxy-2-((3-methyloxetan-3-ynmethoxy)phenyl ^' )isobenzofuran- l(3H ^' )- one (Compound 266)

To a stirring solution of 5-(4-ethoxy-2-hydroxy-3-methoxyphenyl)isobenzofuran-l(3H)- one (80 mg, 0.266 mmol) in acetonitrile (7 mL) was added potassium carbonate (110 mg, 0.798 mmol) and 3-(bromomethyl)-3-methyloxetane (132 mg, 0.798 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-25% ethyl acetate in pet ether) afforded title compound as a solid (30 mg, 29%).

UPLC-MS (M + l) : 385.16 ; UPLC-MS RT (min) : 2.5

Example 101

5-r4-Ethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethoxy 3-methoxy-phenyll-3H- isobenzofuran-l-one (Compound 267 ^' )

To a stirring solution of 5-(4-ethoxy-2-hydroxy-3-methoxyphenyl)isobenzofuran-l(3H)- one (80 mg, 0.266 mmol) in acetonitrile (7 mL) was added potassium carbonate (110 mg, 0.798 mmol) and (3-Bromomethyl-oxetan-3-yl)-methanol (96 mg, 0.532 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-25% ethyl acetate in pet ether) afforded title compound as a solid (30 mg, 28%).

UPLC-MS (M + l) : 401.16; UPLC-MS RT (min) : 2.2

Example 102 5-(4-Ethoxy-3-methoxy-2-(4-frnethylsulfonynbenzyloxy^phenyni sobenzofuran- K3H )- one (Compound 268)

To a stirring solution of 5-(4-ethoxy-2-hydroxy-3-methoxyphenyl)isobenzofuran-l(3H)- one (80 mg, 0.266 mmol) in acetonitrile (7 mL) was added potassium carbonate (110 mg, 0.80 mmol) and l-(bromomethyl)-4-(methylsulfonyl)benzene (99 mg, 0.399 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-40% ethyl acetate in pet ether) afforded title compound as a solid (20 mg, 16%). UPLC-MS (M + l) : 469.11 ; UPLC-MS RT (min) : 2.5

Preparation 17

4-f3-H droxy-2 _f 4-dimethoxyphenyn-2 _f 3-dihydro-lH-inden-l-one (Compound 317)

To a stirring solution of 2,6-dimethoxy-phenol (2 g, 12.98 mmol) in CCI ₄ (70 mL) at -10 °C was added bromine (2.07 g, 12.98 mmol) and stirred for 2 h. The reaction mixture was diluted with CCI ₄ , washed with water and the combined CCI ₄ layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 3-Bromo-2,6-dimethoxy-phenol as a solid (2 g, 66%).

A stirring solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH- inden-l-one (3 g, 12.87 mmol) in dimethylformamide (30 mL) was purged with argon for 1 h, to this cesium carbonate (12.58 g, 38.61 mmol), Pd (PPh ₃ ) ₄ (743 mg, 0.64 mmol) and 3-bromo-2,6-dimethoxyphenol (3.32 g, 12.87 mmol) were added and the resultant reaction mixture was heated to 80-90 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) afforded the title compound as a solid (1.5 g, 41%).

Example 103

4-(3-Ethoxy-2 4-dimethoxyphenyl)-2 _f 3-dihydro-lH-inden-l-one ( Compound 269)

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l- one (80 mg, 0.281 mmol) in acetonitrile (5 mL) was added potassium carbonate (116 mg, 0.843 mmol) and ethyl iodide (131 mg, 0.843 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (25 mg, 28.7%).

UPLC-MS (M + l) : 313.14 ; UPLC-MS RT (min) : 2.4

Example 104

4- 2.4-Dimethoxy-3-propoxyphenyl)-2 _r 3-dihydro-lH-inden- l-one (Compound 270)

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l- one (80 mg, 0.281 mmol) in acetonitrile (5 mL) was added potassium carbonate (116 mg, 0.843 mmol) and propyl bromide (103 mg, 0.843 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (30 mg, 33.3%).

UPLC-MS (M + l) : 327.16 ; UPLC-MS RT (min) : 2.5 Example 105

4-(3-Isobutox -2.4-dimethoxyphenyl)-2,3-dihydro- l H-inden-l-one (Compound 271 ^' )

5 To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro- lH-inden- l- one (80 mg, 0.281 mmol) in acetonitrile (10 mL) was added potassium carbonate (115 mg, 0.843 mmol) and isobutyl bromide ( 115 mg, 0.843 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue 10 was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (15 mg, 15.7%).

UPLC-MS (M + l) : 341.17 ; UPLC-MS RT (min) : 2.6

Example 106

15 4-[3-f3-Hvdroxy-2,2-dimethyl-propoxyV2.4-dimethoxy-phenyl1-i ndan- l-one

( ^• Com ound 272)

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-l H-inden-l- one (80 mg, 0.281 mmol) in acetonitrile ( 10 mL) was added potassium carbonate ( 155 20 mg, 1.124 mmol) and 3-bromo-2,2-dimethyl-propan- l-ol ( 141 mg, 0.843 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 20%) .

-25- JULELi^M5JM+ l) : 371.19 : UPLC-MS RT (min) : 2.5

Example 107 4-(2,4-Dimethoxy-3-((3-methyloxetan-3-yl)methoxy^phenylV2 _f 3-dihydro-l^ one (Com ound 273)

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l- 5 one (80 mg, 0.281 mmol) in acetonitrile (5 mL) was added potassium carbonate (115 mg, 0.843 mmol) and 3-(bromomethyl)-3-methyloxetane (139 mg, 0.843 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl 10 acetate in pet ether) to afford the title compound as a solid (40 mg, 38.5%).

UPLC-MS (M + l) : 369.17; UPLC-MS RT (min) : 2.7

Example 108

4-(3-((3-(Hvdroxymethyl)oxetan-3-vhmethoxy)-2,4-dimethoxyphe nyn-2.3-dihydro-lH- 15 inden-l-one (Com ound 274)

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l- one (80 mg, 0.281 mmol) in acetonitrile (5 mL) was added potassium carbonate (115 mg, 0.843 mmol) and (3-(bromomethyl)oxetan-3-yl)methanol (153 mg, 0.843 mmol) 20 and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (30 mg, 27.6%).

UPLC-MS (M + l) : 385.17 ; UPLC-MS RT (min) : 2.0

-25

Example 110 4-r2^-Dimethoxy-3-f3-methoxymeth l-oxetan-3-ylmethoxy)-phenyl1-indan-l-one

(Compound 2751

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l- one (80 mg, 0.281 mmol) in acetonitrile (5 ml.) was added potassium carbonate (155 mg, 1.124 mmol) and 3-bromomethyl-3-methoxymethyl-oxetane (82 mg, 0.422 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 17.9%).

Example 111

4-[2,6-Dimethoxy-3-(l-oxo-indan-4-yl1-phenoxymethyn-benzenes ulfonamide

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l- one (80 mg, 0.281 mmol) in acetonitrile (5 mL) was added potassium carbonate (155 mg, 1.126 mmol) and 4-bromomethyl-benzenesulfonamide (84 mg, 0.337 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 15.7%).

UPLC-MS (M + l) : 454.14 ; UPLC-MS RT (min) : 2.3

Example 112

4-(2 _i 4-Dimethoxy-3-(4-(methylsulfonynbenzyloxy ^' )phenyn-2.3-dihvdro-lH-inaen-l-one (Compound 2771

To a stirring solution of 4-(3-hydroxy-2,4-dimethoxyphenyl)-2,3-dihydro-lH-inden-l- one (80 mg, 0.281 mmol) in acetonitrile (5 ml_) was added potassium carbonate (155 mg, 0.843 mmol) and l-(bromomethyl)-4-(methylsulfonyl)benzene (210 mg, 0.843 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0- 50% ethyl acetate in pet ether) to afford the title compound as a solid (50 mg, 39.3%). UPLC-MS (M + l) : 453.14 ; UPLC-MS RT (min) : 2.3

Preparation 18

5-(3-H droxy-2 _f 4-dimethoxy-phenyO-3H-isobenzofuran-l-one (Compound 318)

To a stirring solution of 2,6-dimethoxy-phenol (2 g, 12.98 mmol) in carbon tetrachloride (70 mL) at -10 °C was added bromine (2 g, 12.98 mmol) in carbon tetrachloride and stirred for 2 h. The reaction mixture was diluted with carbon tetrachloride, washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 3-Bromo-2,6-dimethoxy-phenol as a mixture (2 g). A stirring solution of 5-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-3H- isobenzofuran-l-one (2.23 g, 8.58 mmol) in dimethylformamide (30 mL) was purged with argon for 1 h, to this cesium carbonate (8.37 g, 25.74 mmol), Pd(PPh ₃ ) ₄ (495 mg, 0.429 mmol) and 3-bromo-2,6-dimethoxy-phenol (2.0 g, 8.58 mmol) were added and the resultant reaction mixture

was cooled to RT, filtered through celite and the filtrate was diluted with water and extracted with ethyl acetate (3 x ) . The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0- 10% ethyl acetate in pet ether) afforded the title compound as a solid ( 1 g, 40.7%) . Example 113

5-(3-Ethox -2,4-dimethoxy-phenyO-3H-isobenzofuran- l-one ( Compound 278)

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile ( 10 mL) was added potassium carbonate ( 115 mg, 0.837 mmol) and ethyl iodide (130 mg, 0.837 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (50 mg, 57%) .

UPLC-MS (M + l) : 315.13 ; UPLC-MS RT (min) : 2.3

Example 114

5- 2,4-Dimethoxy-3-propoxy-phenvn-3H-isobenzofuran- l-one (Compound 279)

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile ( 10 mL) was added potassium carbonate ( 115 mg, 0.837 mmol) and propyl bromide ( 103 mg, 0.837 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite a n d the filtrate was concerftratetHmder^dtieed^fe-ssw^^ was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (30 mg, 32.8%) .

UPLC-MS (M + l) : 329.14 ; UPLC-MS RT (min) : 2.5 Example 115

5-f3-Isobutox -2 _r 4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (Compound 280)

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile (10 mL) was added potassium carbonate (115 mg, 0.837 mmol) and isobutyl bromide (115 mg, 0.837 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (30 mg, 31.4%).

UPLC-MS (M + l) : 343.16 ; UPLC-MS RT (min) : 2.6

Example 116

5-r2,4-Dimethoxy-3-(3-methyl-oxetan-3-ylmethoxy ^' i-phenyl1-3H-isobenzofuran-l-one

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile (10 mL) was added potassium carbonate (115 mg, 0.837 mmol) and 3-bromomethyl-3-methyl-oxetane (138 mg, 0.837 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (50 mg, 48.4%).

Example 117 5-f3-f f3-f hvdroxymethyl)oxetan-3-yl)methoxy)-2^-dimethoxyphenyl ^' )isobenzofuran- i r3H1-one (Com ound 282).

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile (10 mL) was added potassium carbonate (115 mg, 0.837 mmol) and (3-(bromomethyl)oxetan-3-yl)methanol ( 151 mg, 0.837 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h . The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was pu rified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (25 mg, 23.2%).

UPLC-MS (M + l) : 387.18 ; UPLC-MS RT (min) : 2.2

Example 118

5- 2,4-Dimethoxy-3-(3-methoxymethyl-oxetan-3-ylmethoxy)-phenyl1 -3H- isobenzofuran- l-one (Compound 283)

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran- l-one (80 mg, 0.279 mmol) in acetonitrile ( 10 mL) was added potassium carbonate ( 154 mg, 1.118 mmol) and 3-bromomethyl-3-methoxymethyl-oxetane ( 107 mg, 0.558 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 18%).

UPLC-MS (M + l) : 401.13 ; UPLC-MS RT (min) : 2.3

Example 119 4-[2,6-Dimethoxy-3-( l-oxo-l,3-dihydro-isobenzofuran-5-yl phenoxymethyl1- benzenesulfonamide (Compound 2841

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile (10 mL) was added potassium carbonate (154 mg, 1.118 mmol) and 4-bromomethyl-benzenesulfonamide (104 mg, 0.418 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-25% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 15.7%).

UPLC-MS (M + l) : 456.11 ; UPLC-MS T (min) : 2.3

Example 120

5-(2 _f 4-dimethoxy-3-f4-(methylsulfonynbenzyloxy ^' )phenyl)isobenzofuran-li3H ^' )-one (Com ound 285)

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile (10 mL) was added potassium carbonate (115 mg, 0.837 mmol) and l-(bromomethyl)-4-(methylsulfonyl)benzene (208 mg, 0.837 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (25 mg, 19.7%).

UPLC-MS (M + l) : 455.11 ; UPLC-MS RT (min) : 2.3 Example 121

4-[2,6-Dimethoxy-3-(l-oxo-1.3-dihydro-isobenzofuran-5-ylVphe noxymethyl ^~ l- benzamide (Compound 286)

To a stirring solution of 5-(3-Hydroxy-2,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (80 mg, 0.279 mmol) in acetonitrile (10 mL) was added potassium carbonate (154 mg, 1.118 mmol) and 4-bromomethyl-benzamide (89 mg, 0.419 mmol) and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-25% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 17%).

UPLC-MS (M + l) : 420.14 ; UPLC-MS RT (min) : 2.2

Preparation 19

4- 3-(Oifluoromethoxy^-2-hydroxy-4-methoxyphenvn-2.3-dihvdro-lH -inden-l-one

To a stirring solution of 3-methoxybenzene-l,2-diol (3 g, 21.42 mmol) in carbon tetrachloride (30 mL) was added /V-bromosuccinimide (4.5 g, 25.28 mmol) and the reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with ice-cold water and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The obtained residue has mixture of products (3-Bromo-6- methoxybenzene-l,2-diol) which was used as such for further reactions (4.2 g). To a stirring solution of 3-bromo-6-methoxybenzene-l,2-diol (500 mg, 2.28 mmol) in acetone (40 mL) at 0 °C was added potassium carbonate (314 mg, 2.28 mmol) and methoxymethyl chloride (184 mg, 2.28 mmol) and the resultant reaction mixture was stirred at RT for 2 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure Purification by column chromatography (silica gel, 0-8% ethyl acetate in pet ether) afforded 3-Bromo-6-methoxy-2-(methoxymethoxy)phenol as a liquid (230 mg, 38%).

To a stirring solution of 3-bromo-6-methoxy-2-(methoxymethoxy)phenol (700 mg, 2.64 mmol) in dimethylformamide (15 mL) was added potassium carbonate (729 mg, 5.28 mmol), cooled to -45 °C and chlorodifluoromethane gas was passed for 10 min and the resultant reaction mixture was heated to 80 °C for 2 h. The reaction mixture was quenched with ice-cold water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were dried over sodium sulphate and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 0-5% ethyl acetate in pet ether) afforded l-Bromo-3-(difluoromethoxy)-4-methoxy-2- (methoxymethoxy)benzene as a liquid (250 mg, 30%).

A solution of l-bromo-3-(difluoromethoxy)-4-methoxy-2-(methoxymethoxy)benz ene (3 g, 9.58 mmol) in dimethylformamide (50 mL) was purged with argon for 1 h, to this cesium carbonate (9.34 g, 28.74 mmol), tetrakis(triphenylphosphine) palladium (0) (1.1 g, 0.958 mmol) and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH- inden-l-one (2.96 g, 11.49 mmol) were added and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was cooled to RT and filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 4-(3-(Difluoromethoxy)-4-methoxy-2- (methoxymethoxy)phenyl)-2,3-dihydro-lH-inden-l-one as a solid (1.8 g, 51.6%).

To a stirring solution of 4-(3-(difluoromethoxy)-4-methoxy-2-

(methoxymethoxy)phenyl)-2,3-dihydro-lH-inden-l-one (1 g, 2.747 mmol) in methanol (75 mL) was added concentrated hydrochloride (5 mL) and the reaction mixture was heated to 50 °C for 1 h. The reaction mixture was cooled to RT, concentrated under reduced pressure, the obtained residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (700 mg, 79.6%) .

Example 122

-(3-Difluoromethoxy-2-ethoxy-4-methoxy-Dhenvn-indan- l-one (Compound 287 ^' )

To a stirring solution of 4-(3-(difluoromethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro- lH-inden- l-one (80 mg, 0.25 mmol) in acetonitrile ( 10 mL) was added potassium carbonate ( 103 mg, 0.75 mmol) and ethyl iodide ( 156 mg, 1.0 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0- 15% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 23%).

UPLC-MS (M + l) : 349.13 ; UPLC-MS RT (min) : 2.6

Example 123

-(3-Difluoromethoxy-4-methoxy-2-propoxy-phenyl ^' Hndan- l-one (Compound 288)

To a stirring solution of 4-(3-(difluoromethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-l H-inden- l-one (80 mg, 0.25 mmol) in acetonitrile ( 10 mL) was added potassium carbonate ( 102 mg, 0.75 mmol) and propyl bromide (92 mg, 0.75 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 22%).

UPLC-MS (M + l) : 363.14 ; UPLC-MS RT (min) : 2.6

Example 124 4- 3-Difluoromethoxy-2-isobutoxy-4-methoxy-phenyn-indan-l-one (Compound

To a stirring solution of 4-(3-(difluoromethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.75 mmol) and isobutylbromide (102 mg, 0.75 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 21.2%).

UPLC-MS (M + l) : 377.16 ; UPLC-MS RT (min) : 2.7

Example 125

4- 3-Difluoromethoxy-2-( ^, 3-hvdroxymethyl-oxetan-3-ylmethoxy ^' )-4-methoxy-phenyl1-

To a stirring solution of 4-(3-(difluoromethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.75 mmol) and (3-bromomethyl-oxetan-3-yl)- methanol (68 mg, 0.375 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 19%).

UPLC-MS (M + l) : 421.15 ; UPLC-MS RT (min) : 2.3

Example 126

4-r3-Difluoromethoxy-4-methoxy-2-(3-methoxymethyl-oxetan-3-y lmethoxy)-phenyn- indan-l-one (Compound 291)

To a stirring solution of 4-(3-(difluoromethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (138 mg, 0.75 mmol) and 3-bromomethyl-3-methoxymethyl- oxetane (97.5 mg, 0.5 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column

chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 18%).

UPLC-MS (M + l) : 435.16 ; UPLC-MS RT (min) : 2.4

Example 127

To a stirring solution of 4-(3-(difluoromethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.75 mmol) and 4-bromomethyl-benzenesulfonamide

(94 mg, 0.375 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h.

The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column

chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 16%).

UPLC-MS (M + l) : 490.11 ; UPLC-MS RT (min) : 2.3 Example 128

4- r3-Difluoromethoxy-2-(4-methanesulfonyl-benzyloxy)-4-methoxy -phenyl1-indan-l- one (Compound 2931

To a stirring solution of 4-(3-(difluoromethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.25 mmol) in acetonitrile (10 mL) was added potassium carbonate (105 mg, 0.75 mmol) and l-bromomethyl-4-methanesulfonyl- benzene (93 mg, 0.375 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford the title compound as a solid (25 mg, 20%).

UPLC-MS (M + l) : 489.09 ; UPLC-MS RT (min) : 2.4

Preparation 20

5-(3-(Difluoromethoxy)-2-hydroxy-4-methoxyphenyl)isobenzofur an-l(3HVone

A stirring solution of l-bromo-3-(difluoromethoxy)-4-methoxy-2- (methoxymethoxy)benzene (1.5 g, 4.79 mmol) in dimethylformamide (30 mL) was purged with argon gas for 1 h, to this cesium carbonate (4.7 g, 14.37 mmol), tetrakis(triphenylphosphine) palladium (0) (553 mg, 0.479 mmol) and 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isobenzofuran-l(3H)-one (1.49 g, 5.74 mmol) were added and the resultant reaction mixture was heated to 80 °C for 4 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 5-(3-(Difluoromethoxy)-4-methoxy-2- (methoxymethoxy)phenyl)isobenzofuran-l(3H)-one as a solid (1 g, 56.8%). To a stirring solution of 5-(3-(difluoromethoxy)-4-methoxy-2-

(methoxymethoxy)phenyl)isobenzo furan-l(3H)-one (1 g, 2.7 mmol) in methanol (75 mL) was added concentrated hydrochloride (5 mL) and the reaction mixture was heated to 50 °C for 1 h. The reaction mixture was cooled to RT and concentrated under reduced pressure. The obtained residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (600 mg, 68%).

Example 129

5-(3-Difluoromethoxy-2-ethoxy-4-methoxy-phenylV3H-isobenzofu ran-l-one (Compound 294

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and ethyl iodide (153 mg, 0.98 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-15% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 23%).

UPLC-MS (M + l) : 351.11 ; UPLC-MS RT (min) : 2.5 Example 130

5-(3-Difluoromethoxy-4-methoxy-2-propoxy-phenvn-3H-isobenzof uran-l-one

(Compound 295

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and propyl bromide (60 mg, 0.492 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 22%).

UPLC-MS (M + l) : 365.12 ; UPLC-MS RT (min) : 2.6

Example 131

5-(3-Difluoromethoxy-2-isobutoxy-4-methoxy-phenyl)-3H-isoben zofuran-l-one (Com ound 296

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and isobutylbromide (67 mg, 0.492 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 21.4%).

UPLC-MS (M + l): 379.14 ; UPLC-MS RT (min) : 2.7

Example 132 5-[3-Difluoromethoxy-4-methoxy-2- 3-methyl-oxetan-3-ylmethoxy phenyn-3H- isobenzofuran-l-one (Compound 297Ί

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and 3-bromomethyl-3-methyl- oxetane ( 122 mg, 0.740 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-30% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 20%).

UPLC-MS (M + l) : 407.18 ; UPLC-MS RT (min) : 2.3

Example 133

5- r3-Difluoromethoxy-2-i3-hydroxymethyl-oxetan-3-ylmethoxy ^' )-4-methoxy-phenyl1- -isobenzofuran-l-one (Compound 298

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and (3-bromomethyl-oxetan-3- yl)-methanol (89 mg, 0.493 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 19%).

UPLC-MS (M + l) : 423.12 ; UPLC-MS RT (min) : 2.2 Example 134

5-r3-Difluoromethoxy-4-methoxy-2-(3-methoxymethyl-oxetan-3-y lmethoxy)-phenyl]- 3H-isobenzofuran-l-one ( ^" Compound 299Ί

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and 3-bromomethyl-3- methoxymethyl-oxetane (144 mg, 0.740 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 18%).

UPLC-MS (M + l) : 437.14 ; UPLC-MS RT (min) : 2.4

Example 135

4-((2-(difluoromethoxy ^' )-3-methoxy-6-f l-oxo-1.3-dihydroisobenzofuran-5-

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and 4- (bromomethyl)benzenesulfonamide (124 mg, 0.496 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-70% ethyl acetate in pet ether) to afford the title compound as a solid (40 mg, 33%).

UPLC-MS (M + l) : 492.08 ; UPLC-MS RT (min) : 2.3 Example 136

5-(3-(difluoromethoxy ^' )-4-methoxy-2-(4-

( ^, meth lsulfonynbenzyloxy)phenynisobenzofuran-l(3H ^' )-one (Compound 401)

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate ( 102 mg, 0.738 mmol) and l-(bromomethyl)-4- (methylsulfonyl)benzene (123 mg, 0.496 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-70% ethyl acetate in pet ether) to afford the title compound as a solid (40 mg, 33%).

UPLC-MS (M + l) : 491.08 ; UPLC-MS RT (min) : 2.4

Example 137

4-f(2-idifluoromethoxy ^' )-3-methoxy-6-(l-oxo-l,3-dihydroisobenzofuran-5-

To a stirring solution of 5-(3-(difluoromethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.738 mmol) and 4-

(bromomethyl)benzamide (106 mg, 0.496 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-70% ethyl acetate in pet ether) to afford the title compound as a solid (35 mg, 30.9%).

UPLC-MS (M + l) : 456.11 ; UPLC-MS RT (min) : 2.3

Preparation 21

4-(3-(Cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyn-2 _i 3-dihydro-lH-inden-l-one (Compound 321^

To a stirring solution of 3-methoxybenzene-l,2-diol (3 g, 21.42 mmol) in carbon tetrachloride (30 ml_) was added /V-bromosuccinimide (4.5 g, 25.71 mmol) and the reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with ice-cold water and extracted with dichloromethane (3 x) . The combined dichloromethane layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The obtained residue has mixture of products (3-Bromo-6- methoxybenzene-l,2-diol) which was used as such for further reactions (4.2 g).

To a stirring solution of 3-bromo-6-methoxybenzene-l,2-diol (500 mg, 2.27 mmol) in acetone (40 mL) at 0 °C was added potassium carbonate (313 mg, 2.27 mmol) and methoxymethyl chloride (183 mg, 2.27 mmol) and the resultant reaction mixture was stirred at RT for 2 h. The reaction mixture was filtered and filtrate was concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-8% ethyl acetate in pet ether) afforded 3-Bromo-6-methoxy-2- (methoxymethoxy)phenol as a liquid (230 mg, 38%).

To a stirring solution of 3-bromo-6-methoxy-2-(methoxymethoxy)phenol (12 g, 0.045 mol) in acetonitrile (100 mL) at 0 °C was added potassium carbonate (18 g, 0.135 mol) and cyclopropylmethyl bromide (9 g, 0.067 mol) and the resultant reaction mixture was stirred for 1 h at RT. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-12% ethyl acetate in pet ether) to afford l-Bromo-3- (cyclopropylmethoxy)-4-methoxy-2-(methoxymethoxy)benzene as a solid (5.5 g, 38%).

A stirring solution of l-bromo-3-(cyclopropylmethoxy)-4-methoxy-2- (methoxymethoxy)benzene (3 g, 9.46 mmol) in dimethylformamide (50 mL) was purged with argon for 1 h, to this cesium carbonate (9.23 g, 28.39 mmol), water (3 mL), tetrakis triphenylphosphine palladium (546 mg, 0.472 mmol) and 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l- one (2.93 g, 11.35 mmol) were added and the resultant reaction mixture was heated to 80 °C for 5 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 4-(3-(Cyclopropylmethoxy)-4-methoxy-2- (methoxymethoxy)phenyl)-2,3-dihydro-lH-inden-l-one as a solid (1.8 g, 51%).

To a stirring solution of 4-(3-(cyclopropylmethoxy)-4-methoxy-2- (methoxymethoxy)phenyl)-2,3-dihydro-lH-inden-l-one (1.5 g, 4.076 mmol) in methanol (25 mL) was added concentrated hydrochloride (5 mL) and the reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated under reduced pressure the obtained residue was basified with sodium bicarbonate solution and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (1 g, 75.7%).

Example 138

-(3-Cyclopropylmethoxy-2-ethoxy-4-methoxy-phenyl)-indan-l-on e (Compound 403)

To a stirring solution of 4-(3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.740 mmol) and ethyl iodide (153 mg, 0.984 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-15% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 23%).

UPLC-MS (M + l) : 353.15 ; UPLC-MS RT (min) : 2.7

Example 139

4-(3-C clopropylmethoxy-4-methoxy-2-propoxy-phenyn-indan-l-one (Compound 404)

To a stirring solution of 4-(3-(cydopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.740 mmol) and n-propyl bromide (91 mg, 0.740 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0- 15% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 22%).

UPLC-MS (M + l) : 367.17 ; UPLC-MS RT (min) : 2.8

Example 140

4-(3-C clopropylmethoxy-2-isobutoxy-4-methoxy-phenyl)-indan-l-one ( ^" Compound 405)

To a stirring solution of 4-(3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.740 mmol) and isobutylbromide (101 mg, 0.740 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated und reduced pressure. The residue was purified by column chromatography (silica gel, 0- 20% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 21%).

UPLC-MS (M + l) : 381.2 ; UPLC-MS RT (min) : 2.9 Example 141

4-r3-Cyclopropylmethoxy-4-methoxy-2-(3-methyl-oxetan-3-ylmet hoxyVphenyn-indan- 1-one (Compound 406Ί

To a stirring solution of 4-(3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.740 mmol) and 3-bromomethyl-3-methyl-oxetane ( 122 mg, 0.740 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column

chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 20%).

UPLC-MS (M + l) : 409.19 ; UPLC-MS RT (min) : 2.6

Example 142

4- r3-Cyclopropylmethoxy-2-(3-hydroxymethyl-oxetan-3-ylmethoxy ^' )-4-methoxy- henyll-indan-l-one (Compound 407)

To a stirring solution of 4-(3-(cydopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.740 mmol) and (3-bromomethyl-oxetan-3-yl)- methanol (134 mg, 0.740 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 19.2%).

UPLC-MS (M + l) : 425.18 ; UPLC-MS RT (min) : 2.3 Example 143

4-[ ^' 3-Cyclopropylmethoxy-4-methoxy-2-(3-methoxymethyl-oxet an-3-ylmethoxy ^' )- henyll-indan-l-one (Compound 408)

To a stirring solution of 4-(3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.246 mmol) in acetonitrile (150 mL) was added potassium carbonate (102 mg, 0.740 mmol) and 3-bromomethyl-3-methoxymethyl- oxetane ( 120 mg, 0.615 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (25 mg, 23%).

UPLC-MS (M + l) : 439.19 ; UPLC-MS RT (min) : 2.6

Example 144

4-r3-Cvclopropylmethoxy-2-f4-methanesulfonyl-benzyloxyV4-met hoxy-phenyll-indan- 1-one (Com ound 409)

To a stirring solution of 4-(3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3- dihydro-lH-inden-l-one (80 mg, 0.246 mmol) in acetonitrile (15 mL) was added potassium carbonate (102 mg, 0.740 mmol) and l-bromomethyl-4-methanesulfonyl- benzene (122 mg, 0.493 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-45% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 16%).

UPLC-MS (M + l) : 493.11 ; UPLC-MS RT (min) : 2.6 Example 145

2-f2-Cyclopropylmethoxy-3-methoxy-6-(l-oxo-indan-4-yn-Phenox yl-N-propyl- acetamide (Com ound 410)

To a stirring solution of n-propylamine (1.18 g, 20 mmol) in dichloroethane (10 mL) at 0 °C was added bromo acetyl bromide (2 g, 10 mmol) and further stirred for 10 min. The reaction mixture was diluted with dichloroethane, filtered and the filtrate was

concentrated under reduce pressure to afford 2-Bromo-/V-propylacetamide as a solid (1 g, 55.8%).

4- (3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl)-2,3-dihyd ro-lH-inden-l-one (100 mg, 0.308 mmol) in acetonitrile (15 mL) was added potassium carbonate (127 mg, 0.925 mmol) and 2-bromo-/V-propylacetamide (110 mg, 0.616 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-45% ethyl acetate in pet ether) to afford the title compound as a solid (40 mg, 30.7%).

UPLC-MS (M+ l) : 424.2 ; UPLC-MS RT (min) : 2.5

Preparation 22

5- (3-(Cyclopropylmethoxy)-2-hydroxy-4-methoxyphenynisobenzofur an-l(3H ^' )-one (Com ound 322)

A stirring solution of l-bromo-3-(cyclopropylmethoxy)-4-methoxy-2- (methoxymethoxy)benzene (3 g, 9.46 mmol) in dimethylformamide (50 mL) was with argon for 1 h, to this cesium carbonate (9.23 g, 28.39 mmol), water (3 mL), tetrakis (triphenylphosphine) palladium(O) (546 mg, 0.472 mmol) and 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isobenzofuran-l(3H)-one (2.96 g, 11.47 mmol) were added and the resultant reaction mixture was heated to 80 °C for 5 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded 5-(3-(Cyclopropylmethoxy)-4-methoxy-2- (methoxymethoxy)phenyl)isobenzofuran-l(3H)-one as a solid (1.8 g, 51%).

To a stirring solution of 5-(3-(cyclopropylmethoxy)-4-methoxy-2-

(methoxymethoxy)phenyl) isobenzofuran-l(3H)-one (1.5 g, 4.05 mmol) in methanol (25 mL) was added concentrated hydrochloride (5 mL) and the reaction mixture was stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and the obtained residue was basified with sodium bicarbonate solution and then extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a solid (1 g, 76%). Example 146

5-(3-Cyclopropylmethoxy-2-ethoxy-4-methoxy-phenyl)-3H-isoben zofuran-l-one

(Com ound 411

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl) isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.745 mmol) and ethyl iodide (156 mg, 0.987 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 0-15% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 23%).

UPLC-MS (M + l) : 455.15 ; UPLC-MS RT (min) : 2.6 Example 147

5-i3-Cyclopropylmethoxy-4-methoxy-2-propoxy-phenylV3H-isoben zofuran-l-one Com ound 412)

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.745 mmol) and propyl bromide (91 mg, 0.745 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite. The filtrate was

concentrated under reduced pressure and the residue was purified by column

chromatography (silica gel, 0-15% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 22%).

UPLC-MS ( +l) : 369.17 ; UPLC- S RT (min) : 2.7 Example 148

5-(3-Cyclopropylmethoxy-2-isobutoxy-4-methoxy-phenyn-3H-isob enzofuran-l-one (Com ound 413 ^' )

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4-methoxyphenyl) isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL) was added potassium carbonate (102 mg, 0.745 mmol) and isobutylbromide (102 mg, 0.745 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 0- 20% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 21%). UPLC-MS (M+l) : 383.19 ; UPLC-MS RT (min) : 2.8 Example 149

5-[3-Cyclopropylmethoxy-4-methoxy-2-(3-methyl-oxetan-3-ylmet hoxyVphenyl1-3H- isobenzofuran-l-one (Compound 4141

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL), was added potassium carbonate (102 mg, 0.745 mmol) and 3-bromomethyl-3-methyl- oxetane (122 mg, 0.740 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to T and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford title compound as a solid (20 mg, 20%)

UPLC-MS (M + l): 411.18 ; UPLC-MS RT (min): 2.6 Example 150

5-r3-Cyclopropylmethoxy-2-( ^, 3-hvdroxymethyl-oxetan-3-ylmethoxy ^' )-4-methoxy- phen l ^" ]-3H-isobenzofuran-l-one (Compound 415)

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (10 mL), was added potassium carbonate (102 mg, 0.745 mmol) and (3-bromomethyl-oxetan-3- yl)-methanol (134 mg, 0.745 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 0-50% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 19.2%).

UPLC-MS (M + l) : 427.18 ; UPLC-MS RT (min) : 2.3 Example 151

5-r3-Cyclopropylmethoxy-4-methoxy-2-f3-methoxymethyl-oxetan- 3-ylmethoxy)- henyl1-3H-isobenzofuran-l-one (Compound 416)

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (15 ml_), was added potassium carbonate (101 mg, 0.736 mmol) and 3-bromomethyl-3- methoxymethyl-oxetane (95 mg, 0.490 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to T and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 0-40% ethyl acetate in pet ether) to afford the title compound as a solid (30 mg, 28%).

UPLC-MS (M + l) : 441.19 ; UPLC-MS RT (min) : 2.5

Example 152

5-[3-Cyclopropylmethoxy-2-(4-methanesulfonyl-benzyloxy ^' )-4-methoxy-phenyll-3H- isobenzofuran-l-one (Compound 417 ^' )

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (80 mg, 0.246 mmol) in acetonitrile (15 mL), was added potassium carbonate (102 mg, 0.740 mmol) and l-bromomethyl-4- methanesulfonyl-benzene (122 mg, 0.490 mmol) and the resultant reaction mixture was heated to 70 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 0-45% ethyl acetate in pet ether) to afford the title compound as a solid (20 mg, 16.5%). UPLC-MS (M + l) : 495.15 ; UPLC-MS RT (min) : 2.5

Example 153

2-f2-(Cvclopropylmethoxy)-3-methoxy-6-(l-oxo-l,3-dihydroisob enzofuran-5- vO henoxyVN-propylacetamide (Compound 418 ^' )

To a stirring solution of 5-(3-(cyclopropylmethoxy)-2-hydroxy-4- methoxyphenyl)isobenzofuran-l(3H)-one (250 mg, 0.766 mmol) in acetonitrile (20 mL) was added potassium carbonate (312 mg, 2.3 mmol) and ethylbromoacetate (256 mg, 1.533 mmol) and the reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT and filtered through celite. The filtrate was concentrated under reduced pressure to afford Ethyl 2-(2-(cyclopropylmethoxy)-3-methoxy-6-( l-oxo-l,3- dihydroisobenzofuran-5-yl) phenoxy) acetate as a crude product which was used as such in further reaction (300 mg).

To a stirring solution of ethyl 2-(2-(cyclopropylmethoxy)-3-methoxy-6 ^: (l-oxo-l,3- dihydroisobenzofuran-5-yl) phenoxy) acetate (300 mg, 0.726 mmol) in tetrahydrofuran (15 mL) was added lithium hydroxide (152 mg, 3.631 mmol) in water (5 mL) and the reaction mixture was stirred at RT for 4 h. The reaction mixture was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with water, dried over sodium sulphate and concentrated under reduced pressure to afford the 2-(2-(Cyclopropylmethoxy)-3-methoxy-6-(l-oxo-l,3-dihydroisob enzofuran-5- yl)phenoxy)acetic acid as a solid (200 mg, 71.5%). To a stirring solution of 2-(2-(cyclopropylmethoxy)-3-methoxy-6-(l-oxo-l,3- dihydroisobenzofuran-5-yl)phenoxy)acetic acid (200 mg, 0.519 mmol) in

dichloromethane (20 mL) was added EDCI.HCI (150 mg, 0.779 mmol), triethylamine (156 mg, 1.55 mmol), HOBt (158 mg, 1.038 mmol) and propylamine (91 mg, 1.553 mmol) and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with dichloromethane (3 x). The combined dichloromethane layers were washed with brine, dried over sodium sulphate and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 5-40% ethyl acetate in pet ether) afforded the title compound as a solid (30 mg, 14%).

UPLC-MS (M + l) : 426.18 ; UPLC-MS RT (min) : 2.5

Example 154

5-(3-fcyclopropylmethoxy 2,4-dimethoxyphenyn-2 _r 3-dihydro-lH-inden-l-one

(Com ound 419^

To a stirring solution of 2,6-dimethoxyphenol (2 g, 12.9 mmol) in acetonitrile (50 mL) was added potassium carbonate (3.5 g, 25.8 mmol) and (bromomethyl)cyclopropane (3.5 g, 25.8 mmol) and the resultant reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was

concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) to afford 2- (Cyclopropylmethoxy)-l,3-dimethoxybenzene as a solid (2 g, 74%).

To a stirring solution of 2-(cyclopropylmethoxy)-l,3-dimethoxybenzene (500 mg, 2.40 mmol) in THF (25 mL) was added /V-bromosuccinimide (430 mg, 2.40 mmol) and the resultant reaction mixture was stirred at RT for 4 h. The reaction mixture was concentrated under reduced pressure and the obtained residue was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford l-Bromo-3-(cyclopropylmethoxy)-2,4-dimethoxybenzene as a solid (500 mg, 73%).

To a stirring solution of 5-bromo-2,3-dihydro-lH-inden-l-one (4 g, 18.957 mmol) in dioxane (80 mL) purged with argon was added

bis(triphenylphosphine)palladium(II)chloride (398 mg, 0.568 mmol) and heated to 70 °C. To this was added bis(pinacolato)diboron (9.6 g, 37.91 mmol) and potassium acetate (3.7 g, 37.91 mmol) and the resultant reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-15% ethyl acetate in pet ether) to afford 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l- one (Compound A) as a solid (3.5g, 71%).

A solution of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH-inden-l- one (180mg, 0.69 mmol) in dioxane (25 mL) was purged with argon for 1 h, to this was added cesium carbonate (672 mg, 2.07 mmol), Pd(PPh ₃ ) ₄ (40 mg, 0.034 mmol) and 1- bromo-3-(cyclopropylmethoxy)-2,4-dimethoxybenzene (200 mg, 0.69 mmol) and the resultant reaction mixture was heated to 80-90 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) afforded the title compound as a solid (100 mg and 42.3%).

Example 155

5-(3-(cydopropylmethoxy)-2,4-dimethoxyphenyl)isobenzofuran-l (3l-0-one f Compound 420

To a stirring solution of 5-bromoisobenzofuran-l(3H)-one (500 mg, 2.34 mmol) in dioxane (30 mL) purged with argon was added

bis(triphenylphosphine)palladium(II)chloride (50 mg, 0.070 mmol) and heated to 50 °C. To this was added bis(pinacolato)diboron (1.2 g, 4.6 mmol) and potassium acetate (460 mg, 4.69 mmol) and the resultant reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite bed and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 0-15% ethyl acetate in pet ether) to afford 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isobenzofuran-l(3H)-one (Compound-B) as a solid (400 mg, 65.7%). A solution of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isobenzofuran -l(3H)-one (325 mg, 1.25 mmol) in dioxane (25 mL) was purged with argon for 1 h, to this was added cesium carbonate (1 g, 3.12 mmol), Pd(PPh ₃ ) ₄ (36 mg, 0.031 mmol) and 1- bromo-3-(cyclopropylmethoxy)-2,4-dimethoxybenzene (300 mg, 1.04 mmol) and the resultant reaction mixture was heated to 80-90 °C for 16 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was diluted with water and extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.

Purification of the residue by column chromatography (silica gel, 0-10% ethyl acetate in pet ether) afforded a solid (150 mg, 42.5%).

Example 156

Methyl 3-[2,3-dimethoxy-6-f l-oxo-3H-isobenzofuran-4-ynphenoxy1-2.2-dimethyl- ropanoate (Compound 421

Following the procedure described in example 6 starting from 4-(2-hydroxy-3,4- dimethoxyphenyl)isobenzofuran-l(3H)-one (Compound 304) as the phenol, the title compound was prepared.

UPLC-MS ( + l) : 401.16 ; UPLC-MS RT (min) : 2.5 Example 157

Methyl 3-r2,3-dimethoxy-6-( l-oxo-3H-isobenzofuran-5-ynphenoxyl-2,2-dimethyl- ropanoate, (Compound 422)

To a stirring solution of methyl 3-hydroxy-2,2-dimethylpropanoate (2.76 g, 20.94 mmol, in portions) in tetrahydrofuran (25 mL) was added diethylazodicarboxylate (2.43 g, 13.96 mmol), triphenylphosphine (3.59 g, 13.96 mmol) and 5-(2-hydroxy-3,4- dimethoxyphenyl) isobenzofuran-l(3H)-one (2 g, 6.98 mmol) and the resultant reaction mixture was heated to 70 °C for 6 h. The reaction mixture was diluted with ethyl acetate layer, washed with water, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by flash, column chromatography (silica gel, 0-20% ethyl acetate in pet ether) to afford the title compound as a solid (800 mg, 28.6%).

UPLC-MS (M + l) : 401.16 ; UPLC-MS RT (min) : 2.5

Acid chlorides (53 μηιοΙ) were added to solutions of 4-(2-hydroxy-3,4-dimethoxy- phenyl)-indan-l-one (Compound 303) (35 μητιοΙ) and DIPEA (53 μΐηοΙ) in dichloroethane (0.5 mL). The mixtures were shanked at room temperature overnight and subsequently evaporated to dryness. The crude reaction mixtures were re-dissolved in DMF (0.3 mL), and HPLC purification yielded the below compounds, which were characterized by analytical_UPLC-MS

Compound Structure Compound Name Retention Detected

Time Mass

(minutes) (M)

423 [2,3-dimethoxy-6-(l- 2,41 340,13

oxoindan-4-yl)phenyl]

propanoate

424 [2,3-dimethoxy-6-(l- 2,41 352,13

oxoindan-4-yl)phenyl]

cyclopropanecarboxylate

425 [2,3-dimethoxy-6-(l- 2,50 354, 15

oxoindan-4-yl)phenyl] 2- methylpropanoate

426 [2,3-dimethoxy-6-(l- 2,50 354, 15

oxoindan-4-yl)phenyl]

butanoate 427 [2,3-dimethoxy-6-( l- 2,52 366, 15 oxoindan-4-yl)phenyl]

cyclobutanecarboxylate

428 [2,3-dimethoxy-6-( l- 2, 59 368, 16 oxoindan-4-yl)phenyl] 2- methylbutanoate

429 [2,3-dimethoxy-6-( l- 2,58 368, 16 oxoindan-4-yl)phenyl] 3- methylbutanoate

430 [2,3-dimethoxy-6-(l- 2,58 368, 16 oxoindan-4-yl)phenyl]

pentanoate

431 [2,3-dimethoxy-6-(l- 2,61 380, 16 oxoindan-4-yl)phenyl]

cyciopentanecarboxylate

432 [2,3-dimethoxy-6-( l- 2,67 382, 18 oxoindan-4-yl)phenyl]

hexanoate

433 xr [2,3-dimethoxy-6-( l- 2,67 382, 18 oxoindan-4-yl)phenyl] 2- ethylbutanoate

434 [2,3-dimethoxy-6-( l- 2,67 382, 18 oxoindan-4-yl)phenyl]

3,3-dimethylbutanoate

435 Xr [2,3-dimethoxy-6-( l- 2,46 386, 12 oxoindan-4-yl)phenyl] 3- methylsulfanylpropanoate

436 [2,3-dimethoxy-6-( l- 2,46 394, 10 oxoindan-4-yl)phenyl]

3,3,3-trifluoropropanoate

437 [2,3-dimethoxy-6-(l- 2,70 394, 18 oxoindan-4-yl) phenyl]

cyclohexanecarboxylate

438 [2,3-dimethoxy-6-( l- 2,70 394, 18 oxoindan-4-yl)phenyl] 2- cyclopentylacetate 439 [2,3-dimethoxy-6-(l- 2,28 400,15

il _l . oxoindan-4-yl)phenyl] 2- (2- methoxyethoxy)acetate

440 [2,3-dimethoxy-6-(l- 2,77 408, 19

oxoindan-4-yl)phenyl] 3- cyclopentylpropanoate

Example 159:

Acid chlorides (53 μΐτιοΙ) were added to solutions of 5-(2-hydroxy-3,4-dimethoxyphenyl)- indan-l-one (Compound 305) (35 μΐηοΙ) and DIPEA (53 μηηοΙ) in dichloroethane (0.5 mL). The mixtures were shanked at room temperature overnight and subsequently evaporated to dryness. The crude reaction mixtures were re-dissolved in DMF (0.3 mL), and HPLC purification yielded the below compounds, which were characterized by analytical UPLC-MS

Compound Structure Compound Name Retention Detected

Time Mass

(minutes) (M)

441 [2,3-dimethoxy-6-(l-oxoindan- 2,33 326, 12

5-yl)phenyl] acetate

442 [2,3-dimethoxy-6-(l-oxoindan- 2,42 352,13

5-yl)phenyl]

cyclopropanecarboxylate

443 [2,3-dimethoxy-6-(l-oxoindan- 2,52 354,15

5-yl)phenyl] butanoate

444 [2,3-dimethoxy-6-(l-oxoindan- 2,52 354,15

5-yl)phenyl] 2- methylpropanoate 445 [2,3-dimethoxy-6-(l-oxoindan- 2,54 366,15

5-yl)phenyl]

cyclobutanecarboxylate

446 I ¹ [2,3-dimethoxy-6-(l-oxoindan- 2,21 314,08

5-yl)phenyl] pentanoate

447 [2,3-dimethoxy-6-(l-oxoindan- 2,61 368,16

5-yl)phenyl] 3-methylbutanoate

448 I f [2,3-dimethoxy-6-(l-oxoindan- 2,60 368,16

5-yl)phenyl] 2-methylbutanoate

449 [2,3-dimethoxy-6-(l-oxoindan- 2,63 380,16

5-yl)phenyl]

cyclopentanecarboxylate

450 [2,3-dimethoxy-6-(l-oxoindan- 2,69 382,18

5-yl)phenyl] 2-ethylbutanoate

451 [2,3-dimethoxy-6-(l-oxoindan- 2,69 382, 18

5-yl)phenyl] hexanoate

452 [2,3-dimethoxy-6-(l-oxoindan- 2,69 382, 18

oc ¾ 5-yl)phenyl] 3,3- dimethylbutanoate

453 [2,3-dimethoxy-6-(l-oxoindan- 2,48 386,12

C x 5-yl)phenyl] 3- methylsulfanylpropanoate

454 [2,3-dimethoxy-6-(l-oxoindan- 2,47 394,10

5-yl)phenyl] 3,3,3- trifluoropropanoate

455 [2,3-dimethoxy-6-(l-oxoindan- 2,72 394,18

5-yl)phenyl]

cyclohexanecarboxylate

456 [2,3-dimethoxy-6-(l-oxoindan- 2,72 394,18

5-yl)phenyl] 2- cyclopentylacetate 457 [2,3-dimethoxy-6-(l-oxoindan- 2,30 400,15

5-yl)phenyl] 2-(2- methoxyethoxy)acetate

458 [2,3-dimethoxy-6-(l-oxoindan- 2,80 408,19

5-yl)phenyl] 3- cyclopentylpropanoate

Acid chlorides (53 μΓηοΙ) were added to solutions of 4-(2-hydroxy-3,4- dimethoxyphenyl)isobenzofuran-l(3H)-one (Compound 304)_(35 μηηοΙ) and DIPEA (53 μmol) in dichloroethane (0.5 mL). The mixtures were shanked at room temperature overnight and subsequently evaporated to dryness. The crude reaction mixtures were re-dissolved in DMF (0.3 mL), and HPLC purification yielded the below compounds, which were characterized by analytical UPLC-MS

Compound Structure Compound Name Retention Detected

Time Mass

(minutes) (M)

459 [2,3-dimethoxy-6-(l-oxo-3H- 2,37 342,11 isobenzofuran-4-yl)phenyl]

propanoate

460 Γ [2,3-dimethoxy-6-(l-oxo-3H- 2,37 354,11 isobenzofuran-4-yl)phenyl]

cyclopropanecarboxylate

461 [2,3-dimethoxy-6-(l-oxo-3H- 2,46 356,13 isobenzofuran-4-yl)phenyl]

butanoate

462 [2,3-dimethoxy-6-(l-oxo-3H- 2,46 356,13 isobenzofuran-4-yl)phenyl] 2-

CO methylpropanoate

463 1 ^{C i} [2,3-dimethoxy-6-(l-oxo-3H- 2,48 368,13 isobenzofuran-4-yl)phenyl]

cyclobutanecarboxylate 464 [2,3-dimethoxy-6-(l-oxo-3H- 2,54 370,14 isobenzofuran-4-yl)phenyl]

pentanoate

465 [2,3-dimethoxy-6-(l-oxo-3H- 2,54 370,14 isobenzofuran-4-yl)phenyl] 3-

°pu methylbutanoate

466 [2,3-dimethoxy-6-(l-oxo-3H- 2,57 382,14 isobenzofuran-4-yl)phenyl]

cyclopentanecarboxylate

467 [2,3-dimethoxy-6-(l-oxo-3H- 2,62 384, 16 isobenzofuran-4-yl)phenyl] 3,3-

°pu dimethylbutanoate

468 [2,3-dimethoxy-6-(l-oxo-3H- 2,63 384, 16 isobenzofuran-4-yl)phenyl]

hexanoate

469 [2,3-dimethoxy-6-(l-oxo-3H- 2,62 384,16 isobenzofuran-4-yl)phenyl] 2- ethylbutanoate

470 [2,3-dimethoxy-6-(l-oxo-3H- 2,41 388,10 isobenzofuran-4-yl)phenyl] 3- methylsulfanylpropanoate

471 [2,3-dimethoxy-6-(l-oxo-3H- 2,65 396,16 isobenzofuran-4-yl)phenyl]

cyclohexanecarboxylate

472 [2,3-dimethoxy-6-(l-oxo-3H- 2,65 396, 16 isobenzofuran-4-yl)phenyl] 2- cyclopentylacetate

473 p [2,3-dimethoxy-6-( l-oxo-3H- 2,25 402,13 isobenzofuran-4-yl)phenyl] 2-(2- methoxyethoxy)acetate

474 [2,3-dimethoxy-6-(l-oxo-3H- 2,72 410,17 isobenzofuran-4-yl)phenyl] 3- cyclopentylpropanoate

Example 161

Acid chlorides (53 μΐηοΙ) were added to solutions of 5-(2-hydroxy-3,4- dimethoxyphenyl)isobenzofuran-l(3H)-one (Compound 306)_(35 μmol) and DIPEA (53 μητιοΙ) in dichloroethane (0.5 mL). The mixtures were shanked at room temperature overnight and subsequently evaporated to dryness. The crude reaction mixtures were re-dissolved in DMF (0.3 mL), and HPLC purification yielded the below compounds, which were characterized by analytical UPLC-MS

Compound Structure Compound Name Retention Detected

Time Mass

(minutes) (M)

475 [2,3-dimethoxy-6-(l-oxo-3H- 2,27 328,09 isobenzofuran-5-yl)phenyl]

acetate

476 [2,3-dimethoxy-6-(l-oxo-3H- 2,36 354,11 isobenzofuran-5-yl)phenyl]

cyclopropanecarboxylate

477 [2,3-dimethoxy-6-(l-oxo-3H- 2,45 356, 13 isobenzofuran-5-yl)phenyl]

butanoate

478 [2,3-dimethoxy-6-(l-oxo-3H- 2,44 356,13 isobenzofuran-5-yl)phenyl] 2- methylpropanoate

479 [2,3-dimethoxy-6-(l-oxo-3H- 2,47 368,13 isobenzofuran-5-yl)phenyl]

cyclobutanecarboxylate

480 [2,3-dimethoxy-6-(l-oxo-3H- 2,53 370,14 isobenzofuran-5-yl)phenyl] 3- methylbutanoate

481 [2,3-dimethoxy-6-(l-oxo-3H- 2,53 370,14 isobenzofuran-5-yl)phenyl]

pentanoate

482 [2,3-dimethoxy-6-(l-oxo-3H- 2,52 370,14 isobenzofuran-5-yl)phenyl] 2- methylbutanoate 483 [2,3-dimethoxy-6-(l-oxo-3H- 2,61 384,16 isobenzofuran-5-yl)phenyl] 3,3- dimethylbutanoate

484 [2,3-dimethoxy-6-(l-oxo-3H- 2,60 384,16 isobenzofuran-5-yl)phenyl] 2- ethylbutanoate

485 [2,3-dimethoxy-6-(l-oxo-3H- 2,41 388,10 isobenzofuran-5-yl)phenyl] 3- methylsulfanylpropanoate

486 [2,3-dimethoxy-6-(l-oxo-3H- 2,25 402,13 isobenzofuran-5-yl)phenyl] 2-(2- methoxyethoxy)acetate

487 [2,3-dimethoxy-6-(l-oxo-3H- 2,71 410,17 isobenzofuran-5-yl)phenyl] 3- cyclopentylpropanoate

Acid chlorides (53 μΐηοΙ) were added to solutions of 5-(2-hydroxy-3,4- dimethoxyphenyl)isoindolin-l-one (Compound 307) (35 μηηοΙ) and DIPEA (53 μητιοΙ) in dichloroethane (0.5 mL) . The mixtures were shanked at room temperature overnight and subsequently evaporated to dryness. The crude reaction mixtures were re-dissolved in DMF (0.3 mL), and HPLC purification yielded the below compounds, which were characterized by analytical UPLC-MS

Compound Structure Compound Name Retention Detected

Time Mass

(minutes) (M)

488 [2,3-dimethoxy-6-(l- 2,48 355,14 oxoisoindolin-5-yl)phenyl] 2- methylpropanoate

489 [2,3-dimethoxy-6-(l- 2,52 367,14 oxoisoindolin-5-yl)phenyl]

cyclobutanecarboxylate 490 1 [2,3-dimethoxy-6-(l- 2,57 369, 16 oxoisoindolin-5-yl)phenyl]

pentanoate

491 [2,3-dimethoxy-6-(l- 2,56 369,16 oxoisoindolin-5-yl)phenyl] 3- methylbutanoate

492 Xr [2,3-dimethoxy-6-( l- 2,56 369,16 oxoisoindolin-5-yl)phenyl] 2- methylbutanoate

493 [2,3-dimethoxy-6-( l- 2,61 381, 16 oxoisoindolin-5-yl)phenyl]

cyclopentanecarboxylate

494 [2,3-dimethoxy-6-(l- 2,67 383, 17 oxoisoindolin-5-yl)phenyl]

hexanoate

495 [2,3-dimethoxy-6-(l- 2,66 383, 17 oxoisoindolin-5-yl)phenyl] 3,3- dimethylbutanoate

496 Xr [2,3-dimethoxy-6-(l- 2,64 383,17 oxoisoindolin-5-yl)phenyl] 2- ethylbutanoate

497 [2,3-dimethoxy-6-(l- 2,69 395,17 oxoisoindolin-5-yl)phenyl]

cyclohexanecarboxylate

498 [2,3-dimethoxy-6-(l- 2,78 409,19 oxoisoindolin-5-yl)phenyl] 3- cyclopentylpropanoate

Example 163

A solution of 4-(2-hydroxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound 303) (1.00 mmol), the alky) 3-hydroxypropanoate derivative (3.00 mmol) and triphenylpnospnine (3.00 mmol) in THF (4 mL) was flushed with argon and cooled in an icebath, before a solution of DEAD (3.00 mmol) in THF (3.2 mL) was added dropwise. Subsequently the icebath was removed and the mixture was stirred at room temperature for 3 hours. The crude reaction mixture was diluted with DCM, washed with 1M HCI, water and

evaporated to dryness. Column chromatog raphy (silica gel, 0-100% ethyl acetate in pet ether) afforded the desired ester intermediate.

The ester intermediate was stirred in a mixture of 1 N aqueous LiOH (4 mL) and THF (4 mL) at room temperature overnight. Then water was added and the aqueous phase washed with EtOAc, acidified to pH 1 with concentrated HCI and extracted four times with DCM . Evaporation to dryness of the organic phase afforded the desired carboxylic acid .

Solutions of the carboxylic acid (40 μηηοΙ), EDCI (80 μητιοΙ), DMAP (80 μΐηοΙ) and the selected alcohols in DCM (700 μΐ) were stirred overnight at room temperature, before they were evaporated to dryness. The crude reaction mixtures were re-dissolved in DMF (0.3 mL), and HPLC purification yielded the below compounds, which were characterized by analytical UPLC-MS

Compound Structure Compound Name Retention Detected

Time Mass

(minutes)

499 methyl (2R)-3-[2,3-dimethoxy-6-( l- 2,46 384, 16

° ^{' Jl} oxoindan-4-yl)phenoxy]-2-methyl- propanoate

500 methyl (2S)-3-[2,3-dimethoxy-6-(l- 2,46 384, 16 oxoindan-4-yl)phenoxy]-2-methyl- propanoate 501 methyl l-[[2,3-dimethoxy-6-( l-oxoindan-4- 2,47 396, 16 yl)phenoxy]methyl]cyclopropanecarboxylate

502 ethyl (2S)-3-[2,3-dimethoxy-6-( l- 2,55 398, 17 oxoindan-4-yl)phenoxy]-2-methyl- propanoate

503 ethyl (2R)-3-[2,3-dimethoxy-6-( l- 2,55 398, 17 oxoindan-4-yl)phenoxy]-2-methyl- propanoate

504 ethyl l-[[2,3-dimethoxy-6-( l-oxoindan-4- 2,56 410, 17 yl)phenoxy]methyl]cyclopropanecarboxylate

505

Γ methyl l-[[2,3-dimethoxy-6-( l-oxoindan-4- 2,58 410, 17 yl)phenoxy]methyl]cyclobutanecarboxylate

506 ethyl 3-[2,3-dimethoxy-6-( l-oxoindan-4- 2,65 412, 19 yl)phenoxy]-2,2-dimethyl-propanoate

507 propyl (2R)-3-[2,3-dimethoxy-6-( l- 2,65 412, 19 oxoindan-4-yl)phenoxy]-2-methyl- propanoate

508 propyl (2S)-3-[2,3-dimethoxy-6-( l- 2,65 412, 19

l ⁰ oxoindan-4-yl)phenoxy]-2-methyl- propanoate

509 isopropyl (2S)-3-[2,3-dimethoxy-6-( l- 2,64 412, 19 oxoindan-4-yl)phenoxy]-2-methyl- propanoate

510 isopropyl (2R)-3-[2,3-dimethoxy-6-( l- 2,64 412, 19 oxoindan-4-yl)phenoxy]-2-methyl-

CJO propanoate

51 1 propyl l-[[2,3-dimethoxy-6-( l-oxoindan-4- 2,66 424, 19 yl)phenoxy]methyl]cyclopropanecarboxylate

512 ethyl l-[[2,3-dimethoxy-6-( l-oxoindan-4- 2,67 424, 19 yl)phenoxy]methyl]cyclobutanecarboxylate

513 isopropyl l-[ [2,3-dimethoxy-6-( l-oxoindan- 2,65 424, 19

4- yl)phenoxy]methyl]cyclopropanecarboxylate 514 propyl 3-[2,3-dimethoxy-6-( l-oxoindan-4- 2,74 426,2 yl)phenoxy]-2,2-dimethyl-propanoate

515 isopropyl 3-[2,3-dimethoxy-6-(l-oxoindan- 2,74 426,2

4-yl)phenoxy]-2,2-dimethyl-propanoate

516 cyclobutyl l-[[2,3-dimethoxy-6-( l- 2,69 436, 19 oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

517 isobutyl l-[[2,3-dimethoxy-6-(l-oxoindan- 2,74 438,2

4- yl)phenoxy]methyl]cyclopropanecarboxylate

518 propyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- 2,76 438,2 yl)phenoxy]methyl]cyclobutanecarboxylate

519 butyl l-[[2,3-dimethoxy-6-(l-oxoindan-4- 2,75 438,2 yl)phenoxy]methyl]cyclopropanecarboxylate

520 cyclobutyl 3-[2,3-dimet oxy-6-(l-oxoindan- 2,78 438,2

4-yl)phenoxy]-2,2-dimethyl-propanoate

521 isopropyl l-[[2,3-dimethoxy-6-( l-oxoindan- 2,76 438,2

4- yl)phenoxy]methyl]cyclobutanecarboxylate

522 butyl 3-[2,3-dimethoxy-6-(l-oxoindan-4- 2,83 440,22 yl)phenoxy]-2,2-dimethyl-propanoate

523 isobutyl 3-[2,3-dimethoxy-6-(l-oxoindan-4- 2,83 440,22 yl)phenoxy]-2,2-dimethyl-propanoate

524 3-fluoropropyl l-[[2,3-dimethoxy-6-( l- 2,54 442, 18 oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

525 cyclobutyl l-[[2,3-dimethoxy-6-( l- 2,79 450,2 oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

526 cyclopentyl l-[[2,3-dimethoxy-6-(l- 2,76 450,2 oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate 540

? fa" ³ 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l- 2,91 466,24

¾¾¾ oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

541 cyclohexyl 3-[2,3-dimethoxy-6-(l- 2,94 466,24 oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

542 cyclohexyl l-[[2,3-dimethoxy-6-(l- 2,95 478,24 oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

Example 164

4-(2-Hydroxy-3,4-dimethoxy-phenyl)isoindolin-l-one is synthesized following the same procedure as the one described for the synthesis of Compound 307 using 4-bromo-2,3- dihydro-lH-isoindol-l-one as starting material.

Compounds 543-735 are synthesized following the experimental procedure described for the preparation of Compounds 499-542.

Compound Structure IUPAC name 543 [( lR)-l-methylpropyl] 3-[2,3-dimethoxy-6-( l- oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

544 [(lS)-l-methylpropyl] 3-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

545 3-fluoropropyl 3-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

546 (1-cyano-l-methyl-ethyl) 3-[2,3-dimethoxy-6-

(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

547 [(3S)-tetrahydrofuran-3-yl] 3-[2,3-dimethoxy-

6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

548 [(3R)-tetrahydrofuran-3-yl] 3~[2,3-dimethoxy-

6-(l-oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

549 tetrahydropyran-4-yl 3-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2,2-dimethyl- propanoate

550 cycloheptyl 3-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

Compound Structure Compound name

551 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

552 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

553 (1-cyano-l-methyl-ethyl) l-[[2,3- dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate 554 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

555 [(3 )-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

556 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6- (l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

557 cycloheptyl l-[[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

Compound Structure Compound name

558 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy-6- (l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

559 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy-6- (l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

560 3-fluoropropyl l-[[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

561 cyclobutylmethyl l-[[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

562 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

563 [(3R)-tetrahydrofuran-3-ylJ l-[[2,3- dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

564 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6-(l- oxoindan-4-

96 yl)phenoxy]methyl]cyclobutanecarboxylate cycloheptyl l-[[2,3-dimethoxy-6-(l-oxoindan

4-yl)phenoxy]methyl]cyclobutanecarboxylate

Compound Structure Compound name

566 ethyl 3-[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]-2,2-dimethyl-propanoate

567 propyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

568 isopropyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

569 cyclobutyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

570 isobutyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

571 [(lR)-l-methylpropyl] 3-[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-2,2-dimethyl-propanoate

572 [(lS)-l-methylpropyl] 3-[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-2 _/ 2-dimethyl-propanoate

573 3-fluoropropyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

574 (1-cyano-l-methyl-ethyl) 3-[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-2,2-dimethyl-propanoate

575 cyclobutylmethyl 3-[2,3-dimethoxy-6-

(l-oxoindan-5-yl)phenoxy]-2,2- dimethyl-propanoate 576 cyclopentyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

577 [(3S)-tetrahydrofuran-3-yl] 3-[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-2,2-dimethyl-propanoate

578 [(3R)-tetrahydrofuran-3-yl] 3-[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-2,2-dimethyl-propanoate

579 1-ethylpropyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

580 2,2-dimethylpropyl 3-[2,3-dimethoxy-

6-( l-oxoindan-5-yl)phenoxy]-2,2- dimethyl-propanoate

581 cyclohexyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

582 tetrahydropyran-4-yl 3-[2,3-dimethoxy-

6-(l-oxoindan-5-yl)phenoxy]-2,2- dimethyl-propanoate

583 cycloheptyl 3-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2,2-dimethyl- propanoate

Compound Structure Compound name

584 methyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

585 ethyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

586 propyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate 587 isopropyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

588 cyclobutyl l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropanecarboxylate

589 isobutyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

590 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy-6- (l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

591 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy-6- ( l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

592 3-fluoropropyl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

593 (1-cyano-l-methyl-ethyl) l-[[2,3-dimethoxy- 6-(l-oxoindan-5-

* yl)phenoxy]methyl]cyclopropanecarboxylate

594 cyclobutylmethyl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

595 cyclopentyl l-[[2,3-dimethoxy-6-( l-oxoindan- 5-yl)phenoxy]methyl]cyclopropanecarboxylate

596 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

597 [(3R)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

598 1-ethylpropyl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate 599 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

600 cyclohexyl l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropanecarboxylate

601 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclopropanecarboxylate

602 cycloheptyl l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropanecarboxylate

Compound Structure Structure name

603 methyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

604 ethyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

605 propyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

606 isopropyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

607 cyclobutyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

608 isobutyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

609 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate 610 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

611 3-fluoropropyl l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclobutanecarboxylate

612 (1-cyano-l-methyl-ethyl) l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

613 cyclobutylmethyl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

614 cyclopentyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

615 [(3S)-tetrahydrofuran-3-yl] l-[[2,3-dimethoxy-6- (l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

616 [(3R)-tetrahydrofuran-3-yl] l-[[2,3-dimethoxy-6- (l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

617 l-ethylpropyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

618 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

619 cyclohexyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

620 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate

621 cycloheptyl l-[[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]methyl]cyclobutanecarboxylate Compound Structure Compound name

622 methyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-2,2-dimethyl-propanoate

623 ethyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-2,2-dimethyl-propanoate

624 propyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-2,2-dimethyl-propanoate

625 isopropyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-2,2-dimethyl-propanoate

626 cyclobutyl 3-[2,3-dimethoxy-6-( l-oxoisoindolin- 4-yl)phenoxy]-2,2-dimethyl-propanoate

627 isobutyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-2,2-dimethyl-propanoate

628 [(lR)-l-methylpropyl] 3-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

629 [(lS)-l-methylpropyl] 3-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

630 3-fluoropropyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

631 (1-cyano-l-methyl-ethyl) 3-[2,3-dimethoxy-6-

(l-oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

632 cyclobutylmethyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

633 cyclopentyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin- 4-yl)phenoxy]-2,2-dimethyl-propanoate 634 [(3S)-tetrahydrofuran-3-yl] 3-[2,3-dimethoxy-6-

(l-oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

635 [(3R)-tetrahydrofuran-3-yl] 3-[2,3-dimethoxy-6- few (l-oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

636 1-ethylpropyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

637 2,2-dimethylpropyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

638 cyclohexyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin- 4-yl)phenoxy]-2,2-dimethyl-propanoate

639 tetrahydropyran-4-yl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2,2-dimethyl- propanoate

640 cycloheptyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin- 4-yl)phenoxy]-2,2-dimethyl-propanoate

Compound Structure Compound name

641 methyl l-[[2,3-dimethoxy-6-(l-oxoisoindolin- 4-yl)phenoxy]methyl]cyclopropanecarboxylate

642 ethyl l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

643 propyl l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

644 isopropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate 645 cyclobutyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

646 isobutyl l-[[2,3-dimethoxy-6-(l-oxoisoindolin- 4-yl)phenoxy]methyl]cyclopropanecarboxylate

647 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

648 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

649 3-fluoropropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

650 (1-cyano-l-methyl-ethyl) l-[[2,3-dimethoxy-6- (l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

651 cyclobutyl methyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

652 cyclopentyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

653 t(3S)-tetrahydrofuran-3-yl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

654 [(3R)-tetrahydrofuran-3-yl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

655 1-ethylpropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- O yl)phenoxy]methyl]cyclopropanecarboxylate

656 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate 657 cyclohexyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

658 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

659 cycloheptyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclopropanecarboxylate

Compound Structure Compound name

660 methyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

661 ethyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

662 propyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

663 isopropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4-

90 yl)phenoxy]methyl]cyclobutanecarboxylate

664 cyclobutyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

665 isobutyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

666 t(lR)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

667 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate 668 3-fluoropropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

669 (1-cyano-l-methyl-ethyl) l-[[2,3- dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

670 cyclobutylmethyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

671 cyclopentyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

672 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

673 [(3R)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

674 1-ethylpropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

675 2,2-dimethylpropyl l-[[2,3-dimethoxy-6- (l-oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

676 cyclohexyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

677 tetrahydropyran-4-yl l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

678 cycloheptyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]methyl]cyclobutanecarboxylate

Compound Structure Compound name 679 methyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]-2,2-dimethyl-propanoate

680 ethyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]-2,2-dimethyl-propanoate

681 propyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]-2,2-dimethyl-propanoate

682 isopropyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin- 5-yl)phenoxy]-2,2-dimethyl-propanoate

683 cyclobutyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin- 5-yl)phenoxy]-2,2-dimethyl-propanoate

684 isobutyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]-2,2-dimethyl-propanoate

685 [(lR)-l-methylpropyl] 3-[2,3-dimetboxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

686 [(lS)-l-methylpropyl] 3-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

687 3-fluoropropyl 3-[2,3-dimethoxy-6-(l- fe . oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

688 (1-cyano-l-methyl-ethyl) 3-[2,3-dimethoxy-6-

(l-oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

689 cyclobutylmethyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

690 cyclopentyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate 691 [(3S)-tetrahydrofuran-3-yl] 3-[2,3-dimethoxy-

6-(l-oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

692 [(3R)-tetrahydrofuran-3-yl] 3-[2,3-dimethoxy-

6-(l-oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

693 1-ethylpropyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

694 2,2-dimethylpropyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

695 cyclohexyl 3-[2,3-dimethoxy-6-(l-oxoisoindolin- 5-yl)phenoxy]-2,2-dimethyl-propanoate

696 tetrahydropyran-4-yl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

697 cycloheptyl 3-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2,2-dimethyl- propanoate

Compound Structure Compound name

698 methyl l-[[2,3-dimethoxy-6-( l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

699 ethyl l-[[2,3-dimethoxy-6-(l-oxoisoindolin- 5- yl)phenoxy]methyl]cyclopropanecarboxylate

700 propyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

701 isopropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate 702 cyclobutyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

703 isobutyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

704 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

705 [( lS)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

706 3-fluoropropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

707 (1-cyano-l-methyl-ethyl) l-[[2,3- dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

708 cyclobutylmethyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

709 cyclopentyl l-[[2,3-dimethoxy-6-( l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

710 t(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

711 [(3R)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

712 1-ethylpropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

713 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate 714 cyclohexyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

715 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6- (l-oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

716 cycloheptyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropanecarboxylate

Compound Structure Compound name

717 methyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

718 ethyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

719 propyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

720 isopropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

721 cyclobutyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

722 isobutyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

723 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

724 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate 725 3-fluoropropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

726 (1-cyano-l-methyl-ethyl) l-[[2,3- dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

727 cyclobutylmethyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

728 cyclopentyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

729 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimet oxy-6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

730 [(3R)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

731 1-ethylpropyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

732 2,2-dimethylpropyl l-[[2,3-dimethoxy-6- (l-oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

733 cyclohexyl l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

734 tetrahydropyran-4-yl l-[[2,3-dimethoxy- 6-(l-oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

735 cyclohepty! l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclobutanecarboxylate

Example 165

Compounds 736 - 842 are synthesized as described below. A solution of the appropriate biaryl-alcohol, Compound 304 or 306, the appropriate alcohol ester, for example methyl 3-hydroxy-2,2-dimethyl-propanoate, and triphenylphosphine in THF is flushed with argon and cooled in an icebath, before a solution of DEAD in THF is added dropwise. The mixture is stirred at room temperature. The crude reaction mixture is then diluted with DCM, washed with 1M HCI, water and evaporated to dryness. Column chromatography (silica gel, 0-100% ethyl acetate in pet ether) affords the corresponding O-alkylated bi- aryl compound, for example methyl 3-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]-2,2-dimethyl-propanoate, which is stirred in a mixture of 1 N aqueous LiOH and THF at room temperature. Water is added and the aqueous phase is washed with EtOAc, acidified to pH 1 with concentrated HCI and extracted with DCM. The organic phase is evaporated to dryness and the crude reaction mixture is stirred at room temperature in a HCI/dioxane suspension before it is evaporated to dryness. The obtained carboxylic acid, for example 3-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]-2,2-dimethyl-propanoic acid , EDCI , DMAP and the appropriate alcohol, for example isopropanol, in DCM is stirred overnight at room temperature, before it is evaporated to dryness. The crude reaction mixture is re-dissolved in DMF and purified by HPLC purification to obtain the title compound, for example isopropyl 3-[2,3-dimethoxy- 6-(l-oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propano ate

Compound Structure Compound name

736 ethyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4-yl)phenoxy]-2,2- O dimethyl-propanoate 737 propyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4-yl)phenoxy]-2,2- dimethyl-propanoate

738 isopropyl 3-[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-4-yl)phenoxy]-2,2- dimethyl-propanoate

739 cyclobutyl 3-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4-yl)phenoxy]-2,2- O dimethyl-propanoate

740 isobutyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4-yl)phenoxy]-2,2- dimethyl-propanoate

741 [(lR)-l-methylpropyl] 3-[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-

4-yl)phenoxy]-2,2-dimethyl-propanoate

742 [(lS)-l-methylpropyl] 3-[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran- 4-yl)phenoxy]-2,2-dimethyl-propanoate

743 3-fluoropropyl 3-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4-yl)phenoxy]-

2,2-dimethyl-propanoate

744 (1-cyano-l-methyl-ethyl) 3-[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran- vO 4-yl)phenoxy]-2,2-dimethyl-propanoate

745 cyclobutylmethyl 3-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4-yl)phenoxy]-

2,2-dimethyl-propanoate

746 cyclopentyl 3-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4-yl)phenoxy]-2,2- dimethyl-propanoate

747 [(3S)-tetrahydrofuran-3-yl] 3-[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-

4-yl)phenoxy]-2,2-dimethyl-propanoate

748 t(3R)-tetrahydrofuran-3-yl] 3-[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-

4-yl)phenoxy]-2,2-dimethyl-propanoate 749 1-ethylpropyl 3-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4-yl)phenoxy]- 2,2-dimethyl-propanoate

750 2,2-dimethylpropyl 3-[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-4-yl)phenoxy]-

2,2-dimethyl-propanoate

751 cyclohexyl 3-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4-yl)phenoxy]-2,2- O dimethyl-propanoate

752 tetrahydropyran-4-yl 3-[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-2,2-dimethyl-propanoate

753 cycloheptyl 3-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4-yl)phenoxy]-2,2- dimethyl-propanoate

Compound Structure Compound name

754 methyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

755 ethyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

756 propyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- O yl)phenoxy]methyl]cyclopropanecarboxylate

757 isopropyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4-

CO yl)phenoxy]methyl]cyclopropanecarboxylate

758 cyclobutyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- O yl)phenoxy]methyl]cyclopropanecarboxylate

759 isobutyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yO yl)phenoxy]methyl]cyclopropanecarboxylate 760 V-p [(lR)-l-methylpropyl] l-[[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

761 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy- 6-(l-oxo-3H-isobenzofu ran-4- u yl)phenoxy]methyl]cyclopropanecarboxylate

762 3-fluoropropyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

763 (1-cyano-l-methyl-ethyl) l-[[2,3- dimethoxy-6-( l-oxo-3H-isobenzofuran-4- v yl)phenoxy]methyl]cyclopropanecarboxylate

764 cyclobutylmethyl l-[[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

765 cyclopentyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

766 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

767 [(3R)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

768 1-ethylpropyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

769 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

770 cyclohexyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

771 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate 772 cycloheptyl l-[[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropanecarboxylate

Compound Structure Compound name

843 methyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

844 ethyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

845 propyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

846 isopropyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

847 cyclobutyl l-[[2,3-dimethoxy-6-( l-oxo- 3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

773 isobutyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

774 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4-

CO yl)phenoxy]methyl]cyclobutanecarboxylate

775 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

776 3-fluoropropyl l-[[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

777 (1-cyano-l-methyl-ethyl) l-[[2,3- dimethoxy-6-( l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate 778 cyclobutyl methyl l-[[2,3-dimethoxy-6-( l- oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

779 cyclopentyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

780 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

781 [(3R)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

782 1-ethylpropyl l-[[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

783 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

784 cyclohexyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofu ran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

785 tetrahydropyran-4-yl l-[[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclobutanecarboxylate

786 cycloheptyl l-[[2,3-dimethoxy-6-( l-oxo- 3H-isobenzofuran-4- pD yl)phenoxy]methyl]cyclobutanecarboxylate

6A

Compound Structure Compound name

787 ethyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

788 propyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate 789 isopropyl 3-[2,3-dimethoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

790 cyclobutyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

791 isobutyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

792 [(lR)-l-methylpropyl] 3-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2- dimethyl-propanoate

793 [(lS)-l-methylpropyl] 3-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2- dimethyl-propanoate

794 3-fluoropropyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

795 (1-cyano-l-methyl-ethyl) 3-[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2- dimethyl-propanoate

796 cyclobutylmethyl 3-[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofu ran-5-yl)phenoxy]-2,2-dimethyl- propanoate

797 cyclopentyl 3-[2,3-dimethoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

798 [(3S)-tetrahydrofuran-3-yl] 3-[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2- dimethyl-propanoate

799 t(3R)-tetrahydrofuran-3-yl] 3-[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2- dimethyl-propanoate

800 1-ethylpropyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate 801 2,2-dimethylpropyl 3-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

802 cyclohexyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

803 tetrahydropyran-4-yl 3-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5-yl)phenoxy]-2,2- dimethyl-propanoate

804 cycloheptyl 3-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl- propanoate

6B

Compound Structure Compound name

805 methyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

806 ethyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

807 propyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

808 isopropyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

809 cyclobutyl l-[[2,3-dimethoxy-6-( l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

810 isobutyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

811 [(lR)-l-methylpropyl] l-[[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate 812 [(lS)-l-methylpropyl] l-[[2,3-dimethoxy-6-

(l-oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

813 3-fluoropropyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

814 (1-cyano-l-methyl-ethyl) l-[[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

815 cyclobutyimethyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

816 cyclopentyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

817 [(3S)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-5- a ⁰ yl)phenoxy]methyl]cyclopropanecarboxylate

818 [(3R)-tetrahydrofuran-3-yl] l-[[2,3- dimethoxy-6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

819 1-ethylpropyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

820 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

821 cyclohexyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

822 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate

823 cycloheptyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropanecarboxylate 6C

835 cyclopentyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

836 [(3S)-tetrahydrofuran-3-yl] l-[[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

837 [(3R)-tetrahydrofuran-3-yl] l-[[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

838 1-ethylpropyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

839 2,2-dimethylpropyl l-[[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

840 cyclohexyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

841 tetrahydropyran-4-yl l-[[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

842 cycloheptyl l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclobutanecarboxylate

Example 166

Compounds of the above type are synthesized as described below:

6-bromo-2,3-methoxyphenol is prepared as described in example 169. 6-bromo-2,3- methoxyphenol is alkylated with ethyl bromoacetate in dimethylformamide using potassium carbonate at room temperature. The resulting ester is treated with Methyl Grignard in diethyl ether at room temperature to give the tertiary carbinol.

The bromide is coupled with the requisite arylboronic acid by Suzuki coupling in methanol, using 10% Palladium(bis-triphenylphosphine) dichloride and sodium acetate with conventional heating or microwave heating to give the biaryl compound. The alcohol is acylated upon treatment with an acid chloride in acetonitrile at room temperature using pyridine as a base or as a catalyst.

Example 167

Compounds of the above type are synthesized as described below:

6-bromo-2,3-methoxyphenol is alkylated with bromethanol in dimethylformamide using potassium carbonate as a base under heating.

The bromide is coupled with the requisite arylboronic acid by Suzuki coupling in methanol, using 10% Palladium(bis-triphenylphosphine) dichloride and sodium acetate by conventional heating or microwave heating to give the biaryl compound.

The alcohol is acylated by treatment with an acid chloride in acetonitrile with pyridine as a base. Example 168

Compounds of the above type may be synthesized as described below (ref. Shevchuk, T. A. and Kulinkovich, O. G. Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii), 36(4), 491-495; 2000)

6-bromo-2,3-methoxyphenol is alkylated with ethyl bromoacetate in dimethylformamide using potassium carbonate as a base. The resulting ester is treated with Ethyl Grignard and Titanium tetraisopropoxide in diethyl ether on warming from -60°C to room temperature to give the cyclopropanol.

The bromide is coupled with the requisite arylboronic acid by Suzuki coupling in methanol, using 10% Palladium(bis-triphenylphosphine) dichloride and sodium acetate, with conventional heating or microwave heating to give the biaryl product.

The alcohol is acylated upon treatment with an acid chloride in acetonitrile at room temperature using pyridine either as a base or a catalyst.

Compounds 843 - 1184 are prepared according either to example 166, example 167 or example 168 Compound Structure Compound name

843 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl acetate

844 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl propanoate

845 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl

cyclopropanecarboxylate

846 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl butanoate

847 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 2-methylpropanoate

848 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl

cyclobutanecarboxylate

849 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl pentanoate

850 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 2-methylbutanoate

851 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 3-methylbutanoate

852 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl

cyclopentanecarboxylate

853 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl hexanoate

854 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 2-ethylbutanoate 855 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 3,3- dimethyibutanoate

856 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 3- methylsulfanylpropanoate

857 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 3,3,3- trifluoropropanoate

858 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 2- cyclopentylacetate

859 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl

cyclohexanecarboxylate

860 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl tetrahydropyran-4- carboxylate

861 2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]ethyl 2-(2- methoxyethoxy)acetate

862 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] acetate

863 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] propanoate

864 [l-[[2,3-dimethoxy-6-( l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] cyclopropanecarboxylate

865 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] butanoate

866 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 2- methylpropanoate 867 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] cyclobutanecarboxylate

868 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]nnethyl]cyclopropyl] pentanoate

869 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 2- methylbutanoate

870 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 3- methylbutanoate

871 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] cyclopentanecarboxylate

872 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] hexanoate

873 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 2- ethylbutanoate

874 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 3,3- dimethylbutanoate

875 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 3- methylsulfanylpropanoate

876 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl]

3,3,3-trifluoropropanoate

877 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 2- cyclopentylacetate

878 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] cyclohexanecarboxylate 879 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] tetrahydropyran-4-carboxylate

880 [l-[[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropyl] 2-(2- methoxyethoxy)acetate

881 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] acetate

882 [2-[2,3-dimethoxy-6-( l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] propanoate

883 [2-[2,3-dimethoxy-6-(l-oxotndan-4- yl)phenoxy]-l,l-dimethyl-ethyl] cyclopropanecarboxylate

884 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] butanoate

885 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- methylpropanoate

886 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] cyclobutanecarboxylate

887 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l, l-dimethyl-ethyl] pentanoate

888 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- methylbutanoate

889 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3- methylbutanoate

890 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] cyclopentanecarboxylate 891 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l, l-dimethyl-ethyl] hexanoate

892 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-et yl] 2- ethylbutanoate

893 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3,3- dimethylbutanoate

894 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3- methylsulfanylpropanoate

894 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl]

3,3,3-trifluoropropanoate

896 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- cyclopentylacetate

897 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l, l-dimethyl-ethyl] cyclohexanecarboxylate

898 [2-[2,3-dimethoxy-6-(l-oxoindan-4- yl)phenoxy]-l,l-dimethyl-ethyl] tetrahydropyran-4-carboxylate

899 t2-[2,3-dimethoxy-6-(l-oxoindan-4- y')phenoxy]-l, l-dimethyl-ethyl] 2- (2-methoxyet oxy)acetate

Compound Structure Compound name

900 2-[2,3-dimethoxy-6-(l-oxoindan-5-

V ^» . yl)phenoxy]ethyl acetate

901 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl propanoate 902 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl

cyclopropanecarboxylate

903 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl butanoate

904 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 2- methylpropanoate

905 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl

cyclobutanecarboxylate

906 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl pentanoate

907 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 2-methylbutanoate

908 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 3-methylbutanoate

909 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl

cyclopentanecarboxylate

910 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl hexanoate

911 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 2-ethylbutanoate

912 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 3,3- dimethylbutanoate

913 2-[2,3-dimethoxy-6-( l-oxoindan-5- yl)phenoxy]ethyl 3- methylsulfanylpropanoate 914 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 3,3,3- trifluoropropanoate

915 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 2- cyclopenty!acetate

916 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl

cyclohexanecarboxylate

917 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl tetrahydropyran-4- carboxylate

918 2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]ethyl 2-(2- methoxyethoxy)acetate

919 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)p enoxy]methyl]cyclopropyl] acetate

920 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] propanoate

921 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] cyclopropanecarboxylate

922 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] butanoate

923 [l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropyl] 2- methylpropanoate

924 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] cyclobutanecarboxylate

925 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] pentanoate 926 [l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropyl] 2- methylbutanoate

927 [l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropyl] 3- methylbutanoate

928 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] cyclopentanecarboxylate

929 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] hexanoate

930 [l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropyl] 2- ethylbutanoate

931 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl]

3,3-dimethylbutanoate

932 [l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropyl] 3- methylsulfanylpropanoate

933 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl]

3,3,3-trifluoropropanoate

934 [l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropyl] 2- cyclopentylacetate

935 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] cyclohexanecarboxylate

936 [l-[[2,3-dimethoxy-6-(l-oxoindan-

5-yl)phenoxy]methyl]cyclopropyl] tetrahydropyran-4-carboxylate

937 [l-[[2,3-dimethoxy-6-(l-oxoindan- 5-yl)phenoxy]methyl]cyclopropyl] 2- (2-methoxyethoxy)acetate 938 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] acetate

939 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l, l-dimethyl-ethyl] propanoate

940 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] cyclopropanecarboxylate

941 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] butanoate

942 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] 2- methylpropanoate

943 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l, l-dimethyl-ethyl] cyclobutanecarboxylate

944 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-et yl] pentanoate

945 [2-[2,3-dimethoxy-6-(l-oxoindan-5-

J. J, yl)phenoxy]-l,l-dimethyl-ethyl] 2- methylbutanoate

946 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] 3- methylbutanoate

947 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] cyclopentanecarboxylate

948 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] hexanoate

949 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] 2- ethylbutanoate 950 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] 3,3- dimethylbutanoate

951 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-et yl] 3- methylsulfanylpropanoate

952 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl]

3,3,3-trifluoropropanoate

953 [2-[2,3-dimethoxy-6-(l-oxoindan-5-

T'XTO yl)phenoxy]-l,l-dimethyl-ethyl] 2- cyclopentylacetate

954 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] cyclohexanecarboxylate

955 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l, l-dimethyl-ethyl] tetrahydropyran-4-carboxylate

956 [2-[2,3-dimethoxy-6-(l-oxoindan-5- yl)phenoxy]-l,l-dimethyl-ethyl] 2- (2-methoxyethoxy)acetate

Compound Structure Compound name

957 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl acetate

958 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl propanoate

959 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl cyclopropanecarboxylate

960 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl butanoate 961 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 2-methylpropanoate

962 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl cyclobutanecarboxylate

963 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl pentanoate

964 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 2-methylbutanoate

965 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 3-methylbutanoate

966 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl cyclopentanecarboxylate

967 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl hexanoate

968 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 2-ethylbutanoate

969 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 3,3-dimethylbutanoate

970 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 3-methylsulfanylpropanoate

971 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 3,3,3-trifluoropropanoate

972 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 2-cyclopentylacetate

973 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl cyclohexanecarboxylate 974 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl tetrahydropyran-4-carboxylate

975 2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]ethyl 2-(2-methoxyethoxy)acetate

976 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] acetate

977 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] propanoate

978 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl]

cyclopropanecarboxylate

979 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] butanoate

980 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 2- methylpropanoate

981 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl]

cyclobutanecarboxylate

982 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] pentanoate

983 [l-[[2,3-dimethoxy-6-( l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 2-

CO methylbutanoate

984 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 3- methylbutanoate

985 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl]

cyclopentanecarboxylate 986 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] hexanoate

987 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 2- ethylbutanoate

988 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 3,3- O dimethylbutanoate

989 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methy!]cyclopropyl] 3- methylsulfanylpropanoate

990 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 3,3,3- trifluoropropanoate

991 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 2- cyclopentylacetate

992 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl]

cyclohexanecarboxylate

993 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl]

tetrahydropyran-4-carboxylate

994 [l-[[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]methyl]cyclopropyl] 2-(2- (nethoxyethoxy)acetate

995 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] acetate

996 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] propanoate

997 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl]

cyclopropanecarboxylate 998 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] butanoate

999 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l, l-dimethyl-ethyl] 2- methylpropanoate

1000 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l, l-dimethyl-ethyl]

cyclobutanecarboxylate

1001 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] pentanoate

1002 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- methylbutanoate

1003 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3- methylbutanoate

1004 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl]

cyclopentanecarboxylate

1005 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] hexanoate

1006 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- ethylbutanoate

1007 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3,3- dimethylbutanoate

1008 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3- methylsulfanylpropanoate

1009 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3,3,3- trifluoropropanoate 1010 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- cyclopentylacetate

1011 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl]

cyclohexanecarboxylate

1012 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl]

tetrahydropyran-4-carboxylate

1013 [2-[2,3-dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2-(2- methoxyethoxy)acetate

Compound Structure IUPAC name

1014 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl acetate

1015 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl propanoate

1016 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl cyclopropanecarboxylate

1017 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl butanoate

1018 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl 2-methylpropanoate

1019 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl cyclobutanecarboxylate

1020 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl pentanoate

1021 2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]ethyl 2-methylbutanoate

o6 1035 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- ώ yl)phenoxy]methyl]cyclopropyl]

cyclopropanecarboxylate

1036 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofu ran-4- yl)phenoxy]methyl]cyclopropyl] butanoate

1037 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 2- vO methylpropanoate

1038 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl]

cyclobutanecarboxylate

1039 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] pentanoate

1040 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 2-

CO methylbutanoate

1041 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 3- methylbutanoate

1042 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl]

cyclopentanecarboxylate

1043 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] hexanoate

1044 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 2-ethylbutanoate

1045 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 3,3- dimethylbutanoate

1046 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 3-

CO methylsulfanylpropanoate 1047 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 3,3,3- v trifluoropropanoate

1048 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 2- O cyclopentylacetate

1049 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl]

CO cyclohexanecarboxylate

1050 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yi)phenoxy]methyl]cyclopropyl] tetrahydropyran- 4-carboxylate

1051 [l-[[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]methyl]cyclopropyl] 2-(2- methoxyethoxy)acetate

1052 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] acetate

1053 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] propanoate

1054 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl]

cyclopropanecarboxylate

1055 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofu ran-4- yl)phenoxy]-l,l-dimethyl-ethyl] butanoate

1056 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- methylpropanoate

1057 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl]

cyclobutanecarboxylate

1058 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] pentanoate 1059 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- methylbutanoate

1060 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3- methylbutanoate

1061 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl]

cyclopentanecarboxylate

1062 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] hexanoate

1063 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2-ethylbutanoate

1064 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3,3-

°co dimethylbutanoate

1065 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l, l-dimethyl-ethyl] 3- O methylsulfanylpropanoate

1066 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 3,3,3- trifluoropropanoate

1067 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofu ran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2- cyclopentylacetate

1068 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl]

O cyclohexanecarboxylate

1069 [2-[2,3-dimethoxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] tetra hyd ropy ran - 4-carboxylate

1070 [2-[2,3-dimet oxy-6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-l,l-dimethyl-ethyl] 2-(2- methoxyethoxy)acetate Compound Structure Compound name

1071 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl acetate

1072 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl propanoate

1073 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl cyclopropanecarboxylate

1074 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl butanoate

1075 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 2- methylpropanoate

1076 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl cyclobutanecarboxylate

1077 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl pentanoate

1078 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 2- methylbutanoate

1079 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 3- methylbutanoate

1080 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl cyclopentanecarboxylate

1081 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl hexanoate

1082 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 2- ethylbutanoate 1083 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 3,3- dimethylbutanoate

1084 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 3- methylsulfanylpropanoate

1085 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yf)phenoxy]ethyf 3,3,3- trifluoropropanoate

1086 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 2- cyclopentylacetate

1087 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl cyclohexanecarboxylate

1088 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl tetrahydropyran-4-carboxylate

1089 2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]ethyl 2-(2- methoxyethoxy)acetate

1090 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] acetate

1091 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] propanoate

1092 [l-[[2,3-dimethoxy-6-(l-oxo-3H- fey isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl]

cyclopropanecarboxylate

1093 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] butanoate

1094 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 2- methylpropanoate

1095 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl]

cyclobutanecarboxylate

1096 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] pentanoate

1097 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 2- methylbutanoate

1098 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 3- methylbutanoate

1099 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl]

cyclopentanecarboxylate

1100 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] hexanoate

1101 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 2- ethylbutanoate

1102 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 3,3- dimethylbutanoate

1103 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 3- methylsulfanylpropanoate 1104 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 3,3,3- trifluoropropanoate

1105 [l-[[2,3-dimethoxy-6-( l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 2- cyclopentylacetate

1106 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl]

cyclohexanecarboxylate

1107 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl]

tetrahydropyran-4-carboxylate

1108 [l-[[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]methyl]cyclopropyl] 2-(2- methoxyethoxy)acetate

1109 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] acetate

1110 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- et yl] propanoate

1111 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] cyclopropanecarboxylate

1112 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] butanoate

1113 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] 2-methylpropanoate 1114 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] cyclobutanecarboxylate

1115 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] pentanoate

1116 [2-[2,3-dimethoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] 2-methylbutanoate

1117 [2-[2,3-dimethoxy-6-(l-oxo-3H-

T vQ isobenzofuran-5-yl)phenoxy]-l, l-dimethyl- ethyl] 3-methylbutanoate

1118 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l, l-dimethyl- ethyl] cyclopentanecarboxylate

1119 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] hexanoate

1120 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] 2-ethylbutanoate

1121 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] 3,3-dimethylbutanoate

1122 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l, l-dimethyl- ethyl] 3-methylsulfanylpropanoate

1123 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] 3,3,3-trifluoropropanoate

1124 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] 2-cyclopentylacetate

1125 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] cyclohexanecarboxylate 1126 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l, l-dimethyl- ethyl] tetrahydropyran-4-carboxylate

1127 [2-[2,3-dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-l,l-dimethyl- ethyl] 2-(2-methoxyethoxy)acetate

Compound Structure ComDOund name

1128 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl acetate

1129 2-[2,3-dimethoxy-6-( l- oxoisoindolin-5-yl)phenoxy]ethyl propanoate

1130 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl cyclopropanecarboxylate

1131 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl butanoate

1132 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

2-methylpropanoate

1133 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl cyclobutanecarboxylate

1134 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl pentanoate

1135 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

2-methylbutanoate

1136 2- [2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

3- methylbutanoate 1137 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl cyclopentanecarboxylate

1138 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl exanoate

1139 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

2-ethylbutanoate

1140 2-[2,3-dimethoxy-6-( l- oxoisoindolin-5-yl)phenoxy]ethyl 3,3-dimet ylbutanoate

1141 2- [2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

3- methylsulfanylpropanoate

1142 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

3,3,3-trifluoropropanoate

1143 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

2-cyclopentylacetate

1144 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl cyclohexanecarboxylate

1145 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl tetrahydropyran-4-carboxylate

1146 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]ethyl

2-(2-methoxyethoxy)acetate

1147 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] acetate

1148 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] propanoate

1149 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] cyclopropanecarboxylate

1150 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] butanoate

1151 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 2-methylpropanoate

1152 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] cyclobutanecarboxylate

1153 [l-[[2,3-dimethoxy-6-(l- oxoiso/ndolin-5- yl)phenoxy]methyl]cyclopropyl] pentanoate

1154 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 2-methylbutanoate

1155 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 3-methylbutanoate

1156 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] cyclopentanecarboxylate 1157 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] hexanoate

1158 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 2-ethylbutanoate

1159 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 3,3-dimethylbutanoate

1160 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 3-methylsulfanylpropanoate

1161 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 3,3,3-trifluoropropanoate

1162 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 2-cyclopentylacetate

1163 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] cyclohexanecarboxylate

1164 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] tetrahydropyran-4-carboxylate

1165 [l-[[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]methyl]cyclopropyl] 2-(2-methoxyethoxy)acetate 1166 [2-[2,3-dimethoxy-6-( l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] acetate

1167 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] propanoate

1168 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl]

cyclopropanecarboxylate

1169 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] butanoate

1170 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l ^" dimethyl-ethyl] 2- methylpropanoate

1171 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl]

cyclobutanecarboxylate

1172 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] pentanoate

1173 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 2- methylbutanoate

1174 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 3- methylbutanoate

1175 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl]

cyclopentanecarboxylate 1176 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] hexanoate

1177 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 2-ethylbutanoate

1178 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 3,3- dimethylbutanoate

1179 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 3- methylsulfanylpropanoate

1180 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 3,3,3- trifluoropropanoate

1181 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 2- cyclopentylacetate

1182 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl]

cyclohexanecarboxylate

1183 [2-[2,3-dimethoxy-6-(l-

X¾ f° oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] tetrahydropyran- 4-carboxylate

1184 [2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-l,l- dimethyl-ethyl] 2-(2- methoxyethoxy)acetate

Example 169

2,3-dihydroxybenzaldehyde is deuteromethylated in position 2 and 3 (ref. Staveris, S. et al Journal of Labelled Compounds and Radiopharmaceuticals, 23(1), 51-7; 1986) employing bis-deuteromethyl sulphate, in combination with potassium carbonate in acetone, or in acetonitrile, or in DMF. In the same manner, the 2,3-dimethylated product is prepared using dimethyl sulphate or methyl iodide under the same conditions. Selective methylation or deuteromethylation ortho to the carbonyl is achieved with methyl iodide or deuteromethyl iodide, combined with potassium bicarbonate in DMF by the method of Lowell, Andrew IM. et. al. Tetrahedron, 66(30), 5573-5582; 2010, followed by methylation or deuteromethylation of the remaining phenolic hydroxyl group. In this fashion, products are obtained that are deuteromethylated selectively at the 2- or 3- position, respectively.

The compound is oxidised (ref. Roy, Amrita et. al. Synthetic Communications, 29(21), 3781-3791; 1999) using hydrogen peroxide and boric acid in a mixed solvent of water and THF to give the di-alkylated phenol. Bromination ortho to the phenol is performed with bromine in carbontetrachloride (ref. Sargent, Melvyn V. Journal of the Chemical Society, Perkin Transactions 1 (11), 2553-63; 1987).

The deuterated bromo-phenols are coupled with the appropriate boronic acid esters by Suzuki coupling, as for example described for the preparation of compounds 303 - 307. Alternatively they are converted into the corresponding boronic acid as described for 6- bromo-2,3-dimethoxyphenol in preparation 1 and subsequently converted into the deuterated analogues of compounds 303-307 as described in preparations 3-7. The introduction of the substituents in position R3 is performed as described in the preparation of the analogous non-deuterated compounds.

Compounds 1185 - 1292 are prepared as described in example 169 Compound Structure Compound name

1185 A methyl 3-[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1186 ethyl 3-[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1187 isopropyl 3-[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1188 A methyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

1189 A ethyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-( l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

1190 A isopropyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-( l-oxoindan- 4-yl)phenoxy]methyl]cyclopropanecarboxylate

1191 methyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

1192 A ethyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

1193 A isopropyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxoindan- 4-yl)phenoxy]methyl]cyclobutanecarboxylate

1194 methyl 3-[2-methoxy-6-(l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1195 ethyl 3-[2-methoxy-6-(l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1196 isopropyl 3-[2-methoxy-6-( l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate 1197 methyl l-[[2-methoxy-6-(l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1198 ethyl l-[[2-methoxy-6-(l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1199 isopropyl l-[[2-methoxy-6-( l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1200 methyl l-[[2-methoxy-6-(l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1201 ethyl l-[[2-methoxy-6-(l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1202 it isopropyl l-[[2-methoxy-6-(l-oxoindan-4-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1203 methyl 3-[2-(dideuteriometnoxy)-3-methoxy-6-( l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1204 ethyl 3-[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1205 isopropyl 3-[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1206 methyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

1207 ethyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxoindan-4- yl)phenoxy]methyl]cyclopropanecarboxylate

1208 isopropyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxoindan- 4-yl)phenoxy]methyl]cyclopropanecarboxylate

1209 methyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate 1210 ethyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxoindan-4- yl)phenoxy]methyl]cyclobutanecarboxylate

1211 isopropyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxoindan- 4-yl)phenoxy]methyl]cyclobutanecarboxylate

1212 methyl 3-[3-methoxy-6-(l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1213 ethyl 3-[3-methoxy-6-( l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1214 isopropyl 3-[3-methoxy-6-(l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1215 methyl l-[[3-methoxy-6-(l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1216 ethyl l-[[3-methoxy-6-(l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1217 isopropyl l-[[3-methoxy-6-(l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1218 methyl l-[[3-methoxy-6-(l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1219 ethyl l-[[3-methoxy-6-(l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1220 isopropyl l-[[3-methoxy-6-( l-oxoindan-4-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1221 A methyl 3-[2,3-bis(dideuteriomethoxy)-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1222 A ethyl 3-[2,3-bis(dideuteriomethoxy)-6-(l-oxoindan-4- yl)phenoxy]-2,2-dimethyl-propanoate

1236 methyl l-[[6-(l-oxoindan-4-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1237 ethyl l-[[6-( l-oxoindan-4-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1238 isopropyl l-[[6-( l-oxoindan-4-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1239 methyl 3-[3-(dideuteriomethoxy)-2-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propanoate

1240 ethyl 3-[3-(dideuteriomethoxy)-2-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propanoate

1241 A isopropyl 3-[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propanoate

1242 methyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1243 ethyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1244 A isopropyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1245 A, methyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1246 ethyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1247 A isopropyl l-[[3-(dideuteriomethoxy)-2-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1248 methyl 3-[2-methoxy-6-( l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate 1249 ethyl 3-[2-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1250 isopropyl 3-[2-methoxy-6-( l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1251 methyl l-[[2-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1252 ethyl l-[[2-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1253 isopropyl l-[[2-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1254 methyl l-[[2-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1255 ethyl l-[[2-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1256 4 isopropyl l-[[2-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-3- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1257 methyl 3-[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propanoate

1258 ethyl 3-[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propanoate

1259 isopropyl 3-[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propanoate

1260 methyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1261 ethyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate 1262 isopropyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1263 methyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1264 ethyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1265 isopropyl l-[[2-(dideuteriomethoxy)-3-methoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1266 methyl 3-[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1267 ethyl 3-[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2-

JL (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1268 isopropyl 3-[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]-2,2-dimethyl-propanoate

1269 methyl l-[[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1270 ethyl l-[[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1271 isopropyl l-[[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylate

1272 methyl l-[[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1273 ethyl l-[[3-methoxy-6-( l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1274 isopropyl l-[[3-methoxy-6-(l-oxo-3H-isobenzofuran-5-yl)-2- (trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate 1275 methyl 3-[2,3-bis(dideuteriomethoxy)-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dinnethyl-propanoate

1276 A ethyl 3-[2,3-bis(dideuteriomethoxy)-6-( l-oxo-3H-isobenzofuran- 5-yl)phenoxy]-2,2-dimethyl-propanoate

1277 isopropyl 3-[2,3-bis(dideuteriomethoxy)-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2,2-dimethyl-propanoate

1278 A^^ methyl l-[[2,3-bis(dideuteriomethoxy)-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1279 A ethyl l-[[2,3-bis(dideuteriomethoxy)-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1280 A isopropyl l-[[2,3-bis(dideuteriornethoxy)-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclopropanecarboxylate

1281 methyl l-[[2,3-bis(dideuteriomethoxy)-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1282 A ethyl l-[[2,3-bis(dideuteriomethoxy)-6-( l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1283 isopropyl l-[[2,3-bis(dideuteriomethoxy)-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]methyl]cyclobutanecarboxylate

1284 methyl 2,2-dimethyl-3-[6-( l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]propanoate

1285 ethyl 2,2-dimethyl-3-[6-( l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]propanoate

1286 isopropyl 2,2-dimethyl-3-[6-( l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]propanoate

1287 methyl l-[[6-(l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylat e 1288 ethyl l-[[6-(l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylat e

1289 isopropyl l-[[6-( l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclopropanecarboxylat e

1290 methyl l-[[6-( l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1291 ethyl l-[[6-(l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

1292 isopropyl l-[[6-(l-oxo-3H-isobenzofuran-5-yl)-2,3- bis(trideuteriomethoxy)phenoxy]methyl]cyclobutanecarboxylate

Example 170

Above compounds are prepared by reaction of compounds 303, 305 or 307 with 2- bromo-2-methyl-propanoic acid ethyl ester in a solvent such as DMF, acetonitrile in the presence of potassium carbonate or cesium carbonate either at room temperature or with heating. The alkylated phenol is then submitted to ester hydrolysis in LiOH/H ₂ 0/THF re-esterification using EDCI, DMAP and DCM as described in example 163.

Alternatively the compounds are prepared in analogy with the synthesis described in example 88, starting from 6-bromo-2,3-dimethoxyphenol and 2-bromo-2-methyl- propanoic acid ethyl ester. The amide synthesis in example 88 is replaced with an ester synthesis as described above

Example 171

Above compounds are prepared by reaction of compounds 303, 305 or 307 with 2- bromo-acetic acid ethyl ester in a solvent such as DMF, acetonitrile in the presence of potassium carbonate or cesium carbonate either at room temperature or with heating. The alkylated phenol is then submitted to ester hydrolysis in LiOH/H ₂ 0/THF followed by re-esterification using EDCI, DMAP and DCM as described in example 163. Altenatively the synthesis is performed as described in example 153, replacing the amide synthesis by an ester synthesis as described above.

Or, alternatively the compounds are prepared in analogy with the synthesis described in example 88, starting from 6-bromo-2,3-dimethoxyphenol and 2-bromo-acetic acid ethyl ester. The amide synthesis in example 88 is replaced with an ester synthesis as described above If R2 is ethyl, the starting material is prepared as described for the preparation of compound 321 in preparation 21, replacing cyclopropylmethyl bromide with ethyl bromide or ethyl iodide and coupling the bromide with the appropriate boronic acid ester.

Example 172

Above componds are prepared as described in example 165, only replacing the

Mitsunobu reaction with an alkylation of the phenol using 2-bromo-2-methyl-propa acid ethyl ester in a solvent such as DMF, acetonitriie in the presence of potassium carbonate or cesium carbonate either at room temperature or with heating

Example 173

Above componds are prepared as described in example 165, only replacing the

Mitsunobu reaction with an alkylation of the phenol using 2-bromo-acetic acid ethyl ester in a solvent such as DMF, acetonitriie in the presence of potassium carbonate or cesium carbonate either at room temperature or with heating

Above compounds are prepared starting from compounds 303, 305 or 307. To the solution of the phenol in DMF methyl 2,4-dibromobutyrate and potassium carbonate is added. After stirring the reaction mixture is poured on ethyl acetate and 1 M aqueous hydrochloric acid and extracted. The organic phases are washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue is purified by column

chromatography on silica gel. The residue is dissolved in tetrahydrofuran and cooled to -15.deg. C. and potassium tert-butoxide is added. The cooling bath was removed and the reaction is stirred at room temperature. The solution is poured on ethyl acetate and aqueous hydrochloric acid, extracted and the phases were separated.

The organic layer is washed with brine and the aqueous layers are extracted with ethyl acetate. The combined organic layers are dried over magnesium sulfate, filtered and evaporated. The residue is purified by column chromatography on silica to afford the cyclopropyl derivative. The subsequent esterhydrolysis and re-esterification is performed as described in example 163

Alternatively, the compounds are prepared starting from 6-bromo-2,3-dimethoxyphenol. To the solution of the phenol in DMF methyl 2,4-dibromobutyrate and potassium carbonate is added. After stirring the reaction mixture is poured on ethyl acetate and 1 M aqueous hydrochloric acid and extracted. The organic phases are washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue is purified by column chromatography on silica gel.

The residue is dissolved in tetrahydrofuran and cooled to -15.deg. C. and potassium tert-butoxide is added. The cooling bath was removed and the reaction is stirred at room temperature. The solution is poured on ethyl acetate and aqueous hydrochloric acid, extracted and the phases were separated.

The organic layer is washed with brine and the aqueous layers are extracted with ethyl acetate. The combined organic layers are dried over magnesium sulfate, filtered and evaporated. The residue is purified by column chromatography on silica to afford the cyclopropyl derivative. The subsequent esterhydrolysis and re-esterification is performed as described in example 163. The bromide is coupled with the appropriate boronic acid ester by Suzuki coupling as described in example 88 to afford the biaryl product.

Above compounds are prepared starting from compounds 303, 305 or 307. To the solution of the phenol in DMF methyl 2,4-dibromobutyrate and potassium carbonate is added. After stirring the reaction mixture is poured on ethyl acetate and 1 M aqueous hydrochloric acid and extracted. The organic phases are washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue is purified by column chromatography on silica gel. The residue is dissolved in tetrahydrofuran and cooled to -15.deg. C. and potassium tert-butoxide is added. The cooling bath was removed and the reaction is stirred at room temperature. The solution is poured on ethyl acetate and aqueous hydrochloric acid, extracted and the phases were separated.

The organic layer is washed with brine and the aqueous layers are extracted with ethyl acetate. The combined organic layers are dried over magnesium sulfate, filtered and evaporated .The residue is purified by column chromatography on silica to afford the cyclopropyl derivative. The subsequent esterhydrolysis, lactone formation and re- esterification is performed as described in example 165.

The cyclopropyl derivatives can alternatively be prepared as outlined above.

A mixture of 3-bromo-dihydro-furan-2-one, 6-bromo-2,3-dimethoxyphenol and potassium carbonate in a solvent such as DMF, acetonitrile or 2-butan-one reacts either at room temperature or with heating. The mixture is stirred until completion. After removing solvents, the residue is partitioned between H ₂ 0 and EtOAc and the aqueous layer is extracted with EtOAc. The combined organic layers were dried (MgS0 ) and purified by column chromatography

To a solution of the lacton in MeOH at room temperature NaOMe is added. The resulting mixture is stirred at room temperature or with heating until reaction is finished and quenched with aqueous NH ₄ CI. The mixture was extracted with EtOAc. The organic extracts is dried (MgS0 ) and concentrated. The crude product is purified by column chromatography.

To a solution of the alcohol, methanesulfonyl chloride or p-toluenesulfonyl chloride in a solvent such as CH ₂ CI ₂ , THF or DMF at room temperature is added a base such as Et ₃ N, DIPEA or potassium carbonate. The resulting mixture is stirred either at room

temperature or with heating. The reaction is partitioned between H ₂ 0 and EtOAc and the aqueous layer is extracted with EtOAc. The combined organic layers is dried (MgS0 ) and purified by column chromatography. To a solution of the product in a solvent such as THF, DMF or DMSO at O.deg. C. under N ₂ is added a base such as t-BuOK, NaH MeOINa. The resulting mixture is stirred at O.deg. C or with heating until the reaction is complet and acidified with HCI aq. The reaction is extracted with EtOAc. The combined organic layers are dried (MgS0 ₄ ) and concentrated. The crude product is purified by column, (ref. US2007244094)

The bromide is coupled with the appropriate boronic aced ester by Suzuki coupling as for example described in example 88 to afford the biaryl products. Compounds 1294 - 1558 are prepared according to example 170 _f 171, 172 _f 173 _r 174, 175 or 176.

Compound Structure Compound name

1294 methyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate

1295 methyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1296 methyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1297 methyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]acetate

1298 ethyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate

1299 ethyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1300 ethyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy] acetate

1301 ethyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]acetate 1302 propyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate

1303 propyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1304 propyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1305 propyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]acetate

1306 isopropyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate

1307 isopropyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1308 isopropyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1309 isopropyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]acetate

1310 butyl 2-[2,3-dimethoxy-6-(l- x ^° oxoindan-4-yl)phenoxy]acetate

1311 butyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1312 butyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1313 butyl 2-[2,3-dimethoxy-6-(l-

¾ oxoisoindolin-5-yl)phenoxy]acetate

1314 sec-butyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate 1315 sec-butyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1316 sec-butyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1317 sec-butyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]acetate

1318 isobutyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate

1319 isobutyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1320 isobutyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1321 isobutyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]acetate

1322 cyclobutyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate

1323 ^H,< cyclobutyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1324 cyclobutyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1325 cyclobutyl 2-[2,3-dimethoxy-6-( l- oxoisoindolin-5-yl)phenoxy]acetate

1326 cyclopropyl methyl 2-[2,3- dimethoxy-6-(l-oxoindan-4- yl)phenoxy]acetate 1327 cyclopropylmethyl 2-[2,3- dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1328 cyclopropylmethyl 2-[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]acetate

1329 cyclopropylmethyl 2-[2,3- dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1330 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]acetate

1331 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]acetate

1332 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]acetate

1333 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]acetate

1334 cyclobutylmethyl 2-[2,3-dimethoxy- 6-(l-oxoindan-4-yl)phenoxy]acetate

1335 cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1336 cyclobutylmethyl 2-[2,3-dimethoxy- 6-(l-oxoindan-5-yl)phenoxy]acetate

1337 v cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1338 methyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2-methyl- propanoate 1339 methyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1340 methyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2-methyl- propanoate

1341 methyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1342 ethyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2-methyl- propanoate

1343 ethyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1344 ethyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2-methyl- propanoate

1345 ethyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1346 propyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2-methyl- propanoate

1347 propyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1348 propyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2-methyl- propanoate

1349 propyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1350 isopropyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2-methyl- propanoate 1351 isopropyl 2-[2,3-dimethoxy-6-( l- oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1352 isopropyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2-methyl- propanoate

1353 isopropyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1354 butyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2-methyl- propanoate

1355 butyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1356 butyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2-methyl- propanoate

1357 butyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1358 sec-butyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2-methyl- propanoate

1359 sec-butyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1360 sec-butyl 2-[2,3-dimethoxy-6-( l- oxoindan-5-yl)phenoxy]-2-methyl- propanoate

1361 sec-butyl 2-[2,3-dimethoxy-6-( l- oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1362 ".< isobutyl 2-[2,3-dimethoxy-6-(l- oxoindan-4-yl)phenoxy]-2-methyl- propanoate 1375 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1376 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxoindan-5-yl)phenoxy]-2-methyl- propanoate

1377 cyclopentyl 2-[2,3-dimethoxy-6-(l-

Wo oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1378 cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxoindan-4-yl)phenoxy]-2- methyl-propanoate

1379 cyclobutylmethyl 2-[2,3-dimethoxy- 6-(l-oxoisoindolin-4-yl)phenoxy]-2- methyl-propanoate

1380 cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxoindan-5-yl)phenoxy]-2- methyl-propanoate

1381 cyclobutylmethyl 2-[2,3-dimethoxy- 6-(l-oxoisoindolin-5-yl)phenoxy]-2- methyl-propanoate

1382 methyl l-[2,3-dimethoxy-6-( l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate

1383 methyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1384 methyl l-[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1385 methyl l-[2,3-dimethoxy-6-( l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1386 ethyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate 1387 ethyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1388 X ethyl l-[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1389 Χ ' ethyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1390 propyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate

1391 propyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1392 propyl l-[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1393 propyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1394 isopropyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate

1395 isopropyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1396 isopropyl l-[2,3-dimethoxy-6-( l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1397 isopropyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1398 butyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate 1399 butyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1400 butyl l-[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1401 butyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1402 sec-butyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate

1403 A ^' sec-butyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1404 sec-butyl l-[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1405 sec-butyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1406 isobutyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate

1407 isobutyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1408 isobutyl l-[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1409 isobutyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1410 cyclobutyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate 1411 cyclobutyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1412 cyclobutyl l-[2,3-dimethoxy-6-(l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1413 cyclobutyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1414 cyclopropylmethyl l-[2,3- dimethoxy-6-(l-oxoindan-4- yl)phenoxy]cyclopropanecarboxylate

1415 cyclopropylmethyl l-[2,3- dimethoxy-6-(l-oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1416 cyclopropylmethyl l-[2,3- dimethoxy-6-(l-oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1417 cyclopropylmethyl l-[2,3- dimethoxy-6-(l-oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1418 cyclopentyl l-[2,3-dimethoxy-6-(l- oxoindan-4- yl)phenoxy]cyclopropanecarboxylate

1419 cyclopentyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1420 ^" *£. cyclopentyl l-[2,3-dimethoxy-6-( l- oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1421 cyclopentyl l-[2,3-dimethoxy-6-(l- oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1422 cyclobutylmethyl l-[2,3-dimethoxy- 6-(l-oxoindan-4- yl)phenoxy]cyclopropanecarboxylate 1423 cyclobutylmethyl l-[2,3-dimethoxy-

6-(l-oxoisoindolin-4- yl)phenoxy]cyclopropanecarboxylate

1424 cyclobutylmethyl l-[2,3-dimethoxy- 6-( l-oxoindan-5- yl)phenoxy]cyclopropanecarboxylate

1425 cyclobutylmethyl l-[2,3-dimethoxy-

6-(l-oxoisoindolin-5- yl)phenoxy]cyclopropanecarboxylate

1426 methyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4- yl)phenoxy]acetate

1427 methyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5- yl)phenoxy]acetate

1428 ethyl 2-[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofu ran-4- yl)phenoxy]acetate

1429 ethyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5- yl)phenoxy]acetate

1430 propyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4- yl)phenoxy]acetate

1431 propyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5- yl)phenoxy]acetate

1432 isopropyl 2-[2,3-dimethoxy-6~(l- oxo-3H-isobenzofuran-4-

"CLJ yl)phenoxy]acetate

1433 isopropyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1434 butyl 2-[2,3-dimethoxy-6-(l-oxo- γ γ"— · ^« . 3H-isobenzofuran-4- J yl)phenoxy]acetate 1435 butyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5- yl)phenoxy]acetate

1436 sec-butyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]acetate

1437 sec-butyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1438 isobutyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]acetate

1439 isobutyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1440 cyclobutyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]acetate

1441 cyclobutyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1442 cyclopropylmethyl 2-[2,3- dimethoxy-6-(l-oxo-3H- isobenzofuran-4-yl)phenoxy]acetate

1443 cyclopropylmethyl 2-[2,3- dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]acetate

1444 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yu yl)phenoxy]acetate

1445 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1446 cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4-

£0 yl)phenoxy]acetate 1447 cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1448 methyl 2-[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-4-yl)phenoxy]-2- methyl-propanoate

1449 methyl 2-[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-5-yl)phenoxy]-2-

0 methyl-propanoate

1450 ethyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4-yl)phenoxy]-2- methyl-propanoate

1451 ethyl 2-[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofu ran-5-yl)phenoxy]-2-

0 methyl-propanoate

1452 propyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4-yl)phenoxy]-2- methyl-propanoate

1453 propyl 2-[2,3-dimethoxy-6-(l-oxo- 3H-isobenzofuran-5-yl)phenoxy]-2- methyl-propanoate

1454 isopropyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]-2-methyl-propanoate

1455 isopropyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5-

0 yl)phenoxy]-2-methyl-propanoate

1456 butyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4-yl)phenoxy]-2- methyl-propanoate

1457 butyl 2-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5-yl)phenoxy]-2-

0 methyl-propanoate

1458 sec-butyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4-

0 yl)phenoxy]-2-methyl-propanoate 1459 sec-butyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]-2-methyl-propanoate

1460 isobutyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- ° yl)phenoxy]-2-methyl-propanoate

1461 isobutyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]-2-methyl-propanoate

1462 ^Γ · cyclobutyl 2-[2,3-dimethoxy-6-(l-

W o oxo-3H-isobenzofuran-4-

CO ⁰ yl)phenoxy]-2-methyl-propanoate

1463 cyclobutyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]-2-methyl-propanoate

1464 cyclopropylmethyl 2-[2,3- dimethoxy-6-(l-oxo-3H- isobenzofuran-4-yl)phenoxy]-2- methyl-propanoate

1465 cyclopropylmethyl 2-[2,3- dimethoxy-6-(l-oxo-3H- isobenzofuran-5-yl)phenoxy]-2- methyl-propanoate

1466 cyclopentyl 2-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]-2-methyl-propanoate

1467 cyclopentyl 2-[2,3-dimethoxy-6-(l-

^■ Pro oxo-3H-isobenzofuran-5- yl)phenoxy]-2-methyl-propanoate

1468 cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]-2-methyl-propanoate

1469 cyclobutylmethyl 2-[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]-2-methyl-propanoate 1470 methyl l-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1471 methyl l-[2,3-dimethoxy-6-(l-oxo-

1 3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1472 ethyl l-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1473 ethyl l-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1474 propyl l-[2,3-dimethoxy-6-(l-oxo-

Y 3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1475 propyl l-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1476 isopropyl l-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1477 isopropyl l-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1478 butyl l-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1479 butyl l-[2,3-dimethoxy-6-(l-oxo-

3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1480 Γ sec-butyl l-[2,3-dimethoxy-6-(l-

0 oxo-3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1481 sec-butyl l-[2,3-dimethoxy-6-(l- c oxo-3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate 1482 isobutyl l-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- ° yl)phenoxy]cyclopropanecarboxylate

1483 isobutyl l-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1484 cyclobutyl l-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1485 cyclobutyl l-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1486 cyclopropylmethyl l-[2,3- dimethoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1487 cyclopropylmethyl l-[2,3- dimethoxy-6-( l-oxo-3H- isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1488 cyclopentyl l-[2,3-dimethoxy-6-(l- oxo-3H-isobenzofuran-4- yu ⁰ yl)phenoxy]cyclopropanecarboxylate

1489 cyclopentyl l-[2,3-dimethoxy-6-(l-

Wo oxo-3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

1490 cyclobutylmethyl l-[2,3-dimethoxy-

6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]cyclopropanecarboxylate

1491 cyclobutylmethyl l-[2,3-dimethoxy- 7 6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]cyclopropanecarboxylate

Compound Structure Compound name 1492 methyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoindan-4- yl)phenoxy]acetate

1493 methyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1494 methyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoindan-5- yl)phenoxy]acetate

1495 methyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1496 ethyl 2-[2-ethoxy-3-methoxy-6-

(l-oxoindan-4- yl)phenoxy]acetate

1497 ethyl 2-[2-ethoxy-3-methoxy-6-

(l-oxoisoindolin-4- yl)phenoxy]acetate

1498 ethyl 2-[2-ethoxy-3-methoxy-6-

(l-oxoindan-5- yl)phenoxy]acetate

1499 ethyl 2-[2-ethoxy-3-methoxy-6-

(l-oxoisoindolin-5- yl)phenoxy]acetate

1500 propyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoindan-4- yl)phenoxy]acetate

1501 propyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1502 propyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoindan-5- yl)phenoxy]acetate

1503 " T" propyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoisoindolin-5- yl)phenoxy]acetate 1504 isopropyl 2-[2-ethoxy-3- methoxy-6-(l-oxoiridan-4- yl)phenoxy]acetate

1505 isopropyl 2-[2-ethoxy-3- methoxy-6-( l-oxoisoindolin-4- yl)phenoxy]acetate

1506 isopropyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-5- yl)phenoxy]acetate

1507 isopropyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1508 butyl 2-[2-ethoxy-3-methoxy-6- cx ^° (l-oxoindan-4- yl)phenoxy]acetate

1509 butyl 2-[2-ethoxy-3-methoxy-6-

(l-oxoisoindolin-4- yl)phenoxy]acetate

1510 butyl 2-[2-ethoxy-3-methoxy-6-

( l-oxoindan-5- yl)phenoxy]acetate

1511 butyl 2-[2-ethoxy-3-methoxy-6-

(l-oxoisoindolin-5- yl)phenoxy]acetate

1512 sec-butyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-4- yl)phenoxy]acetate

1513 sec-butyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1514 sec-butyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-5- yl)phenoxy]acetate

1516 or sec-butyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-5- yl)phenoxy]acetate 1517 isobutyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoindan-4- yl)phenoxy]acetate

1518 isobutyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1519 isobutyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoindan-5- yl)phenoxy]acetate

1520 isobutyl 2-[2-ethoxy-3-methoxy-

6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1521 cyclobutyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-4- yl)phenoxy]acetate

1522 cyclobutyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1523 cyclobutyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-5- yl)phenoxy]acetate

1524 cyclobutyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1525 cyclopropylmethyl 2-[2-ethoxy-

3-methoxy-6-(l-oxoindan-4- yl)phenoxy]acetate

1526 cyclopropylmethyl 2-[2-ethoxy-

3-methoxy-6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1527 cyclopropylmethyl 2-[2-ethoxy-

3-methoxy-6-(l-oxoindan-5- yl)phenoxy]acetate

1528 cyclopropylmethyl 2-[2-ethoxy-

3-methoxy-6-(l-oxoisoindolin-5- yl)phenoxy]acetate 1529 cyclopentyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-4- yl)phenoxy]acetate

1530 cyclopentyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-4- yl)phenoxy]acetate

1531 cyclopentyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-5- yl)phenoxy]acetate

1532 cyclopentyl 2-[2-ethoxy-3-

ΓΤΟ methoxy-6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1533 cyclobutylmethyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-4- yl)phenoxy]acetate

1534 cyclobutylmethyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-4- yl)phenoxy acetate

1535 cyclobutylmethyl 2-[2-ethoxy-3- methoxy-6-(l-oxoindan-5- yl)phenoxy]acetate

1536 cyclobutylmethyl 2-[2-ethoxy-3- methoxy-6-(l-oxoisoindolin-5- yl)phenoxy]acetate

1537 methyl 2-[2-ethoxy-3-methoxy-

6-(l-oxo-3H-isobenzofuran-4- yl)phenoxy]acetate

1538 methyl 2-[2-ethoxy-3-methoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1539 ethyl 2-[2-ethoxy-3-methoxy-6-

(l-oxo-3H-isobenzofuran-4- yl)phenoxy]acetate

1540 ethyl 2-[2-ethoxy-3-methoxy-6-

(l-oxo-3H-isobenzofuran-5- yl)phenoxy]acetate 1541 propyl 2-[2-ethoxy-3-methoxy- 6-(l-oxo-3H-isobenzofu ran-4- yl)phenoxy]acetate

1542 propyl 2-[2-ethoxy-3-methoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1543 isopropyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]acetate

1544 isopropyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]acetate

1545 butyl 2-[2-ethoxy-3-methoxy-6-

(l-oxo-3H-isobenzofuran-4- yl)phenoxy]acetate

1546 butyl 2-[2-ethoxy-3-methoxy-6-

(l-oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1547 sec-butyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]acetate

1548 sec-butyl 2-[2-ethoxy-3- met oxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]acetate

1549 isobutyl 2-[2-ethoxy-3-methoxy-

6-(l-oxo-3H-isobenzofuran-4- yu ^° yl)phenoxy]acetate

1550 isobutyl 2-[2-ethoxy-3-methoxy-

6-(l-oxo-3H-isobenzofuran-5- yl)phenoxy]acetate

1551 cyclobutyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]acetate

1552 cyclobutyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]acetate

1553 cyclopropylmethyl 2-[2-ethoxy- 3-methoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]acetate

1554 cyclopropylmethyl 2-[2-ethoxy- 3-methoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]acetate

1555 cyclopentyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]acetate

1556 cyclopentyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]acetate

1557 cyclobutylmethyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-4- yl)phenoxy]acetate

1558 cyclobutylmethyl 2-[2-ethoxy-3- methoxy-6-(l-oxo-3H- isobenzofuran-5- yl)phenoxy]acetate

Example 177

PDE4 assay

Human recombinant PDE4 (Genbank accession no NM_006203) was incubated for 1 hour with the test compound at concentrations up to 10 μΜ, with cAMP (Ixl0-5M), and with a low amount (0.021 MBq) of radioactively labelled cAMP. At the end of the incubation, the cleavage of the substrate was evaluated by the binding of the AMP product to SPA beads, which generate chemoluminescence when bound to the radioactive tracer. The AMP product inhibited the binding of the radioactive tracer to the beads, and the luminescent signal was competed .

The results were calculated as the molar concentrations resulting in 50% inhibition of the substrate cleavage compared to controls samples, and are expressed as a range of ICso (M) . The compounds of the present invention were tested in the PDE4 assay.

Compounds for which IC ₅₀ values are < ΙΟΟηΜ in the PDE4 assay are :

Compounds 101 - 118, 120 - 128, 130 - 150, 152 - 158, 160 - 163, 165 - 166, 169 - 170, 174 - 175, 177 - 181, 183 - 190, 192 - 198, 200 - 206,.210 - 211, 213, 215-219, 221-222, 225-243, 245-253, 256-261, 264-266, 268-270, 287-299, 400-417, 421-422, 428, 429, 433, 434, 466, 483, 484, 520, 522, 523, 528, 532, 535, 536 .

PDE4 IC ₅₀ ranges

* indicates that IC ₅₀ values are > 500 nM

** indicates that IC ₅₀ values are > 100 and < 500 nM

*** indicates that IC ₅₀ values are < 100 nM

Compound name and number PDE4

IC ₅₀ range

4-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-indan- l-one ##*

(Compound 101)

4-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-indan- l-one ##*

(Compound 102)

4-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]- #**

indan- l-one (Compound 103)

4-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- ##*

phenyl]-indan-l-one (Compound 104)

4-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-indan-l-one **#

(Compound 105)

4-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- ***

benzamide (Compound 106)

4-[2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-phenyl]- *** indan-l-one (Compound 107

4-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-N- *** methyl-benzamide (Compound 108)

4-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]-N,N- *** dimethyl-benzamide (Compound 109)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-N,N- #** dimethyl-benzamide (Compound 110

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-N,N- #*# dimethyl-benzenesulfonamide (Compound 111)

4-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]- *** benzenesulfonamide (Compound 112)

4-[2-(3-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]- *## indan-l-one (Compound 113)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]- *#* benzamide (Compound 114)

4-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-3H- #** isobenzofuran-l-one (Compound 115)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-4-yl)- **# phenoxymethyl]-benzamide (Compound 116)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-4-yl)- phenoxymethyl]-N-methyl-benzamide (Compound 117)

4-[2,3-Dimethoxy-6-(l-oxo l,3-dihydro-isobenzofuran-4-yl)- * * * phenoxymethyl]-N,N-dimethyl-benzamide (Compound 118)

4-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- ** phenyl]-3H-isobenzofuran- l-one (Compound 119)

5-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-indan-l-one *** (Compound 120)

5-[2-(2,2-Dimethyl-propoxy)-3,4-dimethoxy-phenyl]-indan-l-on e *** (Compound 121)

5-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-indan-l-one *#* (Compound 122)

5-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-indan-l-one *** (Compound 123)

4-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]- ##* benzamide (Compound 124)

5-[2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-phenyl]- indan-l-one (Compound 125)

4-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]-l\l- *** methyl-benzamide (Compound 126)

4-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]-N,N- *#* dimethyl-benzamide (Compound 127)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxymethyl]-N,N- *#* dimethyl-benzamide (Compound 128)

5-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- ** phenyl]-indan-l-one (Compound 129)

5-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]- *** indan-l-one (Compound 130)

5-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-3H- *#* isobenzofuran-l-one (Compound 131)

5-[2-(2,2-Dimethyl-propoxy)-3,4-dimethoxy-phenyl]-3H- **# isobenzofuran-l-one (Compound 132)

5-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-3H- *** isobenzofuran-l-one (Compound 133)

5-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- *** phenyl]-3H-isobenzofuran-l-one (Compound 134)

5-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-3H- *** isobenzofuran-l-one (Compound 135)

4-[2,3-Dimethoxy-6-( l-oxo-l,3-dihydro-isobenzofuran-5-yl)- *** phenoxymethyl]-benzamide (Compound 136)

5-[2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-phenyl]- #** 3H-isobenzofuran-l-one (Compound 137)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)- *** phenoxymethyl]-N-methyl-benzamide (Compound 138)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)- *** phenoxymethyl]-N,N-dimethyl-benzamide (Compound 139)

3-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)- **# phenoxymethyl]-N,N-dimethyl-benzamide (Compound 140)

4-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)- *** phenoxymethyl]-benzenesulfonamide (Compound 141)

5-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-3H- #** isobenzofuran-l-one (Compound 142)

5-[2-(3-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-3H- isobenzofuran-l-one (Compound 143)

3-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)- *** phenoxymethyl]-benzenesulfonamide (Compound 144)

3-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)- *## phenoxymethyl]-N,N-dimethyl-benzenesulfonamide (Compound

145)

3-[2,3-Dimethoxy-6-(l-oxo-l,3-dihydro-isobenzofuran-5-yl)- *** phenoxymethyl]-benzamide (Compound 146)

5-[3,4-Dimethoxy-2-(3-methyl-butoxy)-phenyl]-2,3-dihydro- *** isoindol-l-one (Compound 147)

5-[2-(2,2-Dimethyl-propoxy)-3,4-dimethoxy-phenyl]-2,3-dihydr o- #** isoindol-l-one (Compound 148)

5-(2-Cyclobutylmethoxy-3,4-dimethoxy-phenyl)-2,3-dihydro- *#* isoindol-l-one (Compound 149)

5-[2-(4-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-2,3 - *** dihydro-isoindol-l-one (Compound 150)

5-[2-(3-Hydroxymethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- ** phenyl -2,3-dihydro-isoindo)-l-one (Compound 151)

5-[2-(3,3-Dimethyl-butoxy)-3,4-dimethoxy-phenyl]-2,3-dihydro - *** isoindol-l-one (Compound 152)

4-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)- *** phenoxymethyl]-benzamide (Compound 153)

5-[2-(3-Hydroxy-2,2-dimethyl-propoxy)-3,4-dimethoxy-phenyl]- *** 2,3-dihydro-isoindol-l-one (Compound 154)

4-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)- *** phenoxymethyl]-N-methyl-benzamide (Compound 155)

4-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)- *** phenoxymethyl]-N,N-dimethyl-benzamide (Compound 156)

3-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)- **# phenoxymethyl]-N,N-dimethyl-benzamide (Compound 157)

3-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)- *** phenoxymethyl]-benzenesulfonamide (Compound 158)

3-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)- ** phenoxymethyl]-benzamide (Compound 159)

5-[2-(3-Methanesulfonyl-benzyloxy)-3,4-dimethoxy-phenyl]-2,3 - *** dihydro-isoindol-l-one (Compound 160) 4-[2,3-Dimethoxy-6-(l-oxo-2,3-dihydro-lH-isoindol-5-yl)- #** phenoxymethyl]-benzenesulfonamide (Compound 161)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimethyl- *** propionic acid methyl ester (Compound 162)

4-[3,4-Dimethoxy-2-(3-methyl-oxetan-3-ylmethoxy)-phenyl]- *#* indan-l-one (Compound 163)

4-[3,4-Dimethoxy-2-(3-methyl-oxetan-3-ylmethoxy)-phenyl]-3H- ** isobenzofuran-l-one (Compound 164)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- #** propionic acid methyl ester (Compound 165)

4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound *** 166)

4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-6,7-dimethoxy-indan-l- ** one (Compound 167)

4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-7-methoxy-indan-l-one * (Compound 168)

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-indan-l-one (Compound #*# 169)

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one (Compound 170)

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2,3-dimethyl-2,3-dihydr o- * isoindol-l-one (Compound 171)

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2-methyl-2,3-dihydro- * isoindol-l-one (Compound 172)

4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2,3-dihydro-isoindol-l- ** one (Compound 173)

5-(2-Isobutoxy-3,4-dimethoxy-phenyl)-2,3-dihydro-isoindol-l- *** one (Compound 174)

4-(2-Isobutoxy-3,4-dimethoxy-phenyl)-3H-isobenzofuran-l-one *** (Compound 175)

6-(2-Isobutoxy-3,4-dimethoxy-phenyl)-benzofuran-3-one ** (Compound 176)

4-[2-(l-Hydroxymethyl-cyclopropylmethoxy)-3,4-dimethoxy- **# phenyl]-indan-l-one (Compound 177)

4-[3,4-Dimethoxy-2-(l-methoxymethyl-cyclopropylmethoxy)- phenyl]-indan-l-one (Compound 178) Ethyl-carbamic acid l-[2,3-dimethoxy-6-( l-oxo-indan-4-yl)- phenoxymethyl]-cyclopropylmethyl ester (Compound 179)

Isopropyl-carbamic acid l-[2,3-dimethoxy-6-( l-oxo-indan-4-yl)- phenoxymethyl]-cyclopropylmethyl ester (Compound 180)

Benzyl-carbamic acid l-[2,3-dimethoxy-6-( l-oxo-indan-4-yl)- *** phenoxymethyl]-cyclopropylmethyl ester (Compound 181)

4-[2-( l-Aminomethyl-cyclopropylmethoxy)-3,4-dimethoxy- phenyl]-indan-l-one (Compound 182)

N-{ l-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]- *** cyclopropylmethyl}-isobutyramide (Compound 183)

N-{ l-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- cyclopropylmethyl}-butyramide (Compound 184)

N-{l- [2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]- *** cyclopropylmethyl>-acetamide (Compound 185)

{ l-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- *** cyclopropylmethyl}-carbamic acid ethyl ester (Compound 186)

{ l-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- **# cyclopropylmethyl>-carbamic acid isopropyl ester (Compound

187)

{ l-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- *** cyclopropylmethyl}-carbamic acid 2-methoxy-ethyl ester

(Compound 188)

Ethyl-carbamic acid 3-[2 _/ 3-dimethoxy-6-( l-oxo-indan-4-yl)- *** phenoxymethyl]-oxetan-3-ylmethyl ester (Compound 189)

4- [3,4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy)- *** phenyl]-indan- l-one (Compound 190)

4-[2-(3-Aminomethyl-oxetan-3-ylmethoxy)-3,4-dimethoxy- phenyl]-indan- l-one (Compound 191)

N-{3-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- *** oxetan-3-ylmethyl}-acetamide (Compound 192)

N-{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]- *** oxetan-3-ylmethyl}-isobutyramide (Compound 193)

N-{3-[2,3-Dimethoxy-6-( l-oxo-indan-4-yl)-phenoxymethyl]- oxetan-3-ylmethyl}-butyramide (Compound 194)

N-{3-[2,3-Dimethoxy-6-( l -oxo-indan-4-yl)-phenoxymethyl]- oxetan-3-ylmethyl}-2-methoxy-acetamide (Compound 195) {3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxetan - * * * 3-ylmethyl}-carbamic acid ethyl ester (Compound 196)

{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxetan - 3-ylmethyl}-carbamic acid isopropyl ester (Compound 197)

{3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxymethyl]-oxetan - *** 3-ylmethyl}-carbamic acid 2-methoxy-ethyl ester (Compound

198)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 199)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2,N- *** trimethyl-propionamide (Compound 200)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-N-ethyl-2,2- *** dimethyl-propionamide (Compound 201)

3-[2,3-Dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy]-2,2,N,N- tetramethyl-propionamide (Compound 202)

N-Cyclopropyl-3-[2,3-dimethoxy-6-(l-oxo-indan-4-yl)-phenoxy] - *** 2,2-dimethyl-propionamide (Compound 203)

4-[2-(2,2-Dimethyl-3-morpholin-4-yl-3-oxo-propoxy)-3,4- *** dimethoxy-phenyl]-indan-l-one (Compound 204)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- propionic acid (Compound 205)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2,N- *** trimethyl-propionamide (Compound 206)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2,N,N- ** tetramethyl-propionamide (Compound 207)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-N-isopropyl- * 2,2-dimethyl-propionamide (Compound 208)

3-[2,3-Dimethoxy-6-(l-oxo-indan-5-yl)-phenoxy]-2,2-dimethyl- ** N-propyl-propionamide (Compound 209)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-l,3-dihydro- *#* isobenzofuran-5-yl)-phenoxy]-2,2-dimethyl-propyl ester

(Compound 210)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-indan-4-yl)- *** phenoxy]-2,2-dimethyl-propyl ester (Compound 211)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH- * isoindol-5-yl)-phenoxy]-2,2-dimethyl-propyl ester (Compound

212) Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-l,3-dihydro- *** isobenzofuran-5-yl)-phenoxymethyl]-oxetan-3-ylmethyl ester

(Compound 213)

Ethyl-carbamic acid 3-[2,3-dimethoxy-6-(l-oxo-2,3-dihydro-lH- * isoindol-5-yl)-phenoxymethyl]-oxetan-3-ylmethyl ester

(Compound 214)

5-[3,4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy)- phenyl]-3H-isobenzofuran-l-one (Compound 215)

5-[3,4-Dimethoxy-2-(3-methoxymethyl-oxetan-3-ylmethoxy)- phenyl]-2,3-dihydro-isoindol-l-one (Compound 216)

4-[3,4-Dimethoxy-2-(3-methoxy-2,2-dimethyl-propoxy)-phenyl]- *** indan-l-one (Compound 217)

5-[3,4-Dimethoxy-2-(3-methoxy-2,2-dimethyl-propoxy)-phenyl]- 3H-isobenzofuran-l-one (Compound 218)

5-[3,4-Dimethoxy-2-(3-methoxy-2,2-dimethyl-propoxy)-phenyl]- *** 2,3-dihydro-isoindol-l-one (Compound 219)